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Abstract
A review of the British Society for Histocompatibility and Immunogenetics (BSHI) 
Guideline ‘HLA matching and donor selection for haematopoietic progenitor cell 
transplantation’ published in 2016 was undertaken by a BSHI appointed writing com-
mittee. Literature searches were performed and the data extracted were presented 
as recommendations according to the GRADE nomenclature.
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1  | INTRODUC TION
The infusion (transplantation) of haematopoietic progenitor 
stem cells (HPC) into a patient with haematological failure due 
to malignant or nonmalignant causes can result in successful en-
graftment of donor- derived HPC which undergo haemopoiesis to 
replace the malfunctioning cells of the patient's immune system. 
The effectiveness of these transplants in terms of patient over-
all survival (OS) and disease- free survival (DFS) has improved 
with each decade due to accurate histocompatibility matching 
between donor and patient; use of alternative donors; improved 
patient conditioning protocols; use of therapeutic agents; pre-
vention and treatment of infections and post- transplant support-
ive care.
This guideline is an update to the previous published guideline 
(Little et al., 2016) and describes the selection of donors for alloge-
neic, that is the donor is not genetically identical to the patient, HPC 
transplantation (HPCT).
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2  | METHOD
This guideline was produced by the following actions:
1. A writing committee (authors of this manuscript) comprising 
Histocompatibility and Immunogenetics (H&I) scientists providing 
an H&I clinical service for related and unrelated donor haema-
topoietic progenitor cell transplantation was established. Ann- 
Margaret Little was appointed as the chair of the committee.
2. A search of peer- reviewed literature to 31 December 2019 was 
undertaken, with additional literature reviews conducted in re-
sponse to reviewers' comments.
3. Recommendations were produced from evidence obtained from 
the literature search. Due to the specialist nature of histocompat-
ibility testing in the context of haematopoietic progenitor cell al-
lotransplantation, there are few large and/or multicentre studies 
and meta- analyses are not available. Some recommendations are 
based on both literature review and consensus of expert opinion.
4. The evidence collected was evaluated using a modification of the 
GRADE nomenclature (https://www.grade worki nggro up.org/). 
For each recommendation, the strength of recommendation has 
been indicated as one of:
Level 1 (we recommend)
Level 2 (we suggest)
Not graded (where there is not enough evidence to allow formal 
grading)




These recommendations represent consensus opinion from experts 
in the field of H&I within the United Kingdom. They represent a 
snapshot of the evidence available at the time of writing. This evi-
dence may become superseded with time. It is recognized that rec-
ommendations have been made even when the evidence is weak. 
The British Society for Histocompatibility and Immunogenetics 
(BSHI) cannot attest to the accuracy, completeness or currency of 
the opinions and information contained herein and does not accept 
any responsibility or liability for any loss or damage caused to any 
practitioner or any third party as a result of any reliance being placed 
on this guideline or as a result of any inaccurate or misleading opin-
ion contained in the guideline.
3  | RECOMMENDATIONS AND 
SUGGESTIONS
Recommendations and suggestions are summarized in Tables 1 and 
2. These evidence- based recommendations expand and adapt previ-
ous guidance (Little et al., 2016).
4  | HL A MATCHING IN HPC 
TR ANSPL ANTATION
Amongst the many factors that contribute to successful transplanta-
tion, the most significant is the degree of human leucocyte antigen 
(HLA) compatibility between donor and patient.
Unlike most genes in the human genome, HLA genes are hyper- 
polymorphic, that is there are many variations within their gene se-
quences and each variant is called an allele. Most allele differences 
are nonsynonymous and the majority of amino acid variations im-
pact on the structure of the peptide- binding domains thus directly 
influencing how self and non- self peptides are presented to T cells 
and how they are recognized by natural killer (NK) cells.
In a HPCT, alloreactive cells of the patient can initiate an immune 
response against non- self antigens expressed by the transplanted 
donor cells, causing rejection of the donor cells. This is defined 
as either lack of initial engraftment of donor cells (primary graft 
failure) or loss of donor cells after initial engraftment (secondary 
graft failure). Pre- transplant conditioning of the patient with che-
motherapy and/or irradiation reduces this HVG response allowing 
the donor cells to engraft. Conversely, immune reactive cells from 
the donor can target non- self patient antigens, expressed by tis-
sues of the recipient, causing a graft versus host (GVH) immune 
response. This acute GVH disease (aGVHD) is graded from I to IV 
(mild to severe) and involves multiple organs of the patient includ-
ing skin, gut and liver with grade IV aGVHD being life- threatening. 
Alloreactive immune responses are reduced by the use of immuno-
suppression and by using T cell- depleted HPC products. The GVH 
response can also be beneficial when directed to cells expressing 
malignancy- specific antigens, that is graft- versus- leukaemia (GVL) 
(Craddock & Chakraverty, 2016).
The impact of matching HLA alleles of patients with donors, as 
is the case when the donor is an HLA- matched sibling, contributes 
significantly to optimal outcome by reducing the allo- reactions that 
contribute to HVG and GVHD responses. In addition to HLA variabil-
ity, non- HLA genetic polymorphisms can impact on GVHD and these 
are more frequent in unrelated donor transplants where there is less 
genetic compatibility outwith the Major Histocompatibility Complex 
(MHC, Petersdorf, 2017).
5  | HL A T YPING AND HL A 
ALLOANTIBODY IDENTIFIC ATION
5.1 | HLA testing methodologies
HLA typing and HLA alloantibody identification can be undertaken 
by various methods. It is not the scope of this guideline to advo-
cate which methods should be utilized. All methods used must be 
validated and/or verified within the laboratory where used. Within 
the United Kingdom, HLA typing and HLA alloantibody identifica-
tion for HPCT must be performed according to the standards for 
histocompatibility testing produced by the European Federation for 
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TA B L E  1   Recommendations
Supporting text 
location
Section Level 1 (we recommend)
Quality of Evidence: GRADE A (high)
5.1 All laboratories performing H&I testing for allogeneic HPCT in the UK must be accredited by EFI and UKAS
5.2 HLA typing definitions as described by Nunes et al. (2011) and within this document should be used
6 Alternative progenitor cell donors (single mismatched unrelated donor/umbilical cord blood (UCB)/haploidentical) should be 
considered early in the donor search when a patient is unlikely to have an HLA matched unrelated donor
7 HLA typing of patients and all donors (matched and mismatched, related, unrelated and cord) proceeding to transplant should 
be carried out at high resolution for HLA- A, B, C (exons 2 and 3 minimum) and DRB1, DQB1 and DPB1 (exon 2 minimum) 
which identifies polymorphisms within the antigen recognition domain (ARD)
8.3 When selecting an unrelated donor a 10/10 high or UHR/allele resolution HLA- A, - B, - C, - DRB1 and – DQB1 matched donor 
should be preferentially selected over a mismatched donor
8.3.1 Where a 10/10 matched unrelated peripheral blood stem cell (PBSC) or bone marrow donor is not available a single mismatch 
at HLA- A, B, C, DRB1 or DQB1 is acceptable with mismatches at DQB1 preferred
8.3.2 When selecting mismatched donors, avoid amino acid mismatches within the ARD
9.2.1 Ensure shortlisted UCB units meet the minimum threshold required for a single UCB transplant (UCBT), (>3 × 107/kg recipient 
weight). In non- malignant conditions, especially bone marrow failure syndromes, or in cases where HLA match is <6/8, 
consider increasing the total nucleated cell (TNC) threshold to >5.0 × 107/kg. When the patient’s weight indicates that a 
double UCBT is required, maintain a minimum TNC of >3.5 × 107/kg. The minimum TNC required for each unit is 1.5 × 107/
kg, though preference should be given to the best HLA matched UCB with TNC in excess of this minimum threshold, where 
possible
9.2.2 Select UCB units with HLA match ≥4/8 in adults and ≥5/8 in children (nonȁmalignant disease). For double UCBT the unit- unit 
HLA match does not need to be considered.
9.2.3 For single UCBT select UCB units with minimum CD34+ cell dose ≥1.5 × 105/kg; for double UCBT select units with minimum 
CD34+ cell dose ≥1.0 × 105/kg each
9.2.5 Avoid selection of red blood cell (RBC) replete UCB units with Haematocrit of >40%
7, 8, 9 All patients and selected donor/UCB unit(s) must have their HLA types confirmed on a sample independent to the first HLA 
type, prior to commencement of transplant work- up
11.1 Select donors that are cytomegalovirus (CMV) matched with the patients
11.4 Younger donors should be preferentially selected
13 Homozygosity and novel HLA alleles identified within DNA extracted from patients with a high frequency of circulating 
tumour cells should be confirmed by family studies or using DNA extracted from non- diseased cells
14 Individuals actively involved in the provision of a donor selection service should undertake continuing professional 
development (CPD) (Grade A) and the service should be directed by a Royal College of Pathologist Fellow and Consultant in 
H&I
Quality of Evidence: GRADE B (low)
5.3 Testing for HLA antibodies should detect antibodies reactive with HLA- A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, 
DPA1 and DPB1 gene products
6 The clinical urgency should be made available to the individual performing the related and unrelated donor search
7 HLA typing of regions outside the ARD to achieve Ultra High Resolution (UHR) or allelic level typing is recommended
8.3.3 When a choice of otherwise equally matched donors is available, non- permissive HLA- DPB1 mismatches should be avoided. 
Patient HLA- DP expression levels should also be considered
8.3.4 HLA- DRB3, DRB4, DRB5 typing should be performed and, when a choice of otherwise equally matched donors is available, 
mismatches for these should be minimised
10 Additional testing for HLA- DPA1 and DQA1 is required if indicated by patient’s HLA antibody status
10 Recipient HLA alloantibody testing should be monitored such that selection of HLA mismatched donors, against whom the 
patient may have antibodies, is avoided
10 If donor specific antibodies (DSA) are detected, define the risk further by determining the complement binding ability and/or 
perform a crossmatch between the patient and donor as locally agreed with the transplant team
11.2 Major ABO incompatibilities should be avoided when there is a choice of donors
11.3 Male donors should be preferentially chosen where the patient has multiple donor options
12 Identify a back- up donor option
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Immunogenetics (EFI) (https://efi- web.org/) and must be undertaken 
by a laboratory accredited by the United Kingdom Accreditation 
Service (UKAS) (https://www.ukas.com/) and EFI.
5.2 | Definitions of HLA typing resolution
The definitions for low, high and allele resolution typing as com-
piled by a joint international working party: the Harmonisation 
of Histocompatibility Typing Terms Working Group, to define a 
consensual language for laboratories, physicians and registries 
to communicate histocompatibility typing information are used 
within this guideline (Nunes et al., 2011). In addition, we ac-
cept the following definitions for intermediate resolution, and 
ultra- high resolution (UHR) typing (Mayor et al., 2019). Official 
names are assigned to the HLA genes, antigens and alleles by the 
World Health Organisation (WHO) Nomenclature Committee 
for Factors of the HLA System (Marsh et al., 2010). The Immuno 
Polymorphism Database— ImMunoGeneTics (IPD- IMGT)/HLA 
Database is the official repository of the HLA allele sequences 
(Robinson et al., 2015).
5.2.1 | Intermediate resolution
The term intermediate resolution can be applied when high reso-
lution cannot be achieved, and the provided HLA type includes a 
subset of alleles sharing the digits in the first field of their allele 
name, for example A*02:01 or A*02:02 or A*02:07 or A*02:20 but 
not other A*02 alleles due to differences in the second or other 
fields. There may be cases in which the subset of alleles includes 
one or more alleles within a group beginning with different digits 
but these alleles should be the exception, for example A*01:01 
or A*01:02 or A*01:14 or A:36:04. Reporting intermediate resolu-
tion results as high resolution is inaccurate and could lead to inap-
propriate selection of optimum donor by missing rare and novel 
alleles.
5.2.2 | Genotyping outside of the antigen 
recognition domain
As most HLA typing strategies now target regions beyond the exons 
encoding the ARD, the impact of genetic variation within other 
TA B L E  2   Suggestions
Supporting text 
location
Section Level 2 (we suggest)
Quality of Evidence: GRADE A (high)
9.2.5 When considering an older UCB unit, evaluate infectious disease markers (IDM), sterility and haemoglobinopathy test results 
at early stages of UCB unit selection. This allows time for any missing mandatory tests to be undertaken by the cord blood 
bank (CBB), or the transplant centre
Quality of Evidence: GRADE B (low)
8.3.2 When selecting donors with mismatches outside the ARD consideration of the location of the mismatched amino acid 
residues and avoidance of described nonpermissive mismatches may contribute to better outcome. For HLA- B mismatches, 
exon 1 sequences may be assessed and for HLA- C mismatches, apparent expression levels may also be considered
8.3.2 Use the PIRCHE algorithm in aiding selection of mismatched donors
8.3.5 For mismatched donor selection, host- versus- graft (HVG) mismatches are favoured over bidirectional and graft- versus- host 
(GVH) mismatches, unless there is a high risk of graft rejection due to stem cell source (e.g. UCB) or patient's disorder
6 Where HLA- DQA1 and HLA- DPA1 typing has been performed and there is a choice of otherwise equally matched donors, 
consider avoiding donors with mismatches at these loci
9.2.2 Where a choice of UCB unit is available, where possible, priority should be given to unidirectional GVH mismatches over HVG 
unidirectional mismatches
9.2.5 In case of a choice of equally mismatched UCB units with similar potency, the transplant centre may prefer units matching a 
patient on paternal antigens and/or where the patient HLA mismatches match the noninherited maternal antigen (NIMA) of 
the UCB
10 Post- transplant HLA alloantibody testing should be performed in cases of failed engraftment if there are mismatches in the 
HVG direction
11.5.1 If an HLA- B- mismatched donor is selected, consider MICA- 129 dimorphism
11.5.4 Where a choice of fully HLA- matched donors exists, recipients who are homozygous for C2 group HLA- C alleles should 
receive a KIR2DS1- positive donor
11.5.4 Where a choice of fully HLA- matched donors exists, recipients who are mismatched with their donor for CMV serostatus 
should receive a KIR B haplotype- positive donor, ideally categorized ‘better’ or ‘best’ in accordance with the B content 
scoring model (Cooley et al., 2010). If the B content scoring model is used, the IPD- KIR ligand calculator (https://www.ebi.
ac.uk/ipd/kir/donor_b_conte nt.html) should be utilized to avoid ambiguity
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exons, introns, 5′ and 3′ untranslated regions can be investigated. 
Sequence variation within these regions can affect HLA expression, 
for example encode null alleles, and function, for example CD8 and 
CD4 binding (Clayberger et al., 1994) which will impact on the as-
sessment of compatibility between a patient and potential donor. 
Improvements in HLA typing by next- generation sequencing (NGS) 
and third generation sequencing (TGS) enable near full- gene (allele) 
sequencing with greater phase determination facilitating the poten-
tial matching of HLA genes beyond previously considered criteria, 
including polymorphisms in noncoding regions and consideration of 
synonymous nucleotide mismatches (Petersdorf & O'hUigin, 2019). 
The terminology ‘UHR’ was introduced by Mayor et al. (2019) to de-
scribe HLA typing resolution achieved using these techniques which 
give greater than high but not quite achieving complete allele level. 
Table 3 gives examples of acceptable reporting conventions.
5.3 | HLA antibodies
The role of HLA alloreactive antibodies in HPCT outcome is de-
scribed in Section 10. Laboratories should be able to detect IgG 
(at a minimum) antibodies reactive with HLA- A, HLA- B, HLA- C, 
HLA- DRB1, HLA- DRB3, HLA- DRB4, HLA- DRB5, HLA- DQA1, HLA- 
DQB1, HLA- DPA1 and HLA- DPB1 gene products. The use of mul-
tiple different testing assays may be required to allow detection of 
antibodies reactive with all donor mismatches.
6  | STAGE OF DISE A SE AND TIME TO 
TR ANSPL ANT
One of the earliest steps in donor selection is to consider the dis-
ease status of the patient. Depending on the disease type and treat-
ment plan, patients will have different timescales to transplant. In 
acute leukaemia, where the patient's condition can rapidly deterio-
rate, there may only be a limited window of opportunity to trans-
plant when the patient is in clinical remission, thus limiting the time 
available for an extended related or unrelated donor search (Cutler 
et al., 2004). A patient progressing to an advanced disease usually has 
a higher mortality risk from the disease than the added risk of a trans-
plant from a single allele mismatch donor or alternative donor therapy 
such as UCB or haploidentical donor transplantation. The impact of 
the time required to identify an optimum matching donor has to be 
offset against the potential negative impact of the disease stage and 
progression and will determine the source of progenitor cells selected 
for treatment (Brissot et al., 2017; Weisdorf, 2008). The H&I scien-
tists should be given an indication of the clinical urgency and the H&I 
specialist must advise on the likelihood of finding a matched or other 
donor within the time frame defined by the transplant team.
7  | HISTOCOMPATIBILIT Y MATCHING: 
REL ATED DONOR SELEC TION
The initial search for an HLA- matched donor is usually within the 
patient's family although for certain genetic diseases a related donor 
may not be appropriate if they are a carrier of the same genetic mu-
tation. Even if studies show good outcomes with both related and 
unrelated donors (Robin et al., 2013; Shouval et al., 2019), there is 
still an advantage in selecting a related donor. Related donors are 
usually quick to identify and cheaper to workup and are flexible in 
terms of timing the transplant; thus, transplants can be expedited to 
suit the patient's clinical condition.
7.1 | HLA matching for related donor selection
There is a 25% theoretical chance of a patient and a sibling being an 
HLA match. However due to parents sharing common haplotypes, 
the actual number of patients identifying an HLA- A, B, C, DRB1, 
DQB1- matched sibling donor is closer to 30%. The selection of mis-
matched and haploidentical relatives increases the options of finding 
a donor within the patient's family. Single allele- mismatched related 
donors may be identified within families when an HLA- matched 
donor is not identified and outcome data support no difference in 





The patient and donor have been typed to high resolution, i.e. the 
polymorphisms within the ARD have been defined
10/10 UHR 
match
The patient and donor have been typed to ultra high resolution, i.e. 
polymorphisms within and outside the ARD have been defined
10/10 allele 
match
The patient and donor have been typed to allele resolution, i.e. the 
polymorphisms within the full HLA gene sequence, that is exons and introns 






The patient and donor have no mismatches at high resolution HLA typing for 
HLA- A, HLA- B, HLA- C, HLA- DRB1 and HLA- DQB1. A mismatch outside the 
ARD has been identified for HLA- B by UHR typing
TA B L E  3   Suggested reporting 
comments for indicating level of HLA 
typing used to assess matching between 
patient and donor
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aGVHD (Valcárcel et al., 2011). Haploidentical transplantation is dis-
cussed in Section 7.2.
The availability of parental HLA typing data are useful for assign-
ment of haplotypes. These data can usually be derived for paediatric 
patients but are rarely available for adult patients. Although meet-
ing current EFI standards, HLA- A, HLA- B and HLA- DRB1 typing of 
siblings (without parents), to identify potential matches, does not 
allow accurate determination of haplotypes and can lead to wrongly 
F I G U R E  1   (a) Low resolution typing at five HLA loci identifies both sibling 1 and 2 as having the same HLA type. (b) HLA allele level 
typing identifies the father as being heterozygous and sibling 1 and 2 have inherited different haplotypes from the father resulting in sibling 
1 being an 8/10 match and sibling 2 being a 10/10 match for the patient
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establishing presumptive matches. This is a particular concern when 
there is haplotype sharing between parents or apparent homozy-
gosity (at low/intermediate resolution HLA typing) for a parent. This 
is illustrated in Figure 1. Also, novel alleles and recombination (es-
pecially between HLA- DQ and HLA- DP genes) may be undetected 
if HLA typing is restricted to only HLA- A, B, DRB1 loci. High, UHR 
or allelic HLA typing resolution is required as low/intermediate res-
olution typing could mask additional mismatches (Hansen, 2012; 
Kanda et al., 2012). HLA- DPB1 typing is also useful in identifying 
fully matched sibling donors when common haplotypes are present.
7.2 | Haploidentical family donors
The use of haploidentical donors has had a significant positive impact 
on the transplant opportunities for patients who do not have an HLA- 
identical sibling or volunteer unrelated donor option, as most patients 
will have a haploidentical relative within their family (Fuchs, 2012). 
Current protocols include the post- transplant administration of cy-
clophosphamide (PTCy) to actively destroy proliferating alloreactive 
lymphocytes, without impairing haematopoietic progenitor cells, thus 
reducing the risk of severe GVHD caused by HLA mismatches (Chang 
& Huang, 2014; Reisner et al., 2011). As the clinical outcome of hap-
loidentical transplants is proving to be comparable to matched related 
donors (Rashidi et al., 2019), an increase in the number of haploidenti-
cal transplants has been documented (Passweg et al., 2019). For the 
majority of paediatric patients, the donor will either be the patient's 
mother or father. For adult patients, this choice is often impracticable 
and siblings and children are usually considered, with second degree- 
related donors also possible (Elmariah et al., 2018). Preferred donor 
characteristics, which vary depending on the transplant protocol (T- 
cell deplete or T- cell replete), have been reviewed and published in 
the European Society for Blood and Marrow Transplant (EBMT) con-
sensus recommendations (Ciurea et al., 2020). For T- cell deplete hap-
loidentical transplants, the preference is a first degree relative over 
second degree and when parents are being considered the mother 
is preferred over the father due to the benefit of NIMA, discussed 
further in Sections 8.3.6 and 9.2.5.5. For T- cell replete transplants, 
siblings (NIMA mismatched) and children are preferred over a par-
ent donor (Wang et al., 2014) and the father is the preferred parental 
donor. When multiple haploidentical donors are available, the donor 
may be selected based on non- HLA donor characteristics discussed 
in Section 11.
As for other related donor transplants, high, UHR or allelic res-
olution typing (HLA- A, B, C, DRB1, DQB1, DPB1) of the potential 
haplotype- matched donor is recommended to aid assignment of 
haplotypes. All haploidentical donors will be at least a 5/10 match to 
the patient. There are currently no data that suggest a different out-
come for haploidentical donors who may have no sharing of DP type 
due to recombination, that is 5/12 v 6/12 (Jaime- Pérez et al., 2020). 
Additional HLA matching on the mismatched haplotype may be 
observed; however, the EBMT consensus recommendation (Ciurea 
et al., 2020) concluded that there was no evidence to support a 
beneficial effect of selecting haploidentical donors based on the de-
gree of additional HLA matching due to heterogeneity in data cur-
rently available. Patients receiving a haploidentical donor transplant 
require testing for HLA antibodies (discussed in Section 10).
Haploidentical transplantation involves HLA mismatching and 
may include mismatching for HLA proteins that interact with dif-
ferent NK cell inhibitory receptors (Killer- cell Immunoglobulin- 
like Receptors, KIR). The role of NK cell receptors is discussed in 
Section 11.5.
7.3 | Related UCB donor
HLA typing of potential related UCB donors must be performed to 
the same resolution as described for other related donors to allow 
identification of haplotypes. HLA antibody testing of the patient (if 
the UCB is mismatched) is also required.
7.4 | Final donor selection
Both patient and the selected related donor must be HLA typed 
using a second independent sample to exclude any sampling or labo-
ratory errors and must take place prior to the initiation of the pa-
tient's conditioning protocol.
8  | HISTOCOMPATIBILIT Y MATCHING: 
VOLUNTEER UNREL ATED DONOR 
SELEC TION
An unrelated donor search should be carried out for those patients 
without a suitable HLA- matched related donor. For 2018, the 
EBMT reported that there were almost equal numbers of alloge-
neic transplants using unrelated donors (50.5%) and related donors 
(49.5%) (Passweg et al., 2020). These figures and those from pre-
vious years (Passweg et al., 2019) demonstrate a decrease in the 
overall number of unrelated donor transplants due to an increase 
in related donor, particularly haploidentical transplants over the 
last 10 years.
8.1 | The search process
Time to transplant is an important consideration when deciding 
to initiate an unrelated donor search (see Section 6). For those 
patients with high clinical urgency, unrelated donor searches may 
be initiated at the same time as undertaking a search for a related 
donor. Before an unrelated donor search is commenced, it is nec-
essary to gain the appropriate authorization (Scotland) or consent 
(rest of United Kingdom) from the patient to permit the sharing 
of their personal and genetic data with national and international 
donor registries.
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Within the UK, the Anthony Nolan and National Health Service 
(NHS) Stem Cell Donor Register is an aligned unrelated donor reg-
ister, operated by Anthony Nolan, which provides search reports 
including donors from Anthony Nolan; the British Bone Marrow 
Register (BBMR); the Welsh Bone Marrow Donor Register (WBMDR) 
and DKMS UK. Initial search requests are sent, by the transplant 
centre or associated H&I laboratory, to Anthony Nolan who produce 
a search report consisting of potential UK donors, as well as a sum-
mary report generated from the World Marrow Donor Association 
(WMDA) international database of donor registries (WMDA Search 
& Match). The number of potential matched UK donors is used to 
determine the need to initiate searches of international registries. 
Laboratories and transplant centres who routinely request unrelated 
donor searches should establish with the Anthony Nolan Search 
Team a set of criteria for when international donor searches are to 
be initiated. It is the responsibility of the transplant centre to agree 
specific criteria to be used to filter donor lists, for example male in 
preference to female, age and CMV status. It is also essential that the 
urgency of the patient case is communicated to the Anthony Nolan 
Search Team to allow them to take this into account when perform-
ing international searches.
The most useful results from the unrelated donor search are 
obtained when the patient has been HLA typed to high, UHR or 
allelic resolution to eliminate mismatching donors from the search 
summary.
8.1.1 | The search algorithm
The minimum requirements for an unrelated donor search algorithm 
have been published by the WMDA in their ‘Framework for the im-
plementation of HLA matching programs in haematopoietic stem 
cell donor registries and cord blood banks’ (Bochtler et al., 2011). 
The current search algorithm used in the UK by Anthony Nolan 
identifies donors that are potentially matched at 5 HLA loci (HLA- 
A, HLA- B, HLA- C, HLA- DRB1 and HLA- DQB1). Other registries 
such as the NMDP (National Marrow Donor Program, USA reg-
istry) and ZKRD (German registry) use algorithms that match to 
high resolution for HLA- A, HLA- B, HLA- C, HLA- DRB1 and give 
a probability value on the likelihood of a donor being a match for 
a patient based on HLA allele and haplotype frequencies in the 
donor populations.
It is essential that the person interpreting search reports under-
stands the algorithm used by the various different registries to en-
sure optimum donor selection.
8.2 | Factors impacting on the identification of an 
HLA- matched unrelated progenitor cell donor
Caucasoid patients have a 40%– 75% chance of identifying a high- 
resolution matched donor at HLA- A, HLA- B, HLA- C, HLA- DRB1 and 
HLA- DQB1 (10/10 match) and finding this match is highly predictable 
(Gragert et al., 2014; Hirv et al., 2009; Tiercy et al., 2000, 2007). 
The chance of a 10/10 match in other ethnic groups, with HLA 
haplotypes that are less well represented on the unrelated donor 
registries, is significantly lower (Gragert et al., 2014; Heemskerk 
et al., 2005; Schmidt et al., 2009). Hence, patients are less likely to 
find a matched donor from an ethnic group differing from their own 
and patients with parents coming from differing ethnic groups are at 
increased risk of not finding any match.
The use of ‘minimally’ mismatched adult volunteer donors and 
UCB units increases significantly the likelihood of finding a usable 
donor (Gragert et al., 2014). The frequencies of HLA- B and HLA- C 
and/or HLA- DRB1 and HLA- DQB1 associations in differing ethnic 
groups are available for comparison with the HLA type of the pa-
tient (Gragert et al., 2013; Kollman et al., 2007; Mack et al., 2013; 
Maiers et al., 2007; Sanchez- Mazas et al., 2017), and these tools 
can be used to help predict how likely it will be to find a match for 
a patient.
The following factors must be considered when searching for a 
high, UHR or allelic resolution matched unrelated donor.
• Uncommon HLA- B and HLA- C and/or HLA- DRB1 and HLA- DQB1 
associations have a negative impact on likely donor identification.
• When search results reveal mainly low- resolution HLA- typed do-
nors, the presence of a low frequency allele (<5%) in the patient 
(e.g. B*44:05), when other low- resolution matched alleles have 
frequencies >10% (e.g. B*44:02), will negatively impact on the 
identification of a matched donor.
• The presence of alleles from the low- resolution typing group 
HLA- B*51 and HLA- B*18 and the presence of alleles B*27:05, 
B*44:02 and B*44:03 in the patient have an increased risk of a 
HLA- C mismatch.
• The presence of alleles from the low- resolution typing group 
HLA- DRB1*04 and HLA- DRB1*07 in the patient have a raised risk 
of a HLA- DQB1 mismatch.
The optimal number of donors to select for verification HLA 
typing should be decided on a patient by patient basis taking into 
account all the factors that can influence the likelihood of finding a 
suitable donor, including donor factors (Lown et al., 2014) and the 
clinical urgency. Acceptable levels of matching and mismatching 
must be determined and agreed by local transplant policies.
8.3 | HLA matching requirements for unrelated 
donor transplants
Multiple studies have reported optimum transplant outcome is 
achieved when the patient and donor are matched for HLA- A, HLA- 
B, HLA- C and HLA- DRB1 at high resolution (Flomenberg et al., 2004; 
Lee et al., 2007; Mayor et al., 2019; Morishima et al., 2002; Petersdorf 
et al., 2001, 2004, 2020; Woolfrey et al., 2011).
Assessment of matching for full length HLA class I genes (A,B,C) 
and exons encoding the extracellular domains of HLA class II genes 
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(DRB1, DQB1 and DPB1) in a cohort of 891 patients with haemato-
logical malignancies, transplanted with unrelated donors, identified 
better out comes for those patients who were fully matched across 
all regions targeted with their donors (Mayor et al., 2019). These 
data supports a previous finding that MHC haplotype matching is 
beneficial compared with phenotype only matching in related and 
unrelated donor HPCT (Petersdorf et al., 2013).
8.3.1 | Impact of mismatches at individual HLA loci 
on transplant outcome
The role of HLA- DQ matching is less well supported, NMDP data 
from 3,857 transplants for malignant disease (Lee et al., 2007), 
showed that individual mismatches for HLA- DQB1 had no impact 
on survival. However, if the DQB1 mismatch was associated with 
an additional mismatch, for example 7/8 or 6/8 HLA- A, B, C, DRB1 
mismatch, then an association with poorer survival, albeit not statis-
tically significant was observed. Although HLA- DQB1 mismatching 
did not reach significance in relation to survival, in a German study 
(Fürst et al., 2013), HLA- DQ antigen mismatching achieved a higher 
hazards risk for survival compared with HLA- DQ antigen matches. 
A meta- analysis evaluating data from 36 studies published between 
2002 and 2016 concluded that HLA- DQB1 mismatches were better 
tolerated than other HLA loci for acute GVHD, supporting previous 
conclusions (Tie et al., 2017).
There are no data to support matching for HLA- DQA1 (and DPA1 
discussed in Section 8.3.3). However, as many commercial HLA typ-
ing methods include these loci, if transplants are performed that are 
mismatched for DQB1 and/or DPB1, then mismatches are also likely 
to be present for DQA1 and DPA1. Testing for these additional loci 
may inform future matching strategies.
Overall, in the absence of a 10/10 high- resolution matched 
donor, a donor with a selected single mismatch for HLA- A, HLA- B, 
HLA- C, HLA- DRB1 or HLA- DQB1 can be acceptable, with multiple 
mismatches conferring significantly worse outcomes with the effect 
observed greater when the patient had acute leukaemia and was 
transplanted early during first remission compared to patients with 
advanced disease (Crocchiolo, Ciceri, et al., 2009; Tiercy, 2016).
There is no consensus regarding which of the HLA- A, B, C, DRB1 
loci are more detrimental to mismatch. HLA- A and HLA- DRB1 mis-
matching were reported as being less well tolerated compared with 
HLA- B and HLA- C mismatches in a NMDP study with all mismatches 
reducing OS at 1 year by 9%– 10% (Lee et al., 2007). In contrast, the 
Japanese registry reported transplants with HLA- A and HLA- B mis-
matches had worse survival than HLA- C and HLA- DRB1 mismatches 
(Morishima et al., 2002), with single DRB1- mismatched unrelated 
donors being preferentially selected if a matched unrelated donor 
is not available (Atsuta et al., 2019). HLA- B mismatches were asso-
ciated with a higher risk of aGVHD II– IV in an Italian study of 805 
patients transplanted for haematological malignancies (Crocchiolo, 
Ciceri, et al., 2009) whereas HLA- C antigen mismatches were as-
sociated with lower leukaemia- free survival (LFS) and increased 
risk for mortality and grade III- IV GvHD in an NMDP/Centre for 
International Blood and Marrow Transplant Research (CIBMTR) 
study of 1933 patients transplanted with haematological malig-
nancies (Woolfrey et al., 2011). More recent analysis of transplant 
data held by the ‘International Histocompatibility Working Group in 
HPCT’ has demonstrated individual locus- specific risks. In this anal-
ysis, HLA- A, HLA- B and HLA- C mismatches were more detrimental 
than HLA- DRB1 and HLA- DQB1 mismatches for all endpoints with 
the exception of relapse. Mismatching at each locus (compared with 
HLA- DQB1) was detrimental and the risk increased with increasing 
numbers of mismatches (Petersdorf et al., 2020).
The variability in the outcomes of these studies can be attributed 
to differences in study design; patient demographics; source of stem 
cells, including T- cell depletion; differences in HLA polymorphism 
within groups of patients of different ethnicities; use of serotherapy 
and GVHD prophylaxis and also the level of HLA typing resolution 
utilized.
A retrospective analysis of 2,646 T- cell replete transplants per-
formed for haematological malignancies was conducted in Germany 
(Fürst et al., 2013), with all patients and donors HLA typed to high 
resolution. The impact of mismatches, defined at both high and an-
tigen resolution, on OS; DFS; relapse, TRM and primary graft fail-
ure (GF) were analysed. Mismatches of alleles at either of HLA- A, 
HLA- B, HLA- C, HLA- DRB1 and HLA- DQB1 were associated with a 
decrease in OS (only significant for HLA- A, HLA- B, HLA- C and HLA- 
DRB1); a decrease in DFS (significant for HLA- C) and an increase in 
TRM (significant for HLA- A, HLA- B, HLA- C and HLA- DRB1). Thus, 
any type of mismatch can have a negative impact on outcome. Of 
all associations observed, the most significant were with HLA- C an-
tigen mismatches, affecting OS and DFS, with HLA- B high resolu-
tion mismatching being the most significant affecting TRM. HLA- C 
high resolution mismatches gave consistently lower hazard risks for 
the outcomes studied suggesting that there may be permissive mis-
matching at the HLA- C allele level (Fürst et al., 2013). Permissive 
HLA- C mismatching has been described for HLA- C*03:03 and 
HLA- C*03:04, where transplant outcomes for patients receiv-
ing a (C*03:03/C*03:04)- mismatched transplant were not signifi-
cantly different from patients receiving an 8/8 matched transplant 
(Fernandez- Viña et al., 2014).
The impact of HLA- C antigen versus high- resolution (allele) mis-
matches has been further elucidated in a study of 1,975 HLA- C only 
mismatched (matched HLA- A, HLA- B and HLA- DRB1) transplants 
(Petersdorf et al., 2014). HLA- C protein expression varies for differ-
ent HLA allotypes and in this study patients with HLA- mismatched 
HLA- C allotypes with higher expression were significantly associ-
ated with increased risks of aGVHD III- IV; nonrelapse mortality 
(NRM) and overall mortality but with no impact on relapse. When 
the higher expressing HLA- C mismatch allotype was present in the 
donor, an increase in NRM and mortality, but no effect on aGvHD 
or relapse was observed. In this study, the allele mismatches were 
predominantly C*07:01/07:02 and C*03:03/03:04, which have low 
levels of protein expression and this may account for previously re-
ported permissive HLA- C allele mismatches.
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Mismatching for lower expressing HLA- C alleles of the patient 
compared with higher expressing HLA- C alleles may lower the GVH 
immune response supporting selection of mismatches for lower ex-
pressed over mismatches for high expressed alleles and avoidance of 
HLA- C- mismatched donors for patients with two highly expressed 
HLA- C. This study also demonstrated a higher risk in double mismatch 
(8/10) transplants involving a class I and II mismatch compared with 
double class I or double class II. Other research has highlighted the 
impact of the HLA- C bearing haplotype on HLA- C expression which 
could differ in HLA- C- mismatched transplants (Bettens et al., 2014). 
Further to this, Bettens et al. (2016) investigated the cytotoxic T 
lymphocyte response to HLA- C mismatches and identified that spe-
cific mismatches were more immunogenic than others. As predicted 
from earlier work (Fernandez- Vina et al., 2014), HLA- C*03:03/03:04 
mismatching did not initiate a significant alloresponse.
One of the problems making it difficult to define an accurate risk 
estimate for a single locus mismatch is the extensive polymorphism 
exhibited at HLA loci. Mismatches at any locus may involve 1 ver-
sus 10 versus 20 amino acid mismatches, for example a mismatch 
of A*01:01 with A*02:01 will be different to a mismatch of A*01:01 
with A*03:01, which also will differ from a mismatch of A*01:01 with 
A*23:01. Not all mismatches at a given locus will have equal effects 
on GVL and GVH immune responses post- transplant. It has been cal-
culated that a database of 11,000 to 1.3 million transplants would be 
required to provide sufficient statistical power to detect an associa-
tion between particular HLA allele mismatches and survival (Baxter- 
Lowe et al., 2009). In reality, having a choice of a particular locus to 
mismatch is not always available.
8.3.2 | Impact of individual amino acid substitutions 
on transplant outcome
The impact on transplant outcomes (acute, chronic GVHD [cGVHD], 
TRM, relapse and OS) of amino acid substitutions at peptide- binding 
positions 9, 99, 116 and 156, and KIR- binding position at amino acid 
77 was studied in a multivariate analysis of a heterogeneous cohort 
of patients transplanted for haematological malignancies (Pidala 
et al., 2013). Individual mismatches at residues 99 and 116 within 
HLA- C were associated with an increased TRM and severe aGVHD, 
respectively. A mismatch at residue 9 within HLA- B was associated 
with an increase in cGVHD. No mismatches studied had an effect on 
outcome when located within HLA- A.
In the study of Petersdorf et al. (2014), introduced in Section 
8.3.1, patients receiving transplants with ‘high expressing’ HLA- C 
mismatches that were also residue 116 mismatched had an increased 
incidence of NRM compared with patients mismatched for higher 
expressing HLA- C alleles that were residue 116 matched. Similar 
findings were made for patients receiving high expressing HLA- C 
mismatches that were also mismatched for the KIR- interacting res-
idues 77 and 80 (C1 and C2 epitopes discussed in Section 11.5.3). 
Thus, mismatching for HLA- C allotypes that are highly expressed 
and contain mismatches at residues 116 and/or 77 and 80 could be 
taken into account if a choice of different HLA- C- mismatched do-
nors is available.
Analysis of 1,457 unrelated donor transplants with single mis-
matches for HLA- B (HLA- A, C, DRB1, DQB1 matched) by the 
International Histocompatibility Workshop working group for HPCT 
identified an increased risk for grade 3– 4 aGVHD when the mis-
matched HLA- B allele leader peptide (encoded by exon 1, outside 
the ARD) was mismatched at position −21, compared with HLA- B al-
lele mismatches with a match at this residue (Petersdorf et al., 2020). 
The mechanism for this association has yet to be proven and could 
involve the peptide impacting on HLA- E expression and recognition 
by NK and T cells or could also be a marker for another linked func-
tional polymorphism. Thus, consideration of the exon 1 sequence 
of HLA- B- mismatched unrelated donors could improve the risk of 
aGVHD. The findings of this study remain to be confirmed.
The immunogenicity of mismatches beyond the ARD has also 
been investigated using cellular assays (Roelen et al., 2018). This 
study did not identify any class I mismatches that generated an al-
loreaction suggesting that these mismatches are permissive. This 
is in contrast to the UHR matching study where better outcomes 
were observed with greater matching beyond the ARD (Mayor 
et al., 2019). Weak responses in the presence of HLA- DRB1*14:01 
individuals stimulated by DRB1*14:54 mismatches were identified. 
The difference between the proteins encoded by these two alleles 
is a single amino acid residue in the β2 domain. This response was 
only present in one direction, suggesting that the directionality of 
the mismatch can also play a role in its immunogenicity.
In addition to the influence that amino acid substitutions can 
have on peptide and T- cell receptor (TCR) binding, evidence sug-
gests that germline (inherited genome) variation in a patient's HLA 
can have an influence on post- transplant outcomes. Petersdorf 
et al. (2018) reported that specific amino acid substitutions in the 
DRβ peptide- binding groove could be used to determine HLA haplo-
types that lead to increased risk of patient mortality. In a cohort of 
patients receiving a 9/10 HLA- matched transplant from an unrelated 
donor, a series of amino acid substitutions at residues 26/28/30 of 
the HLA- DRβ molecule were identified that impacted on peptide 
binding, potentially resulting in an altered peptide repertoire. Two 
of the peptide motifs, FEY and FDH, were associated with increased 
mortality, whereas another motif, FDY, had a protective role. The 
risk of mortality associated with these motifs was independent of 
any specific HLA mismatch. These results suggest that understand-
ing the variation in HLA molecules, regardless of the mismatches 
involved, has the potential to allow better risk stratification of indi-
vidual patients.
Another approach to assess the impact of amino acid differ-
ences between patient- and donor- mismatched HLA alleles is to 
calculate the number of peptides that can be derived from the 
mismatched HLA molecule that could be presented by matched 
HLA class I or class II molecules with the aim to identify those 
mismatches that can initiate indirect T- cell allo- reactions. The pre-
dicted indirectly recognizable HLA epitopes (PRICHE) algorithm 
(Geneugelijk & Spierings, 2017) determines values for both HLA 
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class I and class II mismatches, and this has been applied in HPCT 
to assess permissiveness versus nonpermissiveness of individual 
transplant mismatches. In a study of patients transplanted with 
a 9/10 matched unrelated donor, patients with a high PIRCHE 
class II score had significantly lower OS, compared to those with 
a low PIRCHE class II score, which was attributed to an increased 
risk for severe aGVHD (Geneugelijk et al., 2019). A multicentre 
German study (Ayuk et al., 2019) of 9/10 matched unrelated donor 
transplants found that PIRCHE mismatches were associated with 
poorer OS and higher NRM in multivariate analysis. Thus when 
there is a choice of mismatched donor, consideration of PIRCHE 
scores may aid identification of permissive over nonpermissive 
donor mismatches.
8.3.3 | Impact of HLA- DPB1 mismatching
Recombination hotspots have been described between HLA- DQB1 
and HLA- DPB1 genes (Cullen et al., 1997); therefore, matching 
patients and unrelated donors with common HLA- A, C, B, DRB1, 
DQB1 haplotypes does not necessarily infer matching for HLA- 
DPB1 and HLA- DPA1 alleles. It is reported that within families up 
to 5% of otherwise 10/10 matched siblings will also be HLA- DPB1 
mismatched, attributed to recombination (Büchler et al., 2002). 
HLA- DP- specific T cells have been detected and associated with 
both GVL (Herr et al., 2017; Rutten et al., 2008, 2013) and GVHD 
(Stevanovic et al., 2013) supporting the direct role of HLA- DP pro-
teins in the immune responses occurring between patient and donor 
cells post- transplant.
Analysis of the impact of HLA- DPB1 matching and mismatching 
on transplant outcome has been studied in both single- centre and 
multicentre studies. In an analysis of a heterogeneous international 
cohort of transplant recipients, allelic HLA- DPB1 mismatches were 
shown to offer a GVL advantage via a reduction in relapse, but this 
was also associated with increased aGVHD and a suggestive in-
crease in mortality (Shaw et al., 2007). In an NMDP study, there was 
no significant association of single or double HLA- DPB1 allele mis-
matches with survival compared with no HLA- DPB1 mismatches in 
an otherwise HLA- A, B, C, DRB1- matched group of recipients. An 
increased risk of TRM and decreased risk of relapse was suggestive 
in this study albeit not significant (Lee et al., 2007).
In a UK multicentre study, the impact of HLA- DPB1 allele match-
ing was associated with better OS in patients transplanted with early 
leukaemia but not in patients transplanted with late stage disease 
(Shaw et al., 2010), supporting other studies where the effect of HLA 
matching is not as strong in patients transplanted at late stage.
A single- centre UK study of 130 patients transplanted for ma-
lignancies demonstrated a trend towards a negative impact of dou-
ble HLA- DPB1 mismatching on OS in patients otherwise matched 
for 10/10 HLA loci (HLA- A, B, C, DRB1, DQB1). This finding was 
more evident in patients receiving myeloablative conditioning com-
pared with those receiving reduced intensity conditioning (RIC, Burt 
et al., 2014).
HLA- DPB1 mismatches have been assigned as either permis-
sive or nonpermissive based on observed immunogenicity to T- cell 
epitopes (TCE, Crocchiolo, Zino, et al., 2009; Zino et al., 2004). The 
effect of dividing HLA- DPB1 mismatches into these two groups has 
provided evidence of DPB1 mismatching impacting on survival in 
some but not all studies. In a study of 621 unrelated donor HPCTs, re-
cipients with permissive DPB1 mismatches had a significantly higher 
2- year survival than those with nonpermissive DPB1 mismatches 
(55% vs. 39%). This improved survival was due to a decrease in NRM 
(Sacchi, et al., 2009). Overall nonpermissive DPB1 mismatches (un-
like earlier studies of DPB1 allele mismatches) were not associated 
with an increase in aGVHD and concomitant GVL. In contrast, a ret-
rospective study of 153 consecutive adult patients receiving a pri-
mary allogeneic transplant for haematological malignancies did not 
detect any effect of HLA- DPB1 mismatching on overall mortality 
or risk of relapse in 10/10 matched transplants (Moyer et al., 2017). 
HLA- DPB1 mismatches (both permissive and nonpermissive) were 
associated with increased risk of cGvHD. The risk of aGvHD and 
severe aGvHD was higher only in those with nonpermissive DPB1- 
mismatched transplants when compared with HLA- DPB1- matched 
and permissive mismatch pairs combined.
The assignment of permissive and nonpermissive DPB1 
mismatches was included in a large multicentre study (8,539 
transplants) conducted by the International Histocompatibility 
Workshop Working Group in HPCT (Fleischhauer et al., 2012). Of 
the patients receiving a 10/10 matched transplant (HLA- A, B, C, 
DRB1, DQB1), HLA- DPB1 nonpermissive mismatches were associ-
ated with a significant increased risk of overall mortality; NRM and 
in this study an association was observed with severe GVHD but 
not relapse compared with permissive mismatches. Although differ-
ences in outcome were observed between the DPB1- matched and 
DPB1 permissive- mismatched patients, this did not affect overall 
mortality.
A CIBMTR study of a patient cohort considered more con-
temporaneous based on patient disease, transplant conditioning 
protocol and HPC source (peripheral blood stem cell, [PBSC] vs. 
bone marrow), has addressed the impact of DPB1 matching versus 
permissible and nonpermissive mismatches (Pidala et al., 2014). An 
increase in aGVHD grades II to IV and III to IV and a decreased risk 
of relapse was observed in patients receiving DPB1- mismatched 
donors. Dividing the DPB1- mismatched donors into permissive 
and nonpermissive mismatches identified the nonpermissive mis-
matches as having an increase in TRM and an increase in overall 
mortality compared with both the permissive mismatched and 
the matched patients. The DPB1 mismatching outcome was only 
significant within patients receiving an 8/8 and a 10/10 matched 
donor.
Variations in the noncoding region of the HLA- DPB1 gene have 
been shown to influence antigen expression and patient outcomes 
in HLA- DPB1- mismatched transplants. A single nucleotide poly-
morphism (SNP) in the 3′ untranslated region (UTR) of the HLA- 
DPB1 gene (rs9277534 A/G) influences the expression of the 
HLA- DP protein. The presence of the high expressing ‘G’ allele in 
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the patient is associated with a higher risk of aGvHD (Petersdorf 
et al., 2015). This SNP is in linkage disequilibrium with the HLA- 
DPB1 exon 3 sequence which can be used as a marker for two highly 
diverged allele clades with low or high expression levels (Klasberg 
et al., 2019; Schöne et al., 2018). A study by Morishima et al. (2018) 
demonstrated the expression level of a patient's mismatched HLA- 
DPB1 allele can influence the effect TCE permissibility status has 
on acute GvHD. In this study, patients with low expressing HLA- 
DPB1 allele mismatches had an increased risk of aGvHD when 
transplanted with a TCE nonpermissive mismatched donor com-
pared with patients transplanted with a TCE permissive donor. For 
patients with high expressing allele mismatches, the risk of aGvHD 
was not significantly different between TCE permissive and TCE 
nonpermissive pairs. The risk of aGvHD was higher in patients with 
high expressing HLA- DPB1 alleles, and this was independent of do-
nor's HLA- DP expression level (Morishima et al., 2018).
HLA- DPA1 is significantly less polymorphic than HLA- DPB1, 
and certain alleles encoded by the two loci are in linkage disequilib-
rium. Analysis of the role of HLA- DPA1 mismatches had no effect 
on transplant outcome observed for the DPB1 permissive and non-
permissive mismatches in an NMDP study of 1,281 10/10 matched 
unrelated donor transplants (Fleischhauer et al., 2014).
Although there are variations in the clinical outcomes for HLA- 
DPB1 allele and nonpermissive mismatched transplants, overall, 
matching for HLA- DPB1 and avoidance of nonpermissive mismatches 
is associated with better OS. Therefore, matching/mismatching at the 
HLA- DPB1 locus should be considered on an individual basis, taking 
into account matching at other loci and following the transplant phy-
sician's evaluation of the patient's transplant related risks. An online 
tool (see Section 15) is available for assignment of permissive and non-
permissive DPB1 mismatches based on the TCE analyses performed 
(Crivello et al., 2015; Shaw et al., 2013).
8.3.4 | Matching for HLA- DRB3, HLA- DRB4 and 
HLA- DRB5
There is evidence for a potent immune response induced by mismatches 
at HLA- DRB3 (van Balen et al., 2017) and a small but significant effect 
of DRB4 mismatches on TRM and survival (Detrait et al., 2015).
Analysis of the NMDP dataset of 3,853 unrelated donor transplants 
has demonstrated that whilst not significant in isolation, mismatching 
for HLA- DRB3, HLA- DRB4, HLA- DRB5, HLA- DQB1 and HLA- DPB1 
(defined as ‘lesser expressed HLA loci’, LEL) increased the risk asso-
ciated with the presence of a mismatch at HLA- A, HLA- B, HLA- C or 
HLA- DRB1 (Fernández- Viña, et al., 2013). Transplants matched for 
7/8 HLA- A, B, C, DRB1 with three or more LEL mismatches in the GvH 
direction had a higher risk of mortality and TRM than 7/8 transplants 
with 0 or 1 LEl mismatches. Thus, HLA typing donors and patients for 
HLA- DRB3, HLA- DRB4, HLA- DRB5, HLA- DQB1 and HLA- DPB1 is 
warranted to minimize the number of mismatches at the LEL.
A retrospective multicentre French study of 1,975 patients with 
haematological malignancies who received 10/10 matched unrelated 
donor transplant showed significant increased risk of grade II- IV 
aGvHD in pairs with HLA- DRB3, DRB4, DRB5 mismatches when 
compared with those with no mismatch at these loci. There was 
no difference in cGvHD, NRM, relapse and OS between these two 
groups (Ducreux et al., 2018).
8.3.5 | Direction of HLA mismatch
Donor and patient HLA mismatches may be bidirectional, that is 
GVH and HVG or unidirectional. The effect of direction of HLA 
mismatch has been investigated within a cohort of 2,687 unre-
lated donor transplants in patients with malignant disease (Hurley 
et al., 2013). In multivariate analyses, patients receiving a 7/8 (HLA- 
A, B, C, DRB1) matching graft with unidirectional GVH mismatch 
and patients receiving a 7/8 bidirectional mismatch had significantly 
worse TRM; OS and DFS compared with patients receiving a 8/8 
matched transplant. This worse transplant outcome (compared with 
8/8 transplants) was not shared with patients receiving a 7/8 match-
ing graft with unidirectional HVG mismatch.
This difference in outcome observed for the 7/8 HVG mis-
matches is likely caused by the observed reduction in probability of 
acute GVHD observed in this group. No differences were observed 
between the three 7/8 mismatched groups and the 8/8 matched 
transplants with other clinical outcomes including engraftment, re-
lapse and chronic GVHD. These findings support selection of a 7/8 
HVG mismatch over a 7/8 bidirectional or 7/8 GVH mismatch un-
related donor for patients with malignant disease. This finding has 
not been reproduced in patients with nonmalignant disorders, nor 
in patients receiving UCB transplants, who may be at higher risk of 
graft rejection. For patients at risk of graft rejection, avoidance of 
HVG mismatches is desirable.
This study did not confirm previous data reported by the Seattle 
group in 2001 where transplants mismatched in the HVG direction 
were associated with lower neutrophil engraftment and secondary 
graft failure. However, the demographics of the transplant group 
in the latter study differ in that the transplants were bone marrow 
and HLA matching was not completely at high resolution (Petersdorf 
et al., 2001). HVG and GVH directional mismatches are illustrated in 
Table 4.




A *02:01 *02:01, *03:01
B *07:02, *08:01 *07:02, *08:01
C *05:01, *07:02 *05:01, *07:02
DRB1 *04:01, *15:01 *04:01, *15:01
DQB1 *03:01, *06:02 *03:01, *06:02
DPB1 *03:01, *04:01 *04:01
Note: The patient and donor differ with an HLA- A mismatch in the HVG 
direction and an HLA- DPB1 mismatch in the GVH direction.
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8.3.6 | NIMA/NIPA
Exposure of the patient to NIMA via transplacental trafficking of ma-
ternal and foetal cells during pregnancy may result in tolerance to 
these antigens when present on cells transplanted to the patient, thus 
reducing HVG immune responses. Additionally GVL reactions may be 
enhanced resulting in lower relapse rates. In a study of 118 patients 
receiving haploidentical transplants, an increase in 5- year event- free 
survival due to reduced relapse and reduced TRM was observed when 
the donor was the mother, compared with the donor being the father 
(Stern et al., 2008). This reduced relapse rate in recipients of maternal 
HPC is independent of NK cell allo- reactions. In contrast, multivari-
ate analyses of 1,210 haploidentical transplants in China have shown 
that transplants where the mother is the donor have increased NRM, 
aGVHD and decreased survival compared with transplants where 
the father is the donor. In this study, a sibling donor with NIMA mis-
matches was deemed the optimum donor (Wang et al., 2014).
The EBMT consensus recommendations (Ciurea et al., 2020) 
concluded that NIMA- mismatched siblings may be preferred over 
NIPA- mismatched ones in T- cell replete haploidentical donor trans-
plants with ATG but that it remains unclear whether this immuno-
logic tolerance is associated with better outcomes in either T- cell 
replete haploidentical donor transplants with PTCy or T- cell deplete 
haploidentical donor transplants. NIMA and NIPA in UCB trans-
plants is discussed in Section 9.2.5.5.
8.3.7 | Other MHC matching
MHC haplotype matching has also been reported as beneficial in 
related and unrelated donor HPCT, by reducing the incidence of 
aGVHD (Petersdorf et al., 2013). HLA class I and II genes are sep-
arated by the MHC class III region, also described as the gamma 
block, which contains genes encoding immune regulatory proteins 
including the complement components Bf, C2 and C4. Comparison 
of SNPs within the complement C4A and C4B genes did not identify 
any association between SNP mismatching and transplant outcome 
(Clancy et al., 2019; Getz et al., 2020). Similarly, no significant as-
sociations between gamma block mismatching and unrelated donor 
HPCT outcomes were observed in a large retrospective cohort from 
the CIBMTR (Askar et al., 2019), nor in multivariate analysis of a 
single- centre cohort (Maskalan et al., 2020).
9  | SELEC TION OF UNREL ATED 
UMBILIC AL CORD BLOOD UNITS
9.1 | Use of UCB
UCB is an alternative source of HPCs that can be used to treat patients 
with both malignant and nonmalignant disorders (Ballen, 2017; Ballen 
et al., 2013). An early study undertaken by the CIBMTR- Eurocord 
showed similar survival outcomes comparing paediatric patients 
receiving HLA- identical UCBT with patients receiving HLA- identical 
sibling donor transplants. This study highlighted delayed granulocyte 
and platelet engraftment in UCBT recipients but also demonstrated 
a reduction in both acute and chronic GVHD (Rocha et al., 2000). 
Similarly, a comparison of unrelated HLA- mismatched UCBT to 
matched unrelated adult donors transplants in paediatric patients 
demonstrated recipients of the UCBT experienced delayed engraft-
ment but less acute and chronic GVHD with a similar relapse rate, OS 
and LFS (Rocha et al., 2001). Similar OS and significantly improved 
cGvHD and relapse- free survival were reported for adult patients with 
different malignant conditions after UCBT compared with matched 
sibling PBSC in a single- centre study in Colorado (Sharma et al., 2020).
The use of UCB was initially restricted to children due to the low 
cell doses obtained and poorer results obtained with adult recipients 
(Laughlin et al., 2001). However, the selection of UCBs with higher 
cell doses and the success with infusion of two UCBs to adult re-
cipients (dUCBT) giving comparable results to matched related and 
matched unrelated donor transplants (Brunstein et al., 2010) to-
gether with improved conditioning protocols has led to UCB being 
a source of HPCs for both children and adults (Barker et al., 2003; 
Scaradavou et al., 2013).
More recently, UCBT has been shown to provide improved out-
come for patients (paediatric and adult) transplanted in the presence 
of minimal residual disease. Significantly higher OS and lower risk 
of relapse was observed in UCBT recipients compared with re-
cipients of HLA- mismatched unrelated donor transplants (Milano 
et al., 2016). Similarly, outcomes for older patients (>50 years) re-
ceiving RIC transplants were comparable when the donor source 
was either matched sibling, unrelated donor or UCB, although there 
was an observed increase in TRM and reduced LFS in the recipi-
ents of UCBT (de Latour et al., 2013; Weisdorf et al., 2014). A joint 
CIBMTR/EBMT/EUROCORD study looking at transplant outcome 
for patients transplanted with FMS- like tyrosine kinase 3+ (FLT3+) 
acute myeloid leukaemia (AML) concluded UCB donor options as ac-
ceptable in the absence of an HLA- matched sibling, as the relapse 
risks were similar, although UCB was associated with higher NRM, 
but also lower chronic GVHD (Ustun et al., 2017).
The reduced incidence and severity of acute and chronic GVHD 
observed following UCBT, and comparable outcome data have al-
lowed the use of mismatched UCB donors which would exceed the 
mismatches accepted in related or unrelated adult donor transplants. 
This has enabled transplantation of patients who do not have an ap-
propriately matched or mismatched adult donor and has significantly 
enhanced the transplant options for patients from Black, Asian and 
Minority ethnicities where unrelated donor options are reduced. 
Although a decrease in UCBT has been observed in the last few years, 
concomitant with an increase in the use of haploidentical donors 
(Passweg et al., 2020), UCB donations remain an important source 
of stem cells for many patients. This has been highlighted during the 
worldwide SARS- CoV- 2 pandemic in 2020 whereby the clinical and 
logistical utility of having a domestic donor HPC source available with-
out the need for international flights or donor medicals has been ad-
vantageous. Over the past 5 years, UCB provisions for UK patients 
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remained at approximately 10% of all stem cell products shipped to 
UK transplant centres. Since the start of the SARS- CoV- 2 pandemic in 
March 2020, a significant increase in UCB unit search and reservations 
have been made, reflecting the use of UCB as a legitimate backup op-
tion by UK transplant centres. As the overall number of UK patients 
receiving HPCT decreased by approximately 10% between April and 
October 2020 compared with the previous year, the number of UCB 
shipments increased by 48% (Anthony Nolan, unpublished data).
9.2 | The UCB unit search process
A search for an UCB unit can be undertaken simultaneously with an 
adult unrelated donor search. This is essential if the patient has a 
rare HLA type or if a transplant is required to be expedited. Within 
the UK, a joint Anthony Nolan and BBMR UCB search report is pro-
duced when requested. International UCB units are available from 
the WMDA ‘Search & Match’ service, and a search report of these 
will be provided along with the UK UCB search results. Additional 
information on UCB units stored within CBB in the USA can be 
obtained via searching the NMDP. As most UCBT are undertaken 
with a degree of HLA mismatching between the patient and the 
transplanted UCB unit, all patients should be screened for HLA al-
loantibodies prior to undertaking UCB selection. The role of HLA 
alloantibodies is discussed in detail in Section 10.
It is suggested that a shortlist of up to 10 UCB units should be 
produced for each patient. These cords are selected based on the 
information extracted from the search reports. Minimally, the search 
results will provide the TNC count and HLA type, with many UCB 
units also having data on CD34+ cell counts. In the majority of cases, 
the search report will also contain information about the accredita-
tion status of the relevant CBB.
9.2.1 | TNC
The TNC of the UCB unit is recognized as having a significant impact 
on the outcome of UCBT. An association between HLA mismatch and 
TNC with TRM was first published by Barker et al. (2010). Several 
years later, a large study found that NRM was increased in recipients 
who received a UCBT with <3 × 107/kg TNC, such that the group 
recommended prioritizing a minimum pre- freeze TNC of 3 × 107/kg 
followed by HLA allele match (Eapen et al., 2014). Recent NMDP/
CIBMTR guidelines confirm the minimum TNC dose of 3 × 107/kg 
(Dehn et al., 2019). It has also been found that increasing the infused 
TNC dose abrogates, to some extent, the presence of HLA mis-
matches. The UK cord selection guidelines recommend increasing the 
TNC from a minimum of 3.0 × 107/kg for 8/8 HLA allele- matched UCB 
to 5.0 × 107/kg for 5– 7/8 HLA match (Hough et al., 2016). NMDP/
CIBMTR guidelines did not mention increasing cell dose beyond 
3 × 107/kg to compensate for HLA mismatch (Dehn et al., 2019), but the 
American Society for Transplantation and Cellular Therapy (ASTCT) 
guidelines for UCB unit selection (Politikos et al., 2020) recommend 
increasing the TNC threshold to 4.0– 5.0 × 107/kg for nonmalignant 
diseases. Achieving this minimum cell dose in paediatric patients is 
rarely an issue, but becomes more problematic for older children and 
adults, where the recipient weight excludes the possibility of a single 
UCBT due to insufficient cell dose with the majority of available UCB 
units. In these cases, dUCBT is a successful transplant option. More 
data are needed to clarify the balance between TNC dose and HLA 
mismatch and how increased TNC can compensate HLA mismatch for 
malignant and nonmalignant conditions, and to resolve some contra-
dictions with the published UK cord selection guidelines.
9.2.2 | HLA matching
Since a joint Eurocord and CIBMTR study, on a predominantly paedi-
atric cohort of 1,568 single UCBT for haematological malignancies, 
demonstrated that HLA allele mismatches were associated with a 
threefold increase in risk of NRM (Eapen et al., 2014), further stud-
ies have evaluated the impact of HLA allele mismatches in other 
clinical conditions. These studies support a significant impact of 
HLA mismatching on clinical outcome in paediatric patients with 
nonmalignant disorders where mortality was higher in transplants 
mismatched for two or more alleles compared with HLA- matched 
and single mismatched transplants (Eapen et al., 2017). Similarly 
fewer HLA allele mismatches predicted more favourable outcomes 
in transplants for inherited metabolic disorders (Mallhi et al., 2017).
The impact of allele level mismatching on outcome in dUCBT was 
described in a single- centre cohort of 133 patients transplanted for 
haematological malignancies where 2- year TRM was significantly 
increased in patients with ≤4/8 allele match (60%), compared with 
5– 6/8 match (39%) and 7– 8/8 match (0%) (Oran et al., 2015). This 
study supports matching at least 5/8 HLA- A, B, C, DRB1 alleles to 
reduce TRM. In contrast, a separate single- centre study, also with 
patients receiving a dUCBT for haematological malignancy, found 
that patients receiving a 2– 5/10 HLA match UCBT had lower relapse 
risk and treatment failure compared with better matched transplants 
(Brunstein et al., 2016). The NMDP/CIBMTR guidelines recommend 
using UCB units with  ≥4/8 high resolution match for patients with 
haematological malignancies, and  ≥5/8 match for children with 
non-malignant disease. Selecting UCB units with a better HLA match 
is recommended in cases where the TNC and CD34+ doses allow, 
otherwise, dose optimisation is considered more important (Dehn 
et al., 2019). For non-malignant diseases a higher HLA match has been 
associated with improved UCBT outcomes (Politikos et al., 2020).
An outcome of dUCBT is that only one of the two transplanted 
units will maintain long term engraftment. A retrospective study under 
the auspices of EBMT could not predict unit dominance but did observe 
that compared with better matched ‘winning’ cords (≥5/6), the poorer 
matched ‘winning’ cords (≤4/6) had lower LFS; lower OS; increased 
NRM and increased aGVHD, thus recommending selection of units 
with lower number of HLA mismatches (Tozatto- Maio et al., 2018).
Larger, multicentre studies are required to resolve the apparent 
disparate data regarding the impact of HLA matching in double cord 
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transplantation. In the meantime, H&I laboratories are recommended 
to continue to identify the best HLA- matched UCB unit possible for 
their patients, without compromising TNC and CD34+ cell doses.
To date, the impact of allele matching in single and dUCBT has 
considered HLA- A, HLA- B, HLA- C and HLA- DRB1 loci. There are 
no data regarding HLA- DQB1, although if DRB1 matching is under-
taken, this will promote HLA- DQB1 matching via linkage disequilib-
rium. There is also no definitive evidence to support the selection of 
HLA- DPB1- matched or HLA- DPB1- mismatched UCB units. In a study 
of 1,157 single UCBT for haematological malignancies, the Japanese 
Cord Blood Transplantation Histocompatibility Research Group 
found HLA- DPB1 allele mismatches associated with a significant re-
duction in leukaemia relapse, whereas other HLA loci mismatches 
were not (Yabe et al., 2018). In addition, the HLA- DPB1 mismatch did 
not affect the risk of acute GVHD, engraftment or mortality, leading 
the authors to suggest that HLA- DPB1 mismatch increased the GVL 
effect without induction of severe acute GVHD or deterioration of 
survival rate. Further data are required before indicating the selec-
tion of an HLA- DPB1- mismatched UCB as the preferable option. The 
role of allele matching for HLA- DQB1 and HLA- DPB1 will only be 
conclusively ascertained following large- scale retrospective analysis.
Evidence indicates that inter- unit HLA matching is not required 
(Brunstein et al., 2017), although this study only considered HLA- A, 
B low- resolution and DRB1 high- resolution typing, excluding the po-
tential impact of allele mismatching as well as mismatching for HLA- 
C, HLA- DQ and HLA- DP. In order to accurately dissect the impact of 
HLA matching, it is important to know the true level of matching, and 
therefore, it is recommended that high (or greater) resolution HLA 
typing is performed for HLA- A, HLA- B, HLA- C, HLA- DRB1, HLA- 
DQB1 and HLA- DPB1 for all recipients and UCB units utilized in a 
single or double UCBT to allow retrospective analyses of outcome 
data. This is also necessary for accurate consideration of the impact 
of recipient HLA alloantibodies.
Direction of HLA mismatch
The effect of direction of HLA mismatch was investigated in a co-
hort of 1,202 single UCBTs. Unidirectional mismatches were iden-
tified and classified as either GVH or HVG (rejection) mismatches. 
Engraftment was faster in patients with GVH unidirectional mis-
matches compared to patients with single bidirectional mismatches 
HR = 1.6, p = .003). Other benefits to unidirectional mismatches 
included lower TRM, lower overall mortality and treatment failures. 
The HVG unidirectional mismatches exhibited slower engraftment, 
higher graft failure and higher relapse rates (Stevens et al., 2011).
However, these findings were not confirmed in a Eurocord study 
of 1,565 single UCBT for malignant disease. In this cohort, one or 
two HLA mismatches in the GVH or HVG direction were not associ-
ated with NRM and survival (Cunha et al., 2014).
A Japanese study of 2,977 single UCBT for malignant disease did 
not find any significant association with overall mortality for trans-
plants performed with unidirectional mismatches in either GVH or 
HVG direction (Kanda et al., 2013). GVH mismatches were associ-
ated with a lower incidence of NRM for paediatric recipients only.
The HLA data included in these three studies were not high res-
olution and HLA- C, HLA- DQ and HLA- DP matching was not con-
sidered; therefore, additional mismatches not accounted for in the 
analysis are likely. The role of HLA alloantibodies was not addressed. 
The impact of NIMA matching (discussed in Section 9.2.5.5) was 
included in the study of Stevens et al. (2011), but not in the oth-
ers. These studies are also complicated as multiple mismatches are 
present and not all mismatches (in the same direction) will impact 
the same biological effect. Further work is required to elucidate the 
impact of unidirectional mismatches.
Verification typing
All UCB units must receive verification HLA typing (VT) prior to infu-
sion. VT is performed on a segment (if available) by the CBB as part 
of the release process. VT on a segment of the shipped UCB unit 
should be performed by the transplant centre upon receipt of the 
unit prior to reinfusion to confirm UCB identity. If a segment is not 
available, the empty UCB bag should be sent to the H&I laboratory 
for a VT to be performed on DNA extracted from residual donor 
cells in the bag.
9.2.3 | CD34+ cell count
The pre- cryopreserved CD34+ cell dose is a marker for haematopoi-
etic progenitor potential post- infusion and is a critical factor to con-
sider for optimal UCB unit selection. Considering TNC dose with no 
knowledge of the CD34+ cell dose can be misleading. It is possible 
that some units selected on adequate TNC dose can contain danger-
ously low CD34+ cell doses, especially if they are not red blood cell 
(RBC) depleted (Barker et al., 2017). The CD34+ cell dose is usually 
provided together with HLA and TNC data, in the UCB search report, 
and can be used to aid then ranking of UCB units. The speed of neu-
trophil, platelet and RBC engraftment has been shown to be signifi-
cantly correlated with pre- cryopreserved CD34+ cell dose (Konuma 
et al., 2017). The risk of developing extensive chronic GVHD was 
associated with the highest CD34+ cell doses, but this did not nega-
tively impact on OS. The pre- cryopreserved CD34+ cell dose can 
reliably predict the post- thaw CD34+ cell yield in most units and 
was shown to be an independent predictor of neutrophil engraft-
ment in a study of single UCB transplants (Sanz et al., 2010). This 
study indicated a pre- cryopreserved CD34+ cell dose of 1.5 × 105/
kg of patient weight as a recommended threshold for faster neutro-
phil engraftment. The same threshold is recommended by NMDP/
CIBMTR (Dehn et al., 2019). The ASTCT guidelines for UCB unit 
selection (Politikos et al., 2020) recommend to select, even higher 
CD34+ cell dose when possible, that is >2.0 × 105/kg for a single 
UCBT. Eurocord gives a range and recommends 1.0– 1.7 × 105/
kg of pre- cryopreserved CD34+ cells in single UCBT (Querol & 
Rocha, 2019). The same findings were demonstrated for dUCBT 
where pre- cryopreservation and post- thaw viable CD34+ cell doses 
were independent statistically significant characteristics associated 
with engraftment, with an arbitrary pre- cryopreservation CD34+ 
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cell dose of ≥0.7 × 105/kg for each unit identified as optimal, and 
0.5 × 105/kg as minimum (Purtill et al., 2014). In Eurocord recom-
mendations, the combined CD34+ cell dose in dUCBT is recom-
mended to be in excess of 1.8 × 105/kg (Querol & Rocha, 2019) with 
the recent NMDP/CIBMTR guideline suggesting 1 × 105/kg mini-
mum for each cord (Dehn et al., 2019) and >1.5 × 105/kg for each 
cord where possible (Politikos et al., 2020).
The UK recommendations for single UCB unit selection suggest 
different CD34+ cell dose thresholds depending on patient condi-
tion: ≥1 × 105/kg for malignant, and ≥1.7 × 105/kg for nonmalig-
nant disorders. For dUCBT, the combined CD34+ cell dose should be 
≥1.8 × 105/kg (Hough et al., 2016).
Analysis of the NMDP CBU inventory on the pre- 
cryopreservation CD34+/TNC ratio as an indicator of the ex-
pected CD34+ content showed that high TNC dose does not 
necessarily correlate with high CD34+ dose. The study recom-
mends using both TNC and CD34+ cell doses as criteria in UCB unit 
selection. The ASTCT guidelines for UCB unit selection (Politikos 
et al., 2020) mention expected median CD34+/TNC ratio of 0.34% 
(range 0.23– 0.48). It is recommended to question and verify cases 
where reported CD34+ cell dose is disproportionally high (Barker 
et al., 2019).
9.2.4 | UCB bank accreditation status
Quality and safety of the UCB unit have paramount importance 
in UCBT outcome, and thus, selecting units from the reliable ac-
credited CBBs is recommended. The NetCord— Foundation for 
the Accreditation of Cellular Therapy (FACT) accreditation is 
a gold standard giving reassurance that the providing CBB fol-
lows agreed quality standards (http://www.factw ebsite.org). 
Separately from FACT, the CBB can be accredited by the AABB, 
which is also a reputable body with a slightly different set of 
standards. It is recommended to avoid nonaccredited CBBs where 
possible (Hough et al., 2016; Politikos et al., 2020) or use extra 
caution in assessing UCB quality and safety information when it 
is not avoidable. Units from non- NetCord- FACT- accredited CBBs 
were more likely to have poorer recovery and together with units 
with cryovolumes outwith 24.5– 26 ml had an increased likeli-
hood of having poor post- thaw viability (Purtill et al., 2014). If 
the accreditation status of the CBB is not marked on the Search 
Report, this information will be available on the UCB unit report 
requested from the bank.
9.2.5 | Secondary criteria in UCB unit selection
For each of the UCB units shortlisted, a request should be made to 
the CBB, via the Anthony Nolan in the UK, for a detailed unit report. 
This will give additional information on factors including quality pa-
rameters further describing potency and safety of the UCB unit that 
can be used to aid selection:
Potency of an UCB unit
The ability of the cells in an UCB unit to regenerate the haemat-
opoietic system in a recipient should be assessed holistically looking 
at a range of parameters. In addition to TNC and CD34+ cell dose, 
these include TNC recovery, viability and capability to form colonies 
in vitro.
TNC recovery describes the percentage of cells recovered after 
thawing a segment attached to a unit. According to the NetCord- 
FACT Standards, v7 (2020), TNC recovery should be no less 
than 60% of the pre- cryopreservation TNC. The Food and Drug 
Administration in the United States of America (FDA) requires ≥70% 
TNC recovery and ≥50% CD34+ cell recovery. Post- thaw information 
from attached segments is not always available at UCB unit selection 
stage. In the majority of cases, especially if the CBB is NetCord- FACT 
accredited, post- thaw cell counts are part of the quality control (QC) 
releasing tests.
Cell viability is another important parameter in UCB unit po-
tency evaluation as it indicates the percentage of live cells that are 
able to divide. There are different methods of viability assessment, 
the most common being 7- aminoactinomycin D (7- AAD) staining. 
Viability of the UCB cells is fundamental for successful engraftment. 
It was clearly shown in the dUCBT setting that increasing CD34+ 
viable cell dose correlated with increased engraftment (Scaradavou 
et al., 2010). NetCord- FACT standards (2020) require TNC viability 
to be ≥85% post- processing (pre- cryopreservation) and post- thaw 
CD34+ viability ≥70%. Some CBBs provide Annexin V viability, which 
can detect apoptotic cells in the UCB unit. When available, it is rec-
ommended to consider the results of both 7- AAD and Annexin V 
methods.
Colony forming unit (CFU) defines the number of viable cells capable 
of proliferating in vitro to form colonies in agar. In a multivariate anal-
ysis of 435 UCB transplants performed at Duke University Medical 
Center (USA), CFU was shown to be the best predictor of engraftment. 
A threshold of 19.1 × 104 total CFU/kg in a fresh sample and 3.3 × 104 
total CFU/kg in a thawed sample were considered good prognostic 
factors for UCBT outcome (Page et al., 2011). Although a numerical 
CFU characteristic gives an opportunity to calculate the UCB unit po-
tency for a particular patient weight, not all CBBs will provide these 
data, as NetCord- FACT Standards require just the evidence of CFU 
growth on a post- thaw segment or representative sample as ‘growth 
or positive result for potency’. Some CBBs provide post- processing and 
even post- thaw CFU data in UCB unit reports. Alternatively, it is pro-
vided as a part of QC releasing tests.
Clonogenic Efficiency (CLONE) is a combined parameter for CBU 
potency assessment to ‘holistically’ describe the ability of stem cells, 
usually measured as the percentage of CD34+ cells, to grow into col-
onies indicating their projected effectiveness in repopulating a re-
cipient's haematopoietic system. It is measured by the ratio between 
post- thaw CFU and pre- cryopreservation CD34+ cells. It is suggested 
that this value should be higher than 10%, and any decrease, below 
this threshold, indicates impairment of the functional ability of CD34+ 
cells and therefore the unit should be considered at risk of engraft-
ment failure (Querol et al., 2010). A later study showed that CLONE 
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≥20% predicted faster neutrophil and platelet engraftment and con-
tributed to a decrease in the nonrelapse mortality (Castillo et al., 2015). 
It is recommended to assess CBU potency holistically looking at pre- 
cryopreservation TNC recovery (≥60%); post- thaw CD34+ viability 
(≥70%); post- thaw CFU (reported growth, ideally 3.3 × 104 total CFU/
kg) and CLONE, if available (minimum 10%, ideally ≥20%).
ABO matching (see also Section 11.2)
There are no conclusive studies showing a beneficial impact of ABO 
matching on UCB transplant outcome, but in general, a match is 
preferred due to fewer risks of adverse events at time of infusion 
of UCB cells. In 2015, the Eurocord group presented the results of 
multivariate analysis demonstrating ABO major and minor incompat-
ibility resulting in a significant increase of TRM in patients receiving 
dUCBT (Rocha et al., 2015). Based on Eurocord data, EBMT recom-
mend where possible to avoid ABO incompatible units in dUCBT 
(Querol & Rocha, 2019).
UCB unit age
Although some published studies demonstrated a lower correla-
tion between pre- cryopreserved and post- thaw CD34+ cell doses 
in units banked before 2005 (Purtill et al., 2014), the general con-
sensus is that UCB age is not a factor of inferior potency. Analysis 
of 530 single UCBTs, received by patients in the USA, with acute 
leukaemia, did not identify differences in haematopoietic recovery 
or OS based on the years of banking experience, year of collection of 
UCB unit or the length of time the UCB unit was stored at the CBB 
(Ballen et al., 2015). Nevertheless, older units have a higher likeli-
hood of lacking important test results as the list of mandatory IDMs 
has changed over the years reflecting new scientific findings. Recent 
units (those collected in last 10– 15 years) are more likely to have un-
dergone more optimized procedures than those collected in earlier 
years (Politikos et al., 2020).
UCB processing method
Variations in UCB manufacturing are common. Nowadays, the ma-
jority of CBBs use automated processing methods, but manually 
processed UCB units are still available in the worldwide inventory. 
Compared with automated processed units, manually processed 
UCB units were reported to be associated with significantly lower 
day 28 neutrophil recovery after single UCBT (Ballen et al., 2015). 
A concern of UCB processing is the method of RBC depletion. 
Manually processed UCB units are more often RBC replete and con-
tain 28– 70 ml of RBC versus 1– 15 ml in RBC reduced products. It 
is expected that 5%– 20% of RBCs would undergo lysis during the 
freeze- thaw cycle; thus, the infusion of RBC lysate may bring cir-
culating free haemoglobin to toxic levels. The infusion dose of UCB 
RBCs ≤0.4 ml/kg is considered safe (Akel et al., 2014).
NIMA/IPA matching
A phenomenon of sensitization and lasting tolerance following foetal 
exposure to NIMAs has been described in relation to its impact on 
UCBT outcome. An additional match on NIMAs in HLA- mismatched 
UCBTs was reported to be associated with higher neutrophil re-
covery, lower NRM and higher OS in several studies performed by 
the New York Blood Centre (van Rood et al., 2009) and Eurocord- 
CIBMTR (Rocha et al., 2012). Considering NIMAs as permissive mis-
matches significantly increases the potential number of ‘virtual’ 5/6 
and 6/6 UCB matches for recipients (van der Zanden et al., 2014) in-
cluding patients with rare HLA alleles and haplotypes, thus increas-
ing chances of finding a suitable graft for Black, Asian and Minority 
Ethnic patients (Powley et al., 2016). This principle has been applied 
by the Hellenic Cord Blood Bank (Panagouli et al., 2018).
Evidence, albeit indirect, of maternal cell microchimerism pres-
ent in UCB units that may mediate a GVL effect in UCBT suggests 
a match on Inherited Paternal Antigens (IPAs) may also be beneficial 
(van Rood et al., 2012), but has not been proven by other studies 
(Politikos et al., 2020).
Advice on UCB unit selection is described in Section 14.
10  | HL A ALLOANTIBODIES
The presence of HLA alloantibodies in recipients directed against 
HLA mismatches of their donors has been linked with primary GF 
characterized by the absence of initial donor neutrophil engraft-
ment. As such patients receiving an HLA- mismatched transplant 
from any donor source must be assessed for the presence of cir-
culating HLA alloantibodies that may react with HLA mismatches 
of the donor (DSA). This is particularly a problem in haploidentical 
transplantation when there are multiple HLA class I and class II 
mismatches, and many patients will have been sensitized by blood 
products. Additionally, female patients are at increased risk to be 
sensitized due to pregnancy and this poses a problem if children 
are considered as haploidentical donors. Overall approximately 
one third of patients requiring a mismatched donor will possess 
HLA alloantibodies reactive with one or more HLA specificity (un-
published data, Anthony Nolan). Several studies have indicated 
that DSA in the recipient are a risk factor for delayed and nonen-
graftment in mismatched unrelated donor, haploidentical donor, 
and single and dUCB transplants (reviewed in Morin- Zorman 
et al., 2016). The data are conflicting with regard to UCBT with 
some groups reporting sustained engraftment in the presence of 
HLA antibodies (Brunstein et al., 2011; Dahi et al., 2014). Also, a 
study of patients receiving transplants for nonmalignant disorders 
did not find an association between presence of DSA and GF and 
OS (Woolfrey et al., 2019). The UK cord guidelines recommend that 
all recipients being considered for HLA- mismatched transplants 
(including HLA- DP mismatches) are screened for HLA- specific an-
tibodies and cognate antigens should be avoided, especially where 
antibodies are identified at ‘high’ level (Hough et al., 2016). This 
approach is supported by the recent NMDP/CIBMTR guidelines 
(Dehn et al., 2019).
Assessment of donor- specific HLA antibodies for hap-
loidentical transplants has been addressed by the EBMT (Ciurea 
et al., 2018), who recommend that all candidate patients for 
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haploidentical (or HLA- mismatched) donor transplants should be 
tested for the presence of DSA. These guidelines recommend the 
consideration of HLA- DRB3, HLA- DRB4, HLA- DRB5, HLA- DQA1, 
HLA- DPA1 and HLA- DPB1 which may be outside of usual donor 
selection protocols but should be considered in the context of an 
alloantibody testing strategy. The guidelines specify that for as-
says that define positivity based on Mean (or median depending 
on commercial assays utilized) Fluorescence Intensity (MFI), pa-
tients possessing DSA with MFI >1,000 require additional testing 
to determine whether the DSA are complement binding and/or 
recommend cell- based (e.g. flow cytometry) cross- match assays to 
further assess the risk to the transplant. DSA that are complement 
binding and/or cause a positive cross- match are likely to have MFI 
>5,000 and these are predicted to pose a higher risk to the trans-
plant recipient. The MFI values quoted may not be relevant to all 
antibody detection assays, and all laboratories should evaluate the 
sensitivity and specificity of the assays utilized and determine ap-
propriate cut- off values.
If no other donor is available, it is recommended that the patient 
undergoes a desensitization protocol to reduce circulating DSA. Not 
all studies show a detrimental impact to transplant outcome in the 
presence of DSA. Currently, there are no data to stratify any differ-
ential impact of HLA class I versus class II DSA or the cumulative im-
pact of multiple antibody specificities. The clinical impact of historic 
versus current DSA is unknown; however, a patient who has had 
historic DSA but is currently negative could be considered to have 
undergone natural desensitization. A differential clinical impact due 
to cause of sensitization, that is pregnancy or transfusion or other 
source, is also unknown.
At present, there is no formal testing of donors for the pres-
ence of antibodies reactive with HLA mismatches of the recipi-
ent; recipient- specific antibodies (RSA). One single- centre study 
has described an increased incidence of either aGVHD or cGVHD 
in patients transplanted with donors who were sensitized to HLA 
class II, predominantly mismatched HLA- DPB1 alleles (Delbos 
et al., 2016). It has been reported that donor- derived HLA anti-
bodies can be detected post- transplant in patients transplanted 
with donors that are positive for HLA antibodies which suggests 
they could impact on engraftment in HLA- mismatched transplants 
(Taniguchi et al., 2012).
If a mismatched donor is being considered for transplant, the 
patient should be tested for HLA antibodies before donor verifica-
tion typing samples are requested, or workup tests are performed 
on an UCB unit. HLA antibody testing should be repeated prior to 
the final donor being selected for workup, and multiple testing is 
recommended to monitor the dynamic antibody response. This is 
particularly relevant for patients undergoing desensitization or an-
tibody reduction treatment or in the presence of continued adminis-
tration of blood products and where a significant delay to transplant 
has occurred. For patients being considered for clinical trials, where 
the presence of DSA is an exclusion criteria, the H&I Laboratory 
should be made aware of the trial protocol determining the exclusion 
threshold MFI and relevant testing timelines.
11  | NON- HL A FAC TORS TO BE 
CONSIDERED FOR REL ATED AND 
UNREL ATED DONOR SELEC TION
11.1 | Cytomegalovirus
Cytomegalovirus (CMV) infection can cause significant complica-
tions post- transplantation. CMV disease affects different organs 
including lung (pneumonia); liver (hepatitis); gut (gastroenteritis); eye 
(retinitis) and the brain (encephalitis). Even with improvements in 
anti- viral prophylactic therapies, CMV seropositivity remains associ-
ated with an adverse prognosis and is still a major cause of morbid-
ity and mortality in allogeneic HPCT (reviewed in Ljungman, 2014). 
CMV positivity can be transmitted from a positive donor to a nega-
tive patient and patients who are CMV- positive pre- transplant are 
susceptible to CMV reactivation post- transplant.
A large study undertaken by EBMT of 16,628 allo- transplanted 
acute leukaemia patients reported that donor or recipient CMV se-
ropositivity (versus donor and recipient CMV seronegativity) was as-
sociated with a significant decrease in LFS and OS with an increase in 
NRM and a small increase in relapse incidence. The negative impact 
on DFS and OS held up in multivariate analyses. There was no ef-
fect of CMV status on acute and chronic GVHD. CMV- seropositive 
patients receiving transplants from CMV- seropositive donors had a 
significantly better OS compared with CMV- seropositive recipients 
of a CMV- seronegative graft, with no difference in LFS observed 
(Schmidt- Hieber et al., 2013).
The negative impact of CMV- seronegative patients receiving 
CMV- seropositive products from unrelated donors was confirmed 
in a second EBMT study of transplants performed in 20,193 CMV- 
seronegative patients. However, a similar effect was not observed 
in related donor transplants (Ljungman et al., 2014). In this study, 
CMV- positive patients receiving myeloablative transplants from 
CMV- positive donors had improved OS and a decreased NRM, com-
pared with CMV- negative donors, but no benefit was seen for pa-
tients receiving RIC transplants.
Two smaller studies of patients transplanted for B- cell lymphoma 
(Mariotti et al., 2014) and myeloma (El- Cheikh et al., 2013) did not 
identify any impact of CMV serostatus on outcome.
The impact of multiple donor factors including CMV on sur-
vival was investigated in a multicentre study of 1,271 UK patients 
transplanted with an unrelated donor for malignant disease (Shaw 
et al., 2014). Patients who were CMV seropositive at the time of 
transplant had a reduced median survival (1.7 years) compared with 
CMV- seronegative patients (2.5 years). The donor and patient CMV- 
matching status had a significant effect with median survivals of 2.8, 
2.2, 1.5 and 1.1 years in the categories of neg/neg, pos/pos, neg/
pos and pos/neg.
Analysis of 29,349 CMV- seropositive transplant recipients 
identified within the EBMT registry found no effect of donor CMV 
status on outcome for transplants performed with a matched or 
mismatched family donor (Ljungman et al., 2014). An effect was 
observed for CMV- seropositive patients receiving transplants from 
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unrelated donors with lower relapse mortality observed albeit at 
borderline significance when a CMV- seropositive donor was used. 
For patients receiving myeloablative conditioning better OS, lower 
NRM and improved relapse- free survival outcomes were observed 
when the donors were CMV seropositive. Similar effects were not 
observed for patients transplanted with RIC. The retention of host 
CMV- specific T- cell function in patients receiving RIC is an explana-
tion for the lack of an association observed (Ljungman et al., 2014).
More recently, a UK study of 1,271 patients receiving unre-
lated donor T cell- depleted grafts demonstrated CMV mismatching 
was significantly associated with inferior survival. Combining HLA 
matching and CMV matching suggested that CMV matching could 
counteract the effect of HLA mismatching, whereas patients receiv-
ing both HLA- and CMV- mismatched transplants have worse overall 
survival (Shaw et al., 2017).
The British Committee for Standards in Haematology, the British 
Society of Blood and Marrow Transplantation and the UK Virology 
Network guideline for Management of cytomegalovirus infection in 
haematopoietic stem cell transplantation recommend CMV match-
ing between patient and donor (Emery et al., 2013). In 2019, the 
National Institute for Health and Care Excellence (NICE) approved 
Letermovir, a novel viral terminase inhibitor, for the prophylaxis of 
CMV reactivation and disease, in adult CMV- seropositive recipi-
ents of an allogeneic HPCT for the first 100 days post- transplant 
(https://www.nice.org.uk/guida nce/TA591). In clinical trials, this 
drug has been shown to be effective in reducing both CMV infec-
tion and the need for pre- emptive therapy. In cases where a suit-
able CMV- matched donor cannot be identified, Letermovir offers 
a prohylactic treatment to reduce the risk of CMV reactivation 
for seropositive patients receiving a seronegative donation. As 
knowledge of the impact of letermovir in HPCT increases and more 
randomized clinical trials are conducted, its best use in CMV man-
agement will be further realized (Anderson et al., 2020; El Helou & 
Razonable, 2019).
In contrast, there are conflicting reports for haploidentical donor 
transplantation resulting in no recommendations for donor selection 
based on donor and recipient CMV serostatus for T- cell replete hap-
loidentical transplantation within the recent EBMT review (Ciurea 
et al., 2020).
11.2 | ABO blood group incompatibility
ABO incompatibility (ABOi) between patient and donor is a com-
mon feature of HPCT. The ABOi can be major, minor or bidirectional 
(Table 5). Major ABOi transplants, in particular for blood group O 
patients, can cause delayed red cell engraftment and infrequently 
pure red cell aplasia (PRCA). Reduced- toxicity regimes such as low 
intensity conditioning and graft versus host prophylactics are asso-
ciated with extended host isohemagglutinin production and PRCA 
(Bolan et al., 2001).
Major and minor ABO incompatibilities do not have a significant 
effect on overall survival and incidence of GVHD (reviewed in Booth 
et al., 2013) and do not constitute a major contraindication to donor 
selection. However, there are several single- centre studies that indi-
cate ABOi having an impact on clinical outcome.
Recipients of major and minor ABOi RIC transplants are depen-
dent on red blood cell transfusions for longer compared with ABO 
compatible RIC transplants (Watz et al., 2014). Patients receiving 
major ABOi RIC transplants who then developed persistent recip-
ient type ABO (PRABO) antibodies had a poorer overall survival 
TRM compared with patients receiving major ABO incompatible RIC 
transplants without PRABO (Watz et al., 2014).
An investigation into red cell aplasia, for transplants performed 
between 2007 and 2008, identified 27% of patients received major 
ABOi transplants and 7.5% of these major ABOi transplanted pa-
tients developed PRCA (Aung et al., 2013). Chimerism studies for T- 
cell and myeloid cell lineage and time to engraftment for neutrophil 
and platelets did not differ significantly for the major ABOi patients 
that did, and did not develop PRCA. All patients with PRCA required 
red cell transfusion support for several months and suffered from 
significant iron overload. These complications can be reduced where 
major ABO mismatches are avoided in donor selection.
Therefore in selection of HPC donors, avoidance of major ABOi 
is preferred, but in the absence of a minor ABOi or ABO compat-
ible donor, major ABO incompatibilities can be selected. When a 
blood group O patient is being considered for ABOi transplant, it 
is useful to determine the patient's anti- A and anti- B titres as this 
may help the selection when there is a choice of ABOi donors.
The EBMT guideline for haploidentical donor transplantation 
recommends that donor ABO compatibility should be considered 
and also recommends, when possible, to use peripheral blood do-
nations when there is a major ABO mismatch (Ciurea et al., 2020).
11.3 | Donor sex
Using a male donor has been reported in some studies as having 
a positive effect on long- term survival regardless of the sex of the 
recipient (Gustafsson- Jernberg et al., 2004; Pond et al., 2006) but 
not in others (Lee et al., 2007). Regardless, donor sex selection 
priority is usually given to male donors due to their usually larger 
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size associated with higher HPC counts obtained and also the in-
crease in GVHD reported with female multiparous donors (Kollman 
et al., 2001). A German study of 2,646 transplants performed in pa-
tients with haematological malignancies found that transplants per-
formed with international donors had a worse outcome compared 
to transplants with national donors and male patients transplanted 
with female international donors showed an even higher hazard ratio 
in analysis of OS than other sex- matched groups (Fürst et al., 2013).
In contrast, a multicentre analysis of the effect of donor char-
acteristics on the outcome of 709 RIC transplants (Passweg 
et al., 2011) demonstrated no association between donor age, parity 
and sex matching with transplant outcome, with only HLA matching 
being predictive for survival.
An investigation into the impact of cord blood donor sex com-
patibility has demonstrated no impact on survival in adults with hae-
matological malignancies receiving a myeloablative single unit cord 
blood transplant. However, a higher incidence of chronic GVHD was 
observed in male recipients of female cord blood donors and a lower 
incidence of platelet engraftment in female recipients with male 
cord blood donors (Yuji et al., 2014). These findings require confir-
mation in further studies.
In unmanipulated haploidentical transplantation, Chang 
et al. (2016) concluded that a male donor is preferred with usage of 
anti- thymocyte globulin (ATG) or PTCy, due to the potential for supe-
rior survival of the patient. The more recent EBMT consensus recom-
mendations for donor selection in haploidentical haematopoietic cell 
transplantation (Ciurea et al., 2020) suggest that a male donor should 
be the preferred choice when selecting a haploidentical donor for a 
male recipient, with PTCy. However, the EBMT recommendation also 
highlights conflicting evidence regarding benefits versus detriments 
of using mothers as donors for their children, regardless of the recip-
ient's sex. These apparently conflicting results suggest that perhaps 
the donor's relationship (mother), rather than the donor's gender (fe-
male) has a stronger influence on transplant outcomes.
11.4 | Donor age
Donor age has been a consideration in unrelated donor selection, 
with younger donors being preferentially selected based on factors 
including their predicted better medical fitness to donate; being 
better HLA typed due to being recruited more recently and also on 
early data that indicated better post- transplant outcome (Kollman 
et al., 2001).
Shaw et al. (2018) have followed up on an earlier CIBMTR study 
(Kollman et al., 2016) which showed that transplants performed with 
HLA mismatches and older donors had worse survival. Multiple vari-
ables in two cohorts from nonoverlapping transplant periods were 
analysed. Increasing donor age was the only variable identified in 
both cohorts, in the presence of an HLA- matched 8/8 transplant, as 
having a negative impact on survival.
In their reviews of the effect of donor age on haploidentical 
donor transplants, both Ciurea et al. (2020) and Chang et al. (2016) 
concluded that younger donors were preferable in both T- cell de-
pleted (TCD) and unmanipulated haploidentical donor transplants.
11.5 | NK cell receptors in graft selection
NK cells participate in the defence against infection, malignancy and 
allo- antigens. These reactions are mediated by receptors on the NK 
cells including KIR and NK cell lectin- like receptors that interact with 
HLA and MICA ligands, plus others, on the target cells and as a con-
sequence may impact upon graft outcome. Although evidence of KIR 
influencing HPCT outcome has been accumulating for over two dec-
ades, considering the interactions of NK cell receptors in the trans-
plant setting has been research focussed, rather than as essential for 
routine testing. Changes to clinical practice during this time span, 
particularly the use of T- cell depletion, alongside variation in trans-
plant protocols and methods of genotyping has complicated the 
potential for direct correlation between studies which report con-
flicting observations. The question which remains to be answered 
is whether there is now sufficient evidence available to justify the 
additional economic impact of assessing KIR in the transplant set-
ting to balance improved quality of life and reduced healthcare costs 
managing clinical complications post- transplant. The evidence for 
considering the impact of some or all known NK cell receptors upon 
transplant outcome is assessed, with the main focus upon additional 
steps that can reasonably be taken during the selection process 
which would significantly improve outcome.
11.5.1 | NK cell lectin- like receptors
NKG2D is an activating C- type lectin- like receptor expressed by NK 
cells, CD8+ T cells and γδ+ T cells where it functions to promote cy-
totoxicity including the elimination of malignant cells expressing its 
ligand (Guerra et al., 2008). One of its ligands, the MHC encoded 
MHC class I like molecule, MICA, possesses a dimorphism at amino 
acid 129 within the α2 domain. MICA molecules expressing methio-
nine at this location bind to NKG2D with high avidity promoting 
strong NK and T- cell activation, whereas MICA molecules express-
ing valine bind to NKG2D with lower avidity resulting in weaker 
NK/T- cell activation (Steinle et al., 2001). Data relating to MICA- 129 
mismatching in recipient and donor are conflicting. Mismatching 
for the MICA- 129 dimorphism has been suggested to be associated 
with reduced overall survival, nonrelapse mortality and disease- free 
survival, and increased severe GvHD, compared with MICA- 129- 
matched transplant pairs, but findings are not consistent across 
studies (Askar et al., 2017; Carapito et al., 2016; Wulf et al., 2016; 
Martin et al., 2020; Patel et al., 2020). In addition, the MICA- 129 V/V 
genotype in the donor (but not MICA- 129 mismatching) has been 
indicated to increase the risk of CMV infection and disease post- 
transplant (Patel et al., 2020).
The likelihood of mismatching at MICA- 129 increases if the 
donor is mismatched at HLA- B, which lies in close proximity to 
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the MICA genes. Linkage disequilibrium confounds analysis of the 
MICA- 129- matching effect independently from HLA mismatch, 
and this is also likely to negate any benefit of additional labora-
tory testing, at least in HLA- identical sibling transplants. In un-
related donation, the risk of mismatching at MICA- 129 decreases 
as the level of the HLA matching increases and, as a priority, HLA 
mismatching should be avoided if possible, especially at HLA- B. 
In cases where HLA mismatching is unavoidable, there may be a 
potential for additional matching for the MICA- 129 dimorphism, 
but the benefit to the patient of the additional matching is difficult 
to assess independently of the HLA matching effect. At present, 
there is no available commercial assay to test for this dimorphism, 
which places any testing performed in the research setting until 
streamlined assays and external proficiency testing schemes are 
available. It is an area to monitor, as this could be an interesting 
additional selection criterion if donors of equivalent HLA match 
cannot be separated using alternative algorithms, and if the facili-
ties exist locally to run this as a test.
11.5.2 | Killer- cell immunoglobulin- like receptors 
(KIR)
The KIR gene cluster on chromosome 19q13.4 encodes KIR glyco-
proteins expressed on the surface of NK cells and some subsets of 
T cells. Most KIR initiate either activating or inhibitory signalling 
pathways within the NK cell in response to engaging with their cor-
responding ligand(s). The KIR genes are inherited as haplotypes, 
broadly classified as ‘A’ or ‘B’. Both haplotypes possess four frame-
work genes: KIR3DL3, 3DP1, 2DL4 and 3DL2. KIR A haplotypes are 
highly conserved containing an additional five KIR genes of which 
only one is an activating gene, KIR2DS4. In contrast, KIR B haplo-
types are highly variable (González- Galarza et al., 2015), containing 
up to 16 KIR genes including two to six activating KIR genes, giv-
ing them the moniker of being ‘activating haplotypes’, and are con-
sidered to effect greater alloreactivity than KIR A haplotypes (Hsu 
et al., 2002; Uhrberg et al., 1997).
The population of the United Kingdom (n = 584) and Ireland 
(n = 319) has been characterized with regard to KIR gene haplotypes 
with KIR A/A genotypes being the most frequently observed (ap-
proximately 27%– 37%) and lowest for KIR B/B genotypes (approx-
imately 11%) with the remainder of the population being KIR A/B 
(Guinan et al., 2010; Hiby et al., 2010). Consequently, the majority 
of individuals possess both inhibitory and activating receptors in dif-
fering combinations according to their KIR haplotype status. Due to 
the inability of presence/absence genotyping to assign KIR genes to 
a defined haplotype, B/B and A/B diplotypes are often described as 
B/x diplotypes.
A hotspot for recombination lies in the middle of the KIR gene 
complex, between KIR3DP1 and 2DL4, dividing the KIR gene 
cluster into two regions: the centromeric region (closest to the 
chromosomal centromere) and telomeric region (closest to the 
chromosomal telomere). As a result, a wide assortment of KIR 
haplotypes can be drawn from a common pool of centromeric 
and telomeric regions. This phenomenon can produce a haplotype 
containing a combination of both A and B haplotype content (Jiang 
et al., 2012; Vierra- Green et al., 2012). As such, KIR haplotypes 
can also be described according to their centromeric and telomeric 
gene content, denoted as cenX/telX or cX- tX, where X describes 
the A or B content, for example cenA/telB or cA- tB for a haplo-
type with A content in the centromeric region and B content in the 
telomeric region.
KIR genes are highly polymorphic, with some suggestions 
that allelic polymorphism may influence HPCT outcomes (Alicata 
et al., 2016; Bari et al., 2013; Boudreau et al., 2017). High- resolution 
sequencing has identified recombinant KIR genes that may be missed 
by some genotyping techniques and defined novel haplotypes that 
would not have been predicted by common imputation techniques 
(Artavanis- Tsakonas et al., 2003; Roe et al., 2017). The clinical value 
of these findings remains unknown.
In contrast to the lectin- like NK cell receptors, testing for KIR 
genes is more advanced, with commercial reagents available to iden-
tify the presence or absence of these genes, and external quality 
assessment schemes are established to ensure parity of testing. 
Commercial genetic sequencing assays, including NGS, are also 
available, facilitating the definition of allele polymorphisms of KIR 
genes.
11.5.3 | KIR ligands
Whilst ligands for some KIR (particularly activating KIR) remain 
unknown, others have been identified as specific motifs on HLA 
class I proteins. Amino acid residue 80 of HLA- C, and residues 
77 and 80 of the HLA- Bw4 epitope represent key ligands for in-
hibitory KIR. Approximately half HLA- C alleles encode proteins 
with asparagine at amino acid 80 (C1 epitope), and the other 
half encode lysine (C2 epitope). Recognition of these epitopes is 
partially restricted, with most KIR2DL2 and 2DL3 glycoproteins 
binding the C1 epitope, most KIR2DL1 glycoproteins binding the 
C2 epitope, and KIR3DL1 binding the HLA- Bw4 epitope. HLA- A3 
and HLA- A11 also share an ‘A3/11’ epitope, which is recognized 
by KIR3DL2.
11.5.4 | KIR: ligand interactions
A number of groups have attempted to apply an algorithm to quan-
tify the complex interaction of activating and/or inhibitory KIR in 
the context of the presence or absence of known ligands. This 
effect was first documented in haploidentical transplantation by 
Ruggeri et al. (1999, 2002). Further evidence followed, to support 
the preferential selection of a donor with an increased number 
of B/x diplotypes (activating haplotypes) in patients with AML, or 
other myeloid malignancies, when unrelated donors are the stem 
cell source (Cooley et al., 2009, 2010, 2014). These studies were 
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performed in a cohort of patients receiving T- cell replete, mye-
loablative conditioning with bone marrow being the predominate 
source of stem cells.
The KIR B content scoring model classifies all potential donors 
as ‘neutral’ (lowest priority ranking), ‘better’ or ‘best’ (highest pri-
ority ranking) according to the donor's A or B haplotype content of 
both the centromeric and telomeric regions, with priority given to 
donors who possess two KIR B haplotypes in the centromeric re-
gion (‘Best’) (Cooley et al., 2009, 2010). In the international donor 
registry pool, approximately 70% of donors are categorized as 
neutral, 20% as better and 10% as best (Weisdorf et al., 2019). By 
selecting donors with activating KIR haplotypes (high B content), 
there is mounting evidence that recipients experience reduced re-
lapse and improved survival, possibly due to selective elimination 
of minimal residual disease (MRD) in the recipient (Bao et al., 2016; 
Cooley et al., 2009, 2010, 2014). This effect has also been observed 
in paediatric haploidentical donor transplantation (Oevermann 
et al., 2014). To aid interpretation of KIR gene content data, the 
European Bioinformatics Institute hosts the online IPD- KIR Ligand 
Calculator to assess the KIR B haplotype content score of potential 
donors according to assignments detailed in Cooley et al. (2010) 
(https://www.ebi.ac.uk/ipd/kir/donor_b_conte nt.html).
Alternatively, KIR receptors can be assessed in the context of 
their biological activity, by considering the presence or absence of a 
KIR gene and its cognate ligand. The level of resolution required for 
HLA matching of HPCT donors and recipients means that the recip-
ient's C1/C2 epitope status is known at the time of donor selection, 
and if the KIR gene content of the donor is also known, the com-
bined data could potentially be used to inform donor choice. Patients 
whose HLA type causes them to be homozygous for C1 or C2 group 
alleles (C1/C1 or C2/C2) are potentially ‘missing’ ligands for either 
their own KIR, or KIR present in a potential donor. ‘Missing’ ligands 
may also occur in individuals who lack HLA- A or HLA- B antigens 
with the Bw4 public epitope, or lack HLA- A3 or HLA- A11.
Lacking a ligand may manifest as improved OS, decreased 
relapse or reduced aGVHD, if the additional presence of a KIR 
B haplotype donor can drive a GVL effect as suggested in HLA- 
matched sibling transplants (Cardozo et al., 2016) unrelated UCBT 
(Martínez- Losada et al., 2017) and in unrelated donor transplants 
(Wu et al., 2010).
In a study of ATG conditioned HLA- matched sibling and unrelated 
donor transplants, patients missing HLA ligands (≥1) for unrelated 
donor inhibitory KIR were associated with a reduction in relapse and 
an improvement in relapse- free survival (Faridi et al., 2016). In the 
same study, recipients possessing at least one HLA- C C1 ligand and 
a KIR genotype- matched donor had significantly improved ‘cGVHD 
and relapse- free’ survival compared with recipients who were C2/
C2. The authors suggest that KIR genotyping potential donors to 
identify a KIR genotype (A/A, B/x) match would have a beneficial 
impact on ‘cGVHD and relapse- free’ survival.
Thus, reports show mixed reproducibility of the positive effect of 
donor KIR B haplotypes, which may reflect the total number of KIR 
ligands present and despite reports describing beneficial outcomes 
for patients with missing KIR ligands, other data support a disadvan-
tage to patients homozygous for HLA C1 or C2 groups. Recent ex-
perimental data supporting the presence, in both patient and donor, 
of ligands (C1, C2 and Bw4) for all donor inhibitory KIR, associated 
with lower relapse rates following haploidentical transplantation. 
This was attributed to better functional NK cell reconstitution post 
transplantation (Zhao et al., 2019).
Worldwide, the evidence base is building to show that recipients 
who are homozygous for HLA C1 or C2 group alleles are disadvan-
taged in the HPCT setting compared with those who are heterozy-
gous (Cook et al., 2004; Cooley et al., 2014; Neuchel et al., 2017; 
Shimoni et al., 2017; Sobecks et al., 2015). Moreover, the evidence 
highlighting worse outcomes for HLA C2/C2 group recipients (ap-
proximately 20% of the population) is reproducible for all donor cat-
egories (related, unrelated, haploidentical, UCB). Without directed 
donor selection, these individuals will experience the poorest out-
come post- transplant (Clausen et al., 2010).
There is supporting evidence that single KIR receptors may exert 
a higher profile than others. For example, Neuchel et al. (2017) and 
Sobecks et al. (2015) have both highlighted the key role for KIR2DS2 
in the donor; a gene present on most KIR B, but not KIR A haplo-
types. Similarly, matching for KIR3DS1, 2DS1, 2DS4 or whole KIR 
haplotypes have also been reported to have an impact upon sur-
vival (Burek- Kamenaric et al., 2017; Faridi et al., 2016; Mancusi 
et al., 2015; Sahin et al., 2018; Sobecks et al., 2015; Venstrom 
et al., 2012).
Donor KIR characteristics not only impact on the GVL effect 
of transplants but can also contribute to immunological responses 
to infectious agents. Reduced incidence of CMV reactivation has 
been observed in transplants using donors who possess ≥5 acti-
vating KIR genes (Sobecks et al., 2011), or B/x diplotype charac-
teristics in the telomeric region (TelB/x) of the KIR gene cluster 
(Heatley et al., 2018; Sobecks et al., 2011). Furthermore, trans-
plantation using donors possessing KIR2DS2, a centromeric 
activating KIR gene, was found to be protective against CMV re-
activation (Behrendt et al., 2013). Preferential cytotoxic activity 
against infected malignant cells may manifest clinically as pro-
moting a GVL effect (Oevermann et al., 2014; Ruggeri et al., 2016; 
Zhao et al., 2007).
Given the strength of the supporting evidence for this effect, 
and the increased clinical complications incurred following an ac-
tive post- transplant infection with CMV, it is economically viable 
to perform additional KIR genotyping to identify donors with high 
activating KIR gene content to support the clinical management of 
recipients at risk of CMV reactivation.
Supporting evidence for the involvement of individual KIR in 
clinical outcome is only just emerging, but suggests that the interac-
tion is complex, and further evidence is required to support a con-
sensus before recommendations for directed donor selection can be 
implemented. Current research into the relationship between KIR 
allelic polymorphism and phenotypical variation of the gene product 
may further our understanding of KIR/HLA interactions for the ben-
efit of clinical algorithms.
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At present, it is within the capabilities of laboratories support-
ing transplant centres to perform KIR presence/absence genotyp-
ing for prospective recipients and donors, and to assign KIR A and 
B diplotype status based on KIR gene content. This process should 
now become incorporated into routine selection procedures for 
recipients at highest risk, such as C2/C2 individuals, especially if 
their donor is mismatched for CMV. There are suggestions that 
these individuals would benefit from a donor who is KIR2DS1 
positive, if available (Sobecks et al., 2015). Unfortunately, many 
existing KIR assessment algorithms for donor selection (such as 
the B content scoring model) have been found to be ineffectual 
in C2/C2 individuals (Cooley et al., 2014; Faridi et al., 2016). For 
those C2/C2 homozygous patients where a choice of fully HLA- 
matched donors exist, the process of additional KIR gene profiling 
should be applied to facilitate optimal outcome with fewest post- 
transplant complications. When considering transplant options, 
HLA typing must remain the primary priority in donor selection, 
as HLA- C mismatching results in detrimental transplant outcomes 
(Hoff et al., 2017).
A second group of recipients in whom there is a recognized risk 
are those with CMV serostatus- mismatched donors. Evidence is ac-
cumulating to suggest that if these transplants are unavoidable, prior 
knowledge of the KIR background of both donors and recipients may 
be able to direct CMV prophylaxis, highlight the requirement for 
closer post- transplant monitoring, and early therapeutic interven-
tion for recipients with KIR B haplotype- negative donors.
11.6 | CCR5- Δ32
The successful transplantation of an HIV- infected patient, with 
AML, using an unrelated donor who was homozygous for a 32 base-
pair deletion in the CCR5 gene (CCR5 Delta 32/Delta32, (Δ32/Δ32)), 
resulted in the patient being free of antiretroviral medication and 
without any evidence of virus (Hűtter et al., 2009). Homozygosity 
for the CCR5Δ32 mutation prevents entry of HIV into target cells 
via the encoded CCR5 receptor. This success was repeated with an 
HIV- positive patient with Hodgkin's Lymphoma (Gupta et al., 2019). 
Individuals homozygous for CCR5Δ32 are present in only approxi-
mately 1% of caucasian populations, and therefore, the chance of 
finding an HLA- matched CCR5Δ32/Δ32 donor is very low; however, 
some bone marrow donor registries have CCR5Δ32 genotypes avail-
able and this information can be requested when conducting an un-
related donor search.
12  | BACKUP OPTIONS
For all transplants, it is advised to identify a backup option in case 
there are last minute issues with the preferred donor option. The 
backup donor could be related or unrelated, but preferably one 
where the workup could be turned around quickly. Consideration 
of location of the preferred and backup donor is a necessity should 
situations affecting global transportation be affected during a crisis, 
for example pandemic 2020.
13  | TUMOUR- SPECIFIC MUTATIONS
The improvement and wide- scale application of high resolution HLA 
typing methods has led to a significant increase in the number of 
mutations identified when HLA typing patients using DNA extracted 
from peripheral blood. These mutations can be attributed to a novel 
HLA allele expressed in all tissues or could be specific to the pa-
tient's tumour (Mrazek et al., 2014). If discovered, effort must be 
made via HLA typing of relatives and HLA typing of DNA extracted 
from patient tissue not affected by disease (e.g. skin plug) to deter-
mine whether the allele is novel or tumour specific. Only novel al-
leles will be assigned an official HLA allele name (Marsh et al., 2010; 
Robinson et al., 2015).
The expression of HLA proteins can be reduced within tumours 
due to deletion or mutations within genes encoding HLA proteins. 
Loss of heterozygosity at HLA loci can also occur. Care must be 
taken when patients are HLA typed from DNA extracted from pe-
ripheral blood with a high frequency of tumour cells in circulation. 
Homozygosity at HLA loci must be confirmed via family studies or 
repeat HLA testing when the patient is in remission or by testing 
DNA extracted from nondiseased cells such as buccal swab or skin 
plug.
14  | GR AF T IDENTIFIC ATION ADVISORY 
SERVICE (GIA S)
The provision of a professional GIAS to a transplant centre re-
quires trained staff able to undertake both straight- forward and 
complex donor selection. GIAS may be delivered from an H&I lab-
oratory supporting the transplant centre; from a donor registry or 
from within the transplant team. Key to the successful selection 
of optimum donors from related and unrelated sources is expert 
knowledge of the HLA system including: polymorphism, linkage 
disequilibrium, impact of recombination, ethnic variation and HLA 
serology. The GIAS team should participate in regular meetings 
with the transplant team, such as multi- disciplinary team meet-
ings or service review meetings, to ensure the needs of individual 
patients are being delivered according to local, national and inter-
national transplant protocols. A GIAS service must be directed by 
a consultant grade Royal College of Pathologists Fellow trained in 
H&I with adequate cover provided during absences. This may be 
achieved via national network arrangements with other laborato-
ries and organizations.
H&I scientists who have completed the British Society for 
Histocompatibility and Immunogenetics (BSHI) Diploma or the 
NHS Scientist Training Programme (STP) and are Health and Care 
Professions Council (HCPC) registered will have achieved an ade-
quate level of education to enable active participation within a 
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GIAS structure. In addition, there are ‘non- H&I laboratory’ train-
ing pathways such as the WMDA Search Coordinator Certification 
Programme that, upon completion, demonstrate the appropriate 
level of understanding to participate in GIAS provision.
All GIAS team members must participate in CPD to ensure 
maintenance of current knowledge and to be aware of future 
developments.
Within the UK, specific assistance in UCB unit shortlisting 
is available from the Anthony Nolan and NHSBT Cord Support 
Programme by emailing: cordsupport@anthonynolan.org.
Further advice on final cord selection is available from the 
Cord Blood Unit Selection Advisory Panel (CBUSAP), established 
under the auspices of the British Society of Blood and Marrow 
Transplantation (BSBMT) and BSHI in 2015. The role of this panel 
is to provide an independent advisory service for transplant phy-
sicians, H&I scientists and referring haematologists in the final se-
lection of UCB units out of a shortlist submitted by the Transplant 
Centre. Guidance for using this service is available at the BSHI 
websites: https://bshi.org.uk/membe rs/bshi- infor matio n/cord- 
blood - unit- selec tion- advis ory- panel/ and enquiries can be made 
at: ggc.cbusap@nhs.scot.
The CBUSAP discuss each case by email and the Chair will col-
late responses and formulate a consensus recommendation for the 
requesting centre that has responsibility for the final decision. Since 
2015, typical cases have been adults or older children often requir-
ing two cords. The patients often have limited unrelated donor op-
tions, have unusual HLA types and almost half have a range of HLA 
alloantibodies which must be considered as well.
15  | USEFUL WEBSITES
Guidance and tools to assist in donor selection and allele frequencies 
are available at the websites listed in Table 6.




HLA nomenclature. Source of information on names, validity, expression, sequences of HLA alleles, information 
on genes, antigens, proteins
http://igdawg.org/cwd.html
https://www.ihiw18.org/
compo nent- immun ogene 
tics/downl oad- commo n- 
and- well- docum ented - allel 
es- 3- 0/
Common, and well- documented alleles catalogue version 2.0. Can be downloaded in several file formats and has 
a lookup tool.
Common, intermediate and well- documented HLA alleles in world populations (Hurley et al., 2020) version 3.0. 
An update to the previous version 2.0
http://www.ebi.ac.uk/ipd/
imgt/hla/
IPD- IMGT/HLA Database permits access to HLA DNA and protein sequences and includes the official sequences 
for the WHO Nomenclature Committee for Factors of the HLA System. The IPD- IMGT/HLA Database is part of 
the Immuno Polymorphism Database (IPD). Provides links to HLA Aligning tool, HLA Dictionary search tool (see 
below), HLA- DPB1 T- Cell Epitope Algorithm (see below)
https://www.ebi.ac.uk/ipd/
imgt/hla/dpb_v2.html
DPB1 T- Cell Epitope Algorithm (version 2, August 2016)
https://www.pirche.com/
pirch e/#/featu res/bioin 
forma tics/The- PIRCH E- 
Algor ithm- in- HSCT
PIRCHE algorithm for assessment of indirect presentation of HLA class I and class II derived peptides in 
mismatched transplants (free for research use)
https://www.ebi.ac.uk/ipd/
imgt/hla/dicti onary.html
The HLA Dictionary search tool (Holdsworth et al., 2009)
https://bioin forma tics.bethe 
match clini cal.org/
NMDP bioinformatics resources. Include information on allele/haplotype frequencies in different ethnic groups 
in USA. Several tools, including Haplostats and multiple allele codes (MAC). Service tool for deciphering MAC 
codes (previously known as DNA Type Lookup Tool)
https://www.haplo stats.org/
haplo stats ?execu tion=e1s1
Haplostats for aiding haplotype prediction. Base on NMDP HLA haplotype frequencies
http://www.allel efreq uenci 
es.net
This website from the Allele Frequency Net Database provides allele frequency information on classic and 
nonclassical HLA genes and other polymorphisms in the human genome for different countries
http://www.pypop.org/
popda ta/
Worldwide allele distribution maps for HLA- A, HLA- B, HLA- C, HLA- DRB1, HLA- DQA1, HLA- DQB1, HLA- DPA1 
and HLA- DPB1 (Solberg et al., 2008)
https://hla- net.eu/ Information on EFI common and well- documented alleles, and population analysis tools
https://www.wmda.info/ World Marrow Donor Association website with information for patients, donors and health professionals. 
Includes Search&Match (former BMDW, requires authorization to access) and NetCord information
     |  99LITTLE ET aL.
CONFLIC T OF INTERE S T
The authors declare that they have no conflict of interests.
AUTHOR CONTRIBUTIONS
All authors have read and approved the final manuscript. A- ML de-
signed the review. All authors performed the literature search, and 
all authors wrote the paper. A- ML completed the final organization 
of the paper.
E THIC AL APPROVAL
This study did not involve human subjects or animals, and therefore, 
no ethical approval was required.
DATA AVAIL ABILIT Y S TATEMENT
Data sharing is not applicable to this article as no new data were cre-
ated or analyzed in this study.
ORCID
Ann- Margaret Little  https://orcid.org/0000-0003-0141-980X 
Kay Poulton  https://orcid.org/0000-0002-5608-8107 
Paul A. Wright  https://orcid.org/0000-0002-0516-3218 
R E FE R E N C E S
Akel, S., Regan, D., Wall, D., Petz, L., & McCullough, J. (2014). Current 
thawing and infusion practice of cryopreserved cord blood: The 
impact on graft quality, recipient safety, and transplantation out-
comes. Transfusion, 54(11), 2997– 3009. https://doi.org/10.1111/
trf.12719
Alicata, C., Pende, D., Meazza, R., Canevali, P., Loiacono, F., Bertaina, 
A., Locatelli, F., Nemat- Gorgani, N., Guethlein, L. A., Parham, P., 
Moretta, L., Moretta, A., Bottino, C., Norman, P. J., & Falco, M. (2016). 
Hematopoietic stem cell transplantation: Improving alloreactive Bw4 
donor selection by genotyping codon 86 of KIR3DL1/S1. European 
Journal of Immunology, 46(6), 1511– 1517. https://doi.org/10.1002/
eji.20154 6236
Anderson, A., Raja, M., Vazquez, N., Morris, M., Komanduri, K., & 
Camargo, J. (2020). Clincal “real- world” experience with Letermovir 
for prevention of cytomegalovirus infection in allogeneic hematopoi-
etic cell transplant recipients. Clinical Transplantation, 34(7), e13866. 
https://doi.org/10.1111/ctr.13866
Artavanis- Tsakonas, K., Eleme, K., McQueen, K. L., Cheng, N. W., Parham, 
P., Davis, D. M., & Riley, E. M. (2003). Activation of a subset of human 
NK cells upon contact with Plasmodium falciparum- infected eryth-
rocytes. The Journal of Immunology, 171(10), 5396– 5405. https://doi.
org/10.4049/jimmu nol.171.10.5396
Askar, M., Sayer, D., Wang, T., Haagenson, M., Spellman, S. R., Lee, S. J., 
Madbouly, A., Fleischhauer, K., Hsu, K. C., Verneris, M. R., Thomas, 
D., Zhang, A., Sobecks, R. M., Majhail, N. S., & Center for International 
Blood and Marrow Transplant Research Immunology Working 
Committee (2019). Analysis of single nucleotide polymorphisms in 
the gamma block of the major histocompatibility complex in associ-
ation with clinical outcomes of hematopoietic cell transplantation: A 
center for international blood and marrow transplant research study. 
Biology of Blood and Marrow Transplantation, 25(4), 664– 672. https://
doi.org/10.1016/j.bbmt.2018.12.008
Askar, M., Sobecks, R., Wang, T., Haagenson, M., Majhail, N., Madbouly, 
A., Thomas, D., Zhang, A., Fleischhauer, K., Hsu, K., Verneris, M., Lee, 
S. J., Spellman, S. R., & Fernández- Viña, M. (2017). MHC class I chain- 
related gene A (MICA) donor- recipient mismatches and MICA- 129 
polymorphism in unrelated donor hematopoietic cell transplanta-
tions has no impact on outcomes in acute lymphoblastic leukemia, 
acute myeloid leukemia, or myelodysplastic syndrome: A center for 
international blood and marrow transplant research study. Biology 
of Blood and Marrow Transplantation, 23(3), 436– 444. https://doi.
org/10.1016/j.bbmt.2016.11.021
Atsuta, Y., Kato, S., Morishima, Y., Ohashi, K., Fukuda, T., Ozawa, Y., Eto, 
T., Iwato, K., Uchida, N., Ota, S., Onizuka, M., Ichinohe, T., Kanda, J., 
& Kanda, Y. (2019). Comparison of HLA allele mismatch and antigen 
mismatch in unrelated bone marrow transplantation in patients with 
leukemia. Biology of Blood and Marrow Transplantation, 25(3), 436– 
442. https://doi.org/10.1016/j.bbmt.2018.10.002
Aung, F. M., Lichtiger, B., Bassett, R., Liu, P., Alousi, A., Bashier, Q., Ciurea, 
S. O., de Lima, M. J., Hosing, C., Kebriaei, P., Nieto, Y., Oran, B., Parmar, 
S., Qazilbash, M., Shah, N., Khouri, I., Champlin, R. E., & Popat, U. 
(2013). Incidence and natural history of pure red cell aplasia in major 
ABO- mismatched haematopoietic cell transplantation. British Journal 
of Haematology, 160(6), 798– 805. https://doi.org/10.1111/bjh.12210
Ayuk, F., Bornhäuser, M., Stelljes, M., Zabelina, T., Wagner, E.- M., Schmid, 
C., Christopeit, M., Guellstorf, M., Kröger, N., & Bethge, W. (2019). 
Predicted indirectly recognizable HLA epitopes (PIRCHE) are asso-
ciated with poorer outcome after single mismatch unrelated donor 
stem cell transplantation: A study of the Cooperative Transplant 
Study Group (KTS) of the German Group for Bone Marrow and 
Stem Cell Transplantation (DAG- KBT). Transfusion Medicine and 
Hemotherapy, 46, 370– 375. https://doi.org/10.1159/00050 2389
Ballen, K. (2017). Update on umbilical cord blood transplantation. 
F1000Research, 6, 1556. https://doi.org/10.12688/ f1000 resea 
rch.11952.1
Ballen, K. K., Gluckman, E., & Broxmeyer, H. E. (2013). Umbilical cord 
blood transplantation: The first 25 years and beyond. Blood, 122(4), 
491– 498. https://doi.org/10.1182/blood - 2013- 02- 453175
Ballen, K. K., Logan, B. R., Laughlin, M. J., He, W., Ambruso, D. R., 
Armitage, S. E., Beddard, R. L., Bhatla, D., Hwang, W. Y. K., Kiss, J. E., 
Koegler, G., Kurtzberg, J., Nagler, A., Oh, D., Petz, L. D., Price, T. H., 
Quinones, R. R., Ratanatharathorn, V., Rizzo, J. D., & Eapen, M. (2015). 
Effect of Cord Blood Processing on Transplantation Outcomes after 
Single Myeloablative Umbilical Cord Blood Transplantation. Biology 
of Blood and Marrow Transplantation, 21(4), 688– 695. https://doi.
org/10.1016/j.bbmt.2014.12.017
Bao, X., Wang, M., Zhou, H., Zhang, H., Wu, X., Yuan, X., Li, Y., Wu, 
D., & He, J. (2016). Donor killer immunoglobulin- like receptor pro-
file Bx1 imparts a negative effect and centromeric B- specific gene 
motifs render a positive effect on standard- risk acute myeloid leu-
kemia/myelodysplastic syndrome patient survival after unrelated 
donor hematopoietic stem cell transplantation. Biology of Blood and 
Marrow Transplantation, 22(2), 232– 239. https://doi.org/10.1016/j.
bbmt.2015.09.007
Bari, R., Rujkijyanont, P., Sullivan, E., Kang, G., Turner, V., Gan, K., & 
Leung, W. (2013). Effect of donor KIR2DL1 allelic polymorphism on 
the outcome of pediatric allogeneic hematopoietic stem- cell trans-
plantation. Journal of Clinical Oncology, 31(30), 3782– 3790. https://
doi.org/10.1200/JCO.2012.47.4007
Barker, J. N., Kempenich, J., Kurtzberg, J., Brunstein, C. G., Delaney, C., 
Milano, F., Politikos, J., Shpall, E.J., Scaradavou, A., & Dehn, J. (2019). 
CD34+ cell content of 126,341 cord blood units in the US inventory: 
Implications for transplantation and banking. Blood Advances, 3(8), 
1267– 1271. https://doi.org/10.1182/blood advan ces.20180 29157
Barker, J. N., Kurtzberg, J., Ballen, K., Boo, M., Brunstein, C., Cutler, 
C., Horwitz, M., Milano, F., Olson, A., Spellman, S., Wagner, J. E., 
Delaney, C., & Shpall, E. (2017). Optimal practices in unrelated donor 
cord blood transplantation for hematologic malignancies. Biology 
of Blood and Marrow Transplantation, 23(6), 882– 896. https://doi.
org/10.1016/j.bbmt.2017.03.006
100  |     LITTLE ET aL.
Barker, J. N., Scaradavou, A., & Stevens, C. E. (2010). Combined effect of 
total nucleated cell dose and HLA match on transplantation outcome 
in 1061 cord blood recipients with hematologic malignancies. Blood, 
115(9), 1843– 1849. https://doi.org/10.1182/blood - 2009- 07- 231068
Barker, J. N., Weisdorf, D. J., DeFor, T. E., Blazar, B. R., Miller, J. S., & 
Wagner, J. E. (2003). Rapid and complete donor chimerism in adult 
recipients of unrelated donor umbilical cord blood transplantation 
after reduced- intensity conditioning. Blood, 102(5), 1915– 1919. 
https://doi.org/10.1182/blood - 2002- 11- 3337
Baxter- Lowe, L. A., Maiers, M., Spellman, S. R., Haagenson, M. D., Wang, 
T., Fernandez- Vina, M., Marsh, S. G. E., Horowitz, M., & Hurley, C. K. 
(2009). HLA disparities illustrate challenges for ranking the impact of 
HLA mismatches on bone marrow transplant outcomes in the United 
States. Biology of Blood and Marrow Transplantation, 15(8), 971– 981. 
https://doi.org/10.1016/j.bbmt.2009.04.015
Behrendt, C. E., Nakamura, R., Forman, S. J., & Zaia, J. A. (2013). Donor 
killer immunoglobulin- like receptor genes and reactivation of cy-
tomegalovirus after HLA- matched hematopoietic stem- cell trans-
plantation: HLA- C allotype is an essential cofactor. Frontiers in 
Immunology, 4, 36. https://doi.org/10.3389/fimmu.2013.00036
Bettens, F., Brunet, L., & Tiercy, J.- M. (2014). High- allelic variability in 
HLA- C mRNA expression: Association with HLA- extended haplo-
types. Genes and Immunity, 15(3), 176– 181. https://doi.org/10.1038/
gene.2014
Bettens, F., Buhler, S., & Tiercy, J.- M. (2016). Allorecognition of HLA- C 
mismatches by CD8+ T cells in hematopoietic stem cell transplanta-
tion is a complex interplay between mismatched peptide- binding re-
gion residues, HLA- C expression, and HLA- DPB1 disparities. Frontiers 
in Immunology, 7, 584. https://doi.org/10.3389/fimmu.2016.00584
Bochtler, W., Maiers, M., Bakker, J. N. A., Oudshoorn, M., Marsh, S. G. E., 
Baier, D., Hurley, C. K., & Müller, C. R. (2011). World Marrow Donor 
Association framework for the implementation of HLA matching 
programs in hematopoietic stem cell donor registries and cord blood 
banks. Bone Marrow Transplantation, 46(3), 338– 343. https://doi.
org/10.1038/bmt.2010.132
Bolan, C. D., Leitman, S. F., Griffith, L. M., Wesley, R. A., Procter, J. L., 
Stroncek, D. F., Barrett, A. J., & Childs, R. W. (2001). Delayed donor 
red cell chimerism and pure red cell aplasia following major ABO- 
incompatible nonmyeloablative hematopoietic stem cell transplan-
tation. Blood, 98(6), 1687– 1694. https://doi.org/10.1182/blood.
v98.6.1687
Booth, G. S., Gehrie, E. A., Bolan, C. D., & Savani, B. N. (2013). Clinical 
guide to ABO- incompatible allogeneic stem cell transplantation. 
Biology of Blood and Marrow Transplantation, 19(8), 1152– 1158. 
https://doi.org/10.1016/j.bbmt.2013.03.018
Boudreau, J. E., Giglio, F., Gooley, T. A., Stevenson, P. A., Le Luduec, J- B., 
Shaffer, B. C., Rajalingam, R., Hou, L., Hurley, C. K., Noreen, H., Reed, 
E. F., Yu, N., Vierra- Green, C., Haagenson, M., Malkki, M., Petersdorf, 
E. W., Spellman, S., & Hsu, K. C. (2017). KIR3DL1/HLA- B Subtypes 
Govern Acute Myelogenous Leukemia Relapse After Hematopoietic 
Cell Transplantation. Journal of Clinical Oncology, 35(20), 2268– 2278. 
https://doi.org/10.1200/jco.2016.70.7059
Brissot, E., Labopin, M., Stelljes, M., Ehninger, G., Schwerdtfeger, R., 
Finke, J., Kolb, H.- J., Ganser, A., Schäfer- Eckart, K., Zander, A. R., 
Bunjes, D., Mielke, S., Bethge, W. A., Milpied, N., Kalhs, P., Blau, I.- W., 
Kröger, N., Vitek, A., Gramatzki, M., & Nagler, A. (2017). Comparison 
of matched sibling donors versus unrelated donors in allogeneic 
stem cell transplantation for primary refractory acute myeloid leu-
kemia: A study on behalf of the Acute Leukemia Working Party of 
the EBMT. Journal of Hematology & Oncology, 10(1), 130. https://doi.
org/10.1186/s1304 5- 017- 0498- 8
Brunstein, C. G., Gutman, J. A., Weisdorf, D. J., Woolfrey, A. E., DeFor, 
T. E., Gooley, T. A., Verneris, M. R., Appelbaum, F. R., Wagner, J. 
E., & Delaney, C. (2010). Allogeneic hematopoietic cell transplan-
tation for hematologic malignancy: Relative risks and benefits of 
double umbilical cord blood. Blood, 116(22), 4693– 4699. https://doi.
org/10.1182/blood - 2010- 05- 285304
Brunstein, C. G., Noreen, H., DeFor, T. E., Maurer, D., Miller, J. S., & 
Wagner, J. E. (2011). Anti- HLA antibodies in double umbilical cord 
blood transplantation. Biology of Blood and Marrow Transplantation, 
17(11), 1704– 1708. https://doi.org/10.1016/j.bbmt.2011.04.013
Brunstein, C. G., Petersdorf, E. W., DeFor, T. E., Noreen, H., Maurer, D., 
MacMillan, M. L., Ustun, C., Verneris, M. R., Miller, J. S., Blazar, B. 
R., McGlave, P. B., Weisdorf, D. J., & Wagner, J. E. (2016). Impact 
of allele- level HLA mismatch on outcomes in recipients of dou-
ble umbilical cord blood transplantation. Biology of Blood and 
Marrow Transplantation, 22(3), 487– 492. https://doi.org/10.1016/j.
bbmt.2015.09.025
Brunstein, C., Zhang, M.- J., Barker, J., St. Martin, A., Bashey, A., de 
Lima, M., Dehn, J., Hematti, P., Perales, M.- A., Rocha, V., Territo, 
M., Weisdorf, D., & Eapen, M. (2017). The effect of inter- unit HLA 
matching in double umbilical cord blood transplantation for acute 
leukemia. Haematologica, 102(5), 941– 947. https://doi.org/10.3324/
haema tol.2016.158584
Büchler, T., Gallardo, D., Rodríguez- Luaces, M., Pujal, J. M., & Grañena, A. 
(2002). Frequency of HLA- DPB1 disparities detected by reference- 
strand- mediated conformation analysis in HLA- A, - B, and – DRB1 
matched siblings. Human Immunology, 63(2), 139– 142. https://doi.
org/10.1016/s0198 - 8859(01)00376 - 7
Burek Kamenaric, M., Stingl Jankovic, K., Grubic, Z., Serventi Seiwerth, 
R., Maskalan, M., Nemet, D., Mikulic, M., & Zunec, R. (2017). The im-
pact of KIR2DS4 gene on clinical outcome after hematopoietic stem 
cell transplantation. Human Immunology, 78(2), 95– 102. https://doi.
org/10.1016/j.humimm.2016.11.010
Burt, C., Parker, A., McQuaker, G., Copland, M., Brierley, C., Little, A.- 
M., & Clark, A. (2014). In a 12- allele analysis HLA- DPB1 matching 
is associated with improved OS in leukaemic and myelopdysplastic 
patients receiving myeloablative T- cell- depleted PBSCT from unre-
lated donors. Bone Marrow Transplantation, 49(5), 657– 663. https://
doi.org/10.1038/bmt.2014.8
Carapito, R., Jung, N., Kwemou, M., Untrau, M., Michel, S., Pichot, 
A., Giacometti, G., Macquin, C., Ilias, W., Morlon, A., Kotova, I., 
Apostolova, P., Schmitt- Graeff, A., Cesbron, A., Gagne, K., Oudshoorn, 
M., van der Holt, B., Labalette, M., Spierings, E., & Bahram, S. (2016). 
Matching for the nonconventional MHC- I MICA gene significantly 
reduces the incidence of acute and chronic GVHD. Blood, 128(15), 
1979– 1986. https://doi.org/10.1182/blood - 2016- 05- 719070
Cardozo, D. M., Marangon, A. V., da Silva, R. F., Aranha, F. J. P., Visentainer, 
J. E. L., Bonon, S. H. A., Costa, S. C. B., Miranda, E. C. M., de Souza, C. 
A., & Guimarães, F. (2016). Synergistic effect of KIR ligands missing 
and cytomegalovirus reactivation in improving outcomes of haema-
topoietic stem cell transplantation from HLA- matched sibling donor 
for treatment of myeloid malignancies. Human Immunology, 77(10), 
861– 868. https://doi.org/10.1016/j.humimm.2016.07.003
Castillo, N., Garcia- Cadenas, I., Barba, P., Martino, R., Azqueta, C., 
Ferrà, C., Canals, C., Sierra, J., Valcárcel, D., & Querol, S. (2015). 
Post- thaw viable CD45+ cells and clonogenic efficiency are associ-
ated with better engraftment and outcomes after single cord blood 
transplantation in adult patients with malignant diseases. Biology of 
Blood and Marrow Transplantation, 21(12), 2167– 2172. https://doi.
org/10.1016/j.bbmt.2015.08.016
Chang, Y.- J., & Huang, X.- J. (2014). Haploidentical SCT, the mechanisms 
underlying the crossing of HLA barriers. Bone Marrow Transplantation, 
49(7), 873– 879. https://doi.org/10.1038/bmt.2014.19
Chang, Y. J., Luznik, L., Ephraim, J., Fuchs, E. J., & Huang, X. J. (2016). How 
do we choose the best donor for T- cell- replete, HLA- haploidentical 
transplantation? Journal of Hematology & Oncology, 9, 35. https://doi.
org/10.1186/s1304 5- 016- 0265- 2
Ciurea, S. O., Al Malki, M. M., Kongtim, P., Fuchs, E. J., Luznik, L., Huang, 
X- J, Ciceri, F., Locatelli, F., Aversa, F., Castagna, Lu., Bacigalupo, A., 
     |  101LITTLE ET aL.
Martelli, M., Blaise, D., Ben Soussan, P., Arnault, Y., Handgretinger, 
R., Roy, D- C., O’Donnell, P. V., Bashey, A., & Nagler, A. (2020). The 
European Society for Blood and Marrow Transplantation (EBMT) 
consensus recommendations for donor selection in haploidentical 
hematopoietic cell transplantation. Bone Marrow Transplantation, 
55(1), 12– 24. https://doi.org/10.1038/s4140 9- 019- 0499- z
Ciurea, S. O., Cao, K., Fernandez- Vina, M., Kongtim, P., Malki, M. A., 
Fuchs, E., Luznik, L., Huang, X.- J., Ciceri, F., Locatelli, F., Aversa, F., 
Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Handgretinger, 
R., Roy, D.- C., O'Donnell, P., Bashey, A., … Nagler, A. (2018). The 
European Society for Blood and Marrow Transplantation (EBMT) 
consensus guidelines for the detection and treatment of donor- 
specific anti- HLA antibodies (DSA) in haploidentical hematopoietic 
cell transplantation. Bone Marrow Transplantation, 53, 521– 534. 
https://doi.org/10.1038/s4140 9- 017- 0062- 8
Clancy, J., Ritari, J., Lobier, M., Niittyvuopio, R., Salmenniemi, U., 
Putkonen, M., Itälä- Remes, M., Partanen, J., & Koskela, S. (2019). 
Increased MHC matching by C4 gene compatibility in unrelated 
donor hematopoietic stem cell transplantation. Biology of Blood and 
Marrow Transplantation, 25, 891– 898. https://doi.org/10.1016/j.
bbmt.2018.12.759
Clausen, J., Kircher, B., Auberger, J., Schumacher, P., Ulmer, H., 
Hetzenauer, G., Wolf, D., Gastl, G., & Nachbaur, D. (2010). The role 
of missing killer cell immunoglobulin- like receptor ligands in T cell re-
plete peripheral blood stem cell transplantation from HLA- identical 
siblings. Biology of Blood and Marrow Transplantation, 16(2), 273– 280. 
https://doi.org/10.1016/j.bbmt.2009.10.021
Clayberger, C., Lyu, S. C., De Kruyff, R., Parham, P., & Krensky, A. M. 
(1994). Peptides corresponding to the CD8 and CD4 binding domains 
of HLA molecules block T lymphocyte immune responses in vitro. 
The Journal of Immunology, 153, 946– 951.
Cook, M. A., Milligan, D. W., Fegan, C. D., Darbyshire, P. J., Mahendra, P., 
Craddock, C. F., Moss, P. A. H., & Briggs, D. C. (2004). The impact of 
donor KIR and patient HLA- C genotypes on outcome following HLA- 
identical sibling hematopoietic stem cell transplantation for myeloid 
leukemia. Blood, 103(4), 1521– 1526. https://doi.org/10.1182/blood 
- 2003- 02- 0438
Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., 
Le, C. T., Marsh, S. G. E., Guethlein, L. A., Parham, P., Miller, J. S., & 
Weisdorf, D. J. (2009). Donors with group B KIR haplotypes improve 
replapse- free survival after unrelated hematopoietic cell transplan-
tation for acute myelogenous leukemia. Blood, 113, 726– 732. https://
doi.org/10.1182/blood - 2008- 07- 171926
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., 
Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., Ladner, 
M., Trachtenberg, E., Parham, P., & Miller, J. S. (2010). Donor selection 
for natural killer cell receptor genes leads to superior survival after 
unrelated transplantation for acute myelogenous leukemia. Blood, 
116, 2411– 2419. https://doi.org/10.1182/blood - 2010- 05- 283051
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Marsh, 
S. G. E., Spellman, S., Haagenson, M. D., Saeturn, K., Ladner, M., 
Trachtenberg, E., Parham, P., & Miller, J. S. (2014). Donor killer cell Ig- 
like receptor B haplotypes, recipient HLA- C1, and HLA- C mismatch 
enhance the clinical benefit of unrelated transplantation for acute 
myelogenous leukemia. Journal of Immunology, 192, 4592– 4600. 
https://doi.org/10.4049/jimmu nol.1302517
Craddock, C., & Chakraverty, R. (2016). Stem cell transplantation. In 
A. V. Hoffbrand, D. R. Higgs, D. M. Keeling, & A. B. Mehta (Eds), 
Postgraduate haematology (7th ed., pp. 651– 675). Wiley Blackwell. 
https://doi.org/10.1002/97811 18853 771.ch35
Crivello, P., Zito, L., Sizzano, F., Zino, E., Maiers, M., Mulder, A., Toffalori, 
C., Naldini, L., Ciceri, F., Vago, L., & Fleischhauer, K. (2015). The 
impact of amino acid variability on alloreactivity defines a func-
tional distance predictive of permissive HLA- DPB1 mismatches 
in hematopoietic stem cell transplantation. Biology of Blood and 
Marrow Transplantation, 21, 233– 241. https://doi.org/10.1016/j.
bbmt.2014.10.017
Crocchiolo, R., Ciceri, F., Fleischhauer, K., Oneto, R., Bruno, B., Pollichieni, 
S., Sacchi, N., Sormani, M. P., Fanin, R., Bandini, G., Bonifazi, F., Bosi, 
A., Rambaldi, A., Alessandrino, P. E., Falda, M., & Bacigalupo, A. 
(2009). HLA matching affects clinical outcome of adult patients un-
dergoing haematopoietic SCT from unrelated donors, a study from 
the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone 
Marrow Donor Registry. Bone Marrow Transplantation, 44, 571– 577. 
https://doi.org/10.1038/bmt.2009.67
Cullen, M., Noble, J., Erlich, H., Thorpe, K., Beck, S., Klitz, W., Trowsdale, 
J., & Carrington, M. (1997). Characterization of recombination in the 
HLA class II region. American Journal of Human Genetics, 60, 397– 407.
Cunha, R., Loiseau, P., Ruggeri, A., Sanz, G., Michel, G., PaolaIori, 
A., Socié, G., Arcese, W., Picardi, A., Dias de Heredia, C., Rio, B., 
Locatelli, F., O'Brien, T. A., Yakoub- Agha, I., Angel Diaz, M., Milpied, 
N., Bittencourt, H., Pedro Souza, M., Aljurf, M., … Rocha, V. (2014). 
Impact of HLA mismatch direction on outcomes after umbilical cord 
blood transplantation for hematological malignant disorders, a retro-
spective Eurocord- EBMT analysis. Bone Marrow Transplantation, 49, 
24– 29. https://doi.org/10.1038/bmt.2013.120
Cutler, C. S., Lee, S. J., Greenberg, P., Deeg, H. J., Perez, W. S., Anasetti, 
C., Bolwell, B. J., Cairo, M. S., Gale, R. P., Klein, J. P., Lazarus, H. M., 
Liesveld, J. L., McCarthy, P. L., Milone, G. A., Rizzo, J. D., Schultz, 
K. R., Trigg, M. E., Keating, A., Weisdorf, D. J., . . ., Horowitz, M. M. 
(2004). A decision analysis of allogeneic bone marrow transplanta-
tion for the myelodysplastic syndromes, delayed transplantation for 
low- risk myelodyplasia is associated with improved outcome. Blood, 
104, 579– 585. https://doi.org/10.1182/blood - 2004- 01- 0338
Dahi, P. B., Ponce, D. M., Devlin, S., Evans, K. L., Lubin, M., Gonzales, 
A. M., Byam, C., Sideroff, M., Wells, D., Giralt, S., Kernan, N. A., 
Scaradavou, A., & Barker, J. N. (2014). Donor- recipient allele- level 
HLA matching of unrelated cord blood units reveals high degrees of 
mismatch and alters graft selection. Bone Marrow Transplantation, 49, 
1184– 1186. https://doi.org/10.1038/bmt.2014.135
de Latour, R. P., Brunstein, C. G., Porcher, R., Chevallier, P., Robin, M., 
Warlick, E., Xhaard, A., Ustun, C., Larghero, J., Dhedin, N., Mohty, M., 
Socié, G., & Weisdorf, D. (2013). Similar overall survival using sibling, 
unrelated donor, and cord blood grafts after reduced- intensity condi-
tioning for older patients with acute myelogenous leukemia. Biology 
of Blood and Marrow Transplantation, 19(9), 1355– 1360. https://doi.
org/10.1016/j.bbmt.2013.06.006
Dehn, J., Spellman, S., Hurley, C. K., Shaw, B. E., Barker, J. N., Burns, 
L. J., Confer, D. L., Eapen, M., Fernandez- Vina, M., Hartzman, R., 
Maiers, M., Marino, S. R., Mueller, C., Perales, M.- A., Rajalingam, 
R., & Pidala, J. (2019). Selection of unrelated donors and cord blood 
units for hematopoietic cell transplantation: Guidelines from the 
NMDP/CIBMTR. Blood, 134(12), 924– 934. https://doi.org/10.1182/
blood.20190 01212
Delbos, F., Barhoumi, W., Cabanne, L., Beckerich, F., Robin, C., Redjoul, 
R., Astati, S., Toma, A., Pautas, C., Ansart- Pirenne, H., Cordonnier, C., 
Bierling, P., & Maury, S. (2016). Donor immunization against human 
leukocyte class II antigens is a risk factor for graft- versus- host dis-
ease. Biology of Blood and Marrow Transplantation, 22(2), 292– 299. 
https://doi.org/10.1016/j.bbmt.2015.09.027
Detrait, M., Morrisset, S., Chalandon, Y., Yakoub- Agha, I., Dufossé, 
F., Labalette, M., Top, I., Elsermans, V., Barraco, F., Quintela, A., 
Tedone, N., Michallet, M., Raus, N., Tiercy, J- M., & Dubois, V. (2015). 
Suggestive evidence of a role of HLA- DRB4 mismatches in the out-
come of allogeneic hematologic stem cell transplantation with HLA- 
10/10- matched unrelated donors: A French- Swiss retrospective 
study. Bone Marrow Transplantation, 50(10), 1316– 1320. https://doi.
org/10.1038/bmt.2015.157
Ducreux, S., Dubois, V., Amokrane, K., Yakoub- Agha, I., Labalette, M., 
Michallet, M., Rubio, M.- T., Kennel, A., Forcade, E., Lafarge, X., 
102  |     LITTLE ET aL.
Bulabois, C.- E., Masson, D., Daguindau, E., Devys, A., Moalic, V., 
Quelvennec, E., Boudifa, A., Picard, C., Van Endert, P., … Peffault de 
Latour, R. (2018). HLA- DRB3/4/5 mismatches are associated with in-
creased risk of acute GvHD in 10/10 matched unrelated donor hema-
topoietic cell transplantation. American Journal of Hematology, 93(8), 
994– 1001. https://doi.org/10.1002/ajh.25133
Eapen, M., Klein, J. P., Ruggeri, A., Spellman, S., Lee, S. J., Anasetti, C., 
Arcese, W., Barker, J. N., Baxter- Lowe, L. A., Brown, M., Fernandez- 
Vina, M. A., Freeman, J., He, W., Iori, A. P., Horowitz, M. M., Locatelli, 
F., Marino, S., Maiers, M., Michel, G., … Rocha, V. (2014). Impact of 
allele- level HLA matching on outcomes after myeloablative sin-
gle unit umbilical cord blood transplantation for hematologic ma-
lignancy. Blood, 123(1), 133– 140. https://doi.org/10.1182/blood 
- 2013- 05- 506253
Eapen, M., Wang, T., Veys, P. A., Boelens, J. J., St Martin, A., Spellman, S., 
Bonfim, C. S., Brady, C., Cant, A. J., Dalle, J.- H., Davies, S. M., Freeman, 
J., Hsu, K. C., Fleischhauer, K., Kenzey, C., Kurtzberg, J., Michel, G., 
Orchard, P. J., Paviglianiti, A., … Ruggeri, A. (2017). Allele- level HLA 
matching for umbilical cord blood transplantation for non- malignant 
diseases in children: A retrospective analysis. Lancet Haematol, 4(7), 
e325– e333. https://doi.org/10.1016/S2352 - 3026(17)30104 - 7
El Helou, G., & Razonable, R. R. (2019). Letermovir for the prevention of 
cytomegalovirus infection and disease in transplant recipients: An 
evidence- based review. Infection and Drug Resistance, 12, 1481– 1491. 
https://doi.org/10.2147/IDR.S180908
El- Cheikh, J., Devillier, R., Crocchiolo, R., Fürst, S., Calmels, B., Faucher, 
C., Stoppa, A. M., Granata, A., Castagna, L., Ladaique, P., Lemarie, 
C., Bouabdallah, R., Zandotti, C., Merlin, M., Berger, P., Chabannon, 
C., & Blaise, D. (2013). Impact of pretransplant donor and recipient 
cytomegalovirus serostatus on outcome for multiple myeloma pa-
tients undergoing reduced intensity conditioning allogeneic stem cell 
transplantation. Mediterranean Journal of Hematology and Infectious 
Diseases, 5(1), e2013026. https://doi.org/10.4084/MJHID.2013.026
Elmariah, H., Kasamon, Y. L., Zahurak, M., Macfarlane, K. W., Tucker, N., 
Rosner, G. L., Bolaños- Meade, J., Fuchs, E. J., Wagner- Johnston, N., 
Swinnen, L. J., Huff, C. A., Matsui, W. H., Gladstone, D. E., McCurdy, 
S. R., Borrello, I., Gocke, C. B., Shanbhag, S., Cooke, K. R., Ali, S. A., … 
Ambinder, R. F. (2018). Haploidentical bone marrow transplantation 
with post- transplant cyclophosphamide using non- first- degree re-
lated donors. Biology of Blood and Marrow Transplantation, 24, 1099– 
1102. https://doi.org/10.1016/j.bbmt.2018.02.005
Emery, V., Zuckerman, M., Jackson, G., Aitken, C., Osman, H., Pagliuca, 
A., Potter, M., Peggs, K., & Clark, A. (2013). Management of cytomeg-
alovirus infection in haemopoietic stem cell transplantation. British 
Journal of Haematology, 162(1), 25– 39. https://doi.org/10.1111/
bjh.12363
Faridi, R. M., Kemp, T. J., Dharmani- Khan, P., Lewis, V., Tripathi, G., 
Rajalingam, R., Daly, A., Berka, N., Storek, J., & Masood Khan, F. 
(2016). Donor- recipient matching for KIR genotypes reduces chronic 
GVHD and missing inhibitory KIR ligands protect against relapse 
after myeloablative, HLA matched hematopoietic cell transplan-
tation. PLoS One, 11(6), e0158242. https://doi.org/10.1371/journ 
al.pone.0158242
Fernández- Viña,, M. A., Klein, J. P., Haagenson, M., Spellman, S. R., 
Anasetti, C., Noreen, H., de Baxter- Lowe, L. A., Cano, P., Flomenberg, 
N., Confer, D. L., Horowitz, M. M., Oudshoorn, M., Petersdorf, E. W., 
Setterholm, M., Champlin, R., Lee, S. J., & de Lima, M. (2013). Multiple 
mismatches at the low expression HLA loci DP, DQ and DRB3/4/5 
associate with adverse outcome in haematopoietic stem cell trans-
plantation. Blood, 121(22), 4603– 4610. https://doi.org/10.1182/
blood - 2013- 02- 481945
Fernandez- Viña, M. A., Wang, T., Lee, S. J., Haagenson, M., Aljurf, M., 
Askar, M., Battiwalla, M., Baxter- Lowe, L.- A., Gajewski, J., Jakubowski, 
A. A., Marino, S., Oudshoorn, M., Marsh, S. G. E., Petersdorf, E. W., 
Schultz, K., Turner, E. V., Waller, E. K., Woolfrey, A., Umejiego, J., … 
Setterholm, M. (2014). Identification of a permissible HLA mismatch 
in hematopoietic stem cell transplantation. Blood, 123(8), 1270– 
1278. https://doi.org/10.1182/blood - 2013- 10- 532671
Fleischhauer, K., Fernandez- Viña, M. A., Wang, T., Haagenson, M., 
Battiwalla, M., Baxter- Lowe, L. A., Ciceri, F., Dehn, J., Gajewski, 
J., Hale, G. A., Heemskerk, M. B. A., Marino, S. R., McCarthy, P. L., 
Miklos, D., Oudshoorn, M., Pollack, M. S., Reddy, V., Senitzer, D., 
Shaw, B. E., … Spellman, S. R. (2014). Risk associations between 
HLA- DPB1 T- cell epitope matching and outcome of unrelated hema-
topoietic cell transplantation are independent of HLA- DPA1. Bone 
Marrow Transplantation, 49(9), 1176– 1183. https://doi.org/10.1038/
bmt.2014.122
Fleischhauer, K., Shaw, B. E., Gooley, T., Malkki, M., Bardy, P., Bignon, 
J. D., Dubois, V., Horowitz, M. M., Madrigal, J. A., Morishima, Y., 
Oudshoorn, M., Ringden, O., Spellman, S., Velardi, A., Zino, E., 
Petersdorf, E. W., & The International Histocompatibility Working 
Group in Hematopoietic Cell Transplantation (2012). Effect of T cell 
epitope matching at HLA- DPB1 in recipients of unrelated donor 
haematopoietic- cell transplantation, a retrospective study. The 
Lancet Oncology, 13(4), 366– 374. https://doi.org/10.1016/S1470 
- 2045(12)70004 - 9
Flomenberg, N., Baxter- Lowe, L. A., Confer, D., Fernandez- Vina, M., 
Filipovich, A., Horowitz, M., Hurley, C., Kollman, C., Anasetti, 
C., Norren, H., Begovich, A., Hildebrand, W., Petersdorf, E., 
Schmeckpeper, B., Setterholm, M., Trachtenberg, E., Williams, T., 
Yunis, E., & Weisdorf, D. (2004). Impact of HLA class I and class II 
high- resolution matching on outcomes of unrelated donor bone mar-
row transplantation, HLA- C mismatching is associated with a strong 
adverse effect on transplantation outcome. Blood, 104(7), 1923– 
1930. https://doi.org/10.1182/blood - 2004- 03- 0803
Fuchs, E. J. (2012). Haploidentical transplantation for hematologic ma-
lignancies: Where do we stand? Hematology: American Society of 
Hematology Education Program, 2012(2012), 230– 236. https://doi.
org/10.1182/ashed ucati on- 2012.1.230
Fürst, D., Müller, C., Vucinic, V., Bunjes, D., Herr, W., Gramatzki, M., 
Schwerdtfeger, R., Arnold, R., Einsele, H., Wulf, G., Pfreundschuh, 
M., Glass, B., Schrezenmeier, H., Schwarz, K., & Mytilineos, J. (2013). 
High resolution HLA- matching in hematopoietic stem cell transplan-
tation, a retrospective collaborative analysis. Blood, 122(18), 3220– 
3229. https://doi.org/10.1182/blood - 2013- 02- 482547
Geneugelijk, K., & Spierings, E. (2017). Matching donor and recipient 
based on predicted indirectly recognizable human leucocyte antigen 
epitopes. International Journal of Immunogenetics, 45, 41– 53. https://
doi.org/10.1111/iji.12359
Geneugelijk, K., Thus, K. A., van Deutekom, H. W. M., Calis, J. J. A., Borst, 
E., Keşmir, C., Oudshoorn, M., van der Holt, B., Meijer, E., Zeerleder, 
S., de Groot, M. R., von dem Borne, P. A., Schaap, N., Cornelissen, 
J., Kuball, J., & Spierings, E. (2019). Exploratory study of predicted 
indirectly recognizable HLA epitopes in mismatched hematopoietic 
cell transplantations. Frontiers in Immunology, 10, 880. https://doi.
org/10.3389/fimmu.2019.00880
Getz, J., Goldenstein, M., Bonfim, C., Funke, V. M., Colturato, V., 
Hamerschlak, N., Torres, M., Sayer, D., Boldt, A., Pasquini, R., & 
Pereira, N. F. (2020). Investigation of MHC gamma block C4A and 
C4B polymorphisms in unrelated hematopoietic stem cell transplan-
tation. Hematology, Transfusion and Cell Therapy, 42, 221– 229. https://
doi.org/10.1016/j.htct.2019.06.004
González- Galarza, F. F., Takeshita, L. Y. C., Santos, E. J. M., Kempson, 
F., Maia, M. H. T., Silva, A. L. S., Silva, A. L. T., Ghattaoraya, G. S., 
Alfirevic, A., Jones, A. R., & Middleton, D. (2015). Allele frequency 
net 2015 update: New features for HLA epitopes, KIR and disease 
and HLA adverse drug reaction associations. Nucleic Acid Research, 
43, D784– D788. https://doi.org/10.1093/nar/gku1166
Gragert, L., Eapen, M., Williams, E., Freeman, J., Spellman, S., Baitty, R., 
Hartzman, R., Rizzo, J. D., Horowitz, M., Confer, D., & Maiers, M. 
     |  103LITTLE ET aL.
(2014). HLA match likelihoods for hematopoietic stem cell grafts in 
the US registry. New England Journal of Medicine, 371(4), 339– 348. 
https://doi.org/10.1056/NEJMs a1311707
Gragert, L., Madbouly, A., Freeman, J., & Maiers, M. (2013). Six- locus 
high resolution HLA haplotype frequencies derived from mixed- 
resolution DNA typing for the entire US donor registry. Human 
Immunology, 74(10), 1313– 1320. https://doi.org/10.1016/j.
humimm.2013.06.025
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N. A., 
Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008). 
NKG2D- deficient mice are defective in tumor surveillance in models 
of spontaneous malignancy. Immunity, 28(4), 571– 580. https://doi.
org/10.1016/j.immuni.2008.02.016
Guinan, K. J., Cunningham, R. T., Meenagh, A., Gonzalez, A., Dring, M. 
M., McGuinness, B. W., Middleton, D., & Gardiner, C. M. (2010). 
Signatures of natural selection and coevolution between killer cell 
immunoglobulin- like receptors (KIR) and HLA class I genes. Genes 
and Immunity, 11(6), 467– 478. https://doi.org/10.1038/gene.2010.9
Gupta, R. K., Abdul- Jawad, S., McCoy, L. E., Mok, H. P., Peppa, D., 
Salgado, M., Martinez- Picado, J., Nijhuis, M., Wensing, A. M. J., Lee, 
H., Grant, P., Nastouli, E., Lambert, J., Pace, M., Salasc, F., Monit, Ch., 
Innes, A. J., Muir, L., Waters, L., … Olavarria, Eduardo (2019). HIV- 1 
remission following CCR5Δ32/Δ32 haematopoietic stem- cell trans-
plantation. Nature, 568(7751), 244– 248. https://doi.org/10.1038/
s4158 6- 019- 1027- 4
Gustafsson- Jernberg, A., Remberger, M., Ringdén, O., & Winiarski, 
J. (2004). Risk factors in pediatric stem cell transplantation for 
leukemia. Pediatric Transplantation, 8(5), 464– 474. https://doi.
org/10.1111/j.1399- 3046.2004.00175.x
Hansen, J. A. (2012). Related or unrelated donor. Blood, 119(10), 2183– 
2184. https://doi.org/10.1182/blood - 2011- 12- 391318
Heatley, S. L., Mullighan, C. G., Doherty, K., Danner, S., O'Connor, G. M., 
Hahn, U., Szer, J., Schwarer, A., Bradstock, K., Sullivan, L. C., Brady, P. 
G., & Brooks, A. G. (2018). Activating KIR haplotype influences clini-
cal outcome following HLA- matched sibling hematopoietic stem cell 
transplantation. HLA, 92, 74– 82. https://doi.org/10.1111/tan.13327
Heemskerk, M. B. A., van Walraven, S. M., Cornelissen, J. J., Barge, R. 
M. Y., Bredius, R. G. M., Egeler, R. M., Tj Lie, J. L. W., Révész, T., 
Sintnicolaas, K., Wulffraat, N. M., Donker, A. E., Hoogerbrugge, P. 
M., van Rood, J. J., Claas, F. H. J., & Oudshoorn, M. (2005). How to 
improve the search for an unrelated haematopoietic stem cell donor. 
Faster is better than more. Bone Marrow Transplantation, 35(7), 645– 
652. https://doi.org/10.1038/sj.bmt.1704865
Herr, W., Eichinger, Y., Beshay, J., Bloetz, A., Vatter, S., Mirbeth, C., 
Distler, E., Hartwig, U. F., & Thomas, S. (2017). HLA- DPB1 mismatch 
alleles represent powerful lekemia rejection antigens in CD4 T- Cell 
immunotherapy after allogeneic stem- cell transplantation. Leukemia, 
31(2), 434– 445. https://doi.org/10.1038/leu.2016.210
Hiby, S. E., Ashrafian- Bonab, M., Farrell, L., Single, R. M., Balloux, F., 
Carrington, M., Moffett, A., & Ebrahimi, Z. (2010). Distribution of 
killer cell immunoglobulin- like receptors (KIR) and their HLA- C li-
gands in two Iranian populations. Immunogenetics, 62(2), 65– 73. 
https://doi.org/10.1007/s0025 1- 009- 0408- 5
Hirv, K., Bloch, K., Fischer, M., Einsiedler, B., Schrezenmeier, H., & 
Mytilineos, J. (2009). Prediction of duration and success rate of unre-
lated hematopoietic stem cell donor searches based on the patient's 
HLA- DRB1 allele and DRB1- DQB1 haplotype frequencies. Bone 
Marrow Transplantation, 44(7), 433– 440. https://doi.org/10.1038/
bmt.2009.53
Hoff, G. A., Fischer, J. C., Hsu, K., Cooley, S., Miller, J. S., Wang, T., 
Haagenson, M., Spellman, S., Lee, S. J., Uhrberg, M., Venstrom, J. M., 
& Verneris, M. R. (2017). Recipient HLA- C haplotypes and miRNA 
148a/b binding sites have no impact on allogeneic hematopoietic cell 
transplant outcomes. Biology of Blood and Marrow Transplantation, 
23(1), 153– 160. https://doi.org/10.1016/j.bbmt.2016.09.028
Holdsworth, R., Hurley, C. K., Marsh, S. G. E., Lau, M., Noreen, H. J., 
Kempenich, J. H., Setterholm, M., & Maiers, M. (2009). The HLA dic-
tionary 2008: A summary of HLA- A, - B, - C, - DRB1/3/4/5, - DQB1 
alleles and their association with serologically defined HLA- A, - B, 
- C, - DR and - DQ antigens. Tissue Antigens, 73(2), 95– 170. https://doi.
org/10.1111/j.1399- 0039.2008.01183.x
Hough, R., Danby, R., Russell, N., Marks, D., Veys, P., Shaw, B., Wynn, 
R., Vora, A., Mackinnon, S., Peggs, K. S., Crawley, C., Craddock, C., 
Pagliuca, A., Cook, G., Snowden, J. A., Clark, A., Marsh, J., Querol, 
S., Parkes, G., … Rocha, V. (2016). Recommendations for a standard 
UK approach to incorporating umbilical cord blood into clinical trans-
plantation practice: An update on cord blood unit selection, donor 
selection algorithms and conditioning protocols. British Journal of 
Haematology, 172(3), 360– 370. https://doi.org/10.1111/bjh.13802
Hsu, K. C., Chida, S., Geraghty, D. E., & Dupont, B. (2002). The killer cell 
immunoglobulin- like receptor (KIR) genomic region: Gene- order, 
haplotypes and allelic polymorphism. Immunological Reviews, 190, 
40– 52. https://doi.org/10.1034/j.1600- 065x.2002.19004.x
Hurley, C. K., Woolfrey, A., Wang, T., Haagenson, M., Umejiego, J., Aljurf, 
M., Askar, M., Battiwalla, M., Dehn, J., Horan, J., Oudshoorn, M., 
Pidala, J., Saber, W., Turner, V., Lee, S. J., & Spellman, S. R. (2013). 
The impact of HLA unidirectional mismatches on the outcome of my-
eloablative hematopoietic stem cell transplantation with unrelated 
donors. Blood, 121(23), 4800– 4806. https://doi.org/10.1182/blood 
- 2013- 01- 480343
Hurley, C. K., Kempenich, J., Wadsworth, K., Sauter, J., Hofmann, J. 
A., Schefzyk, D., Schmidt, A. H., Galarza, P., Cardozo, M. B. R., 
Dudkiewicz, M., Houdova, L., Jindra, P., Sorensen, B. S., Jagannathan, 
L., Mathur, A., Linjama, T., Torosian, T., Freudenberger, R., Manolis, A., 
& Dehn, Jason (2020). Common, intermediate and well- documented 
HLA alleles in world populations: CIWD version 3.0.0. HLA, 95(6), 
516– 531. https://doi.org/10.1111/tan.13811
Hűtter, G., Nowak, D., Mossner, M., Ganepola, S., Műßig, A., Allers, K., … 
Thiel, E. (2009). Long- term control of HIV by CCR5 Delta32/Delta32 
stem- cell transplantation. New England Journal of Medicine, 360, 692– 
698. https://doi.org/10.1056/NEJMo a0802905
Jaime- Pérez, J. C., Cancela- Murrieta, C. O., Salazar- Cavazos, L., Aguilar- 
Calderón, P. E., Salazar- Riojas, R., Méndez- Ramírez, N., Cantú- 
Rodríguez, O. G., Gutiérrez- Aguirre, C. H., & Gómez- Almaguer, 
D. (2020). Impact of HLA- DPB1 matching on clinical outcomes 
after haploidentical- related hematopoietic stem cell transplan-
tation. Revista de Investigacion Clinica, 72(2), 69– 79. https://doi.
org/10.24875/ RIC.19003215
Jiang, W., Johnson, C., Jayaraman, J., Simecek, N., Noble, J., Moffatt, 
M. F., Cookson, W. O., Trowsdale, J., & Traherne, J. A. (2012). Copy 
number variation leads to considerable diversity for B but not A 
haplotypes of the human KIR genes encoding NK cell receptors. 
Genome Research, 22(10), 1845– 1854. https://doi.org/10.1101/
gr.137976.112
Kanda, J., Atsuta, Y., Wake, A., Ichinohe, T., Takanashi, M., Morishima, 
Y., … Kanda, Y. (2013). Impact of the direction of HLA mismatch on 
transplantation outcomes in single unrelated cord blood transplan-
tation. Biology of Blood and Marrow Transplantation, 19(2), 247– 254. 
https://doi.org/10.1016/j.bbmt.2012.09.017.f
Kanda, J., Saji, H., Fukuda, T., Kobayashi, T., Miyamura, K., Eto, T., 
Kurokawa, M., Kanamori, H., Mori, T., Hidaka, M., Iwato, K., Yoshida, 
T., Sakamaki, H., Tanaka, J., Kawa, K., Morishima, Y., Suzuki, R., Atsuta, 
Y., & Kanda, Y. (2012). Related transplantation with HLA- 1 Ag mis-
match in the GVH direction and HLA- 8/8 allele- matched unrelated 
transplantation, a nationwide retrospective study. Blood, 119(10), 
2409– 2416. https://doi.org/10.1182/blood - 2011- 08- 372573
Klasberg, S., Lang, K., Günther, M., Schober, G., Massalski, C., Schmidt, 
A. H., Lange, V., & Schöfl, G. (2019). Patterns of non- ARD variation 
in more than 300 full- length HLA- DPB1 alleles. Human Immunology, 
80(1), 44– 52. https://doi.org/10.1016/j.humimm.2018.05.006
104  |     LITTLE ET aL.
Kollman, C., Howe, C. W. S., Anasetti, C., Antin, J. H., Davies, S. M., 
Filipovich, A. H., Hegland, J., Kamani, N., Kernan, N. A., King, R., 
Ratanatharathorn, V., Weisdorf, D., & Confer, D. L. (2001). Donor 
characteristics as risk factors in recipients after transplantation of 
bone marrow from unrelated donors, the effect of donor age. Blood, 
98(7), 2043– 2051. https://doi.org/10.1182/blood.v98.7.2043
Kollman, C., Maiers, M., Gragert, L., Muller, C., Setterholm, M., 
Oudshoorn, M., & Hurley, C. K. (2007). Estimation of HLA- A, 
- B, - DRB1 haplotype frequencies using mixed resolution data 
from a national registry with selective retyping of volunteers. 
Human Immunology, 68(12), 950– 958. https://doi.org/10.1016/j.
humimm.2007.10.009
Kollman, C., Spellman, S. R., Zhang, M.- J., Hassebroek, A., Anasetti, C., 
Antin, J. H., Champlin, R. E., Confer, D. L., DiPersio, J. F., Fernandez- 
Viña, M., Hartzman, R. J., Horowitz, M. M., Hurley, C. K., Karanes, C., 
Maiers, M., Mueller, C. R., Perales, M.- A., Setterholm, M., Woolfrey, 
A. E., … Eapen, M. (2016). The effect of donor characteristics on 
survival after unrelated donor transplantation for hematologic ma-
lignancy. Blood, 127(2), 260– 267. https://doi.org/10.1182/blood 
- 2015- 08- 663823
Konuma, T., Kato, S., Oiwa- Monna, M., Tanoue, S., Ogawa, M., Isobe, M., 
Tojo, A., & Takahashi, S. (2017). Cryopreserved CD34(+) cell dose, 
but not total nucleated cell dose, influences hematopoietic recov-
ery and extensive chronic graft- versus- host disease after single- unit 
cord blood transplantation in adult patients. Biology of Blood and 
Marrow Transplantation, 23(7), 1142– 1150. https://doi.org/10.1016/j.
bbmt.2017.03.036
Laughlin, M. J., Barker, J., Bambach, B., Koc, O. N., Rizzieri, D. A., Wagner, 
J. E., Gerson, S. L., Lazarus, H. M., Cairo, M., Stevens, C. E., Rubinstein, 
P., & Kurtzberg, J. (2001). Hematopoietic engraftment and survival 
in adult recipients of umbilical- cord blood from unrelated donors. 
New England Journal of Medicine, 344(24), 1815– 1822. https://doi.
org/10.1056/NEJM2 00106 14344 2402
Lee, S. J., Klein, J., Haagenson, M., Baxter- Lowe, L. A., Confer, D. L., 
Eapen, M., Fernandez- Vina, M., Flomenberg, N., Horowitz, M., 
Hurley, C. K., Noreen, H., Oudshoorn, M., Petersdorf, E., Setterholm, 
M., Spellman, S., Weisdorf, D., Williams, T. M., & Anasetti, C. (2007). 
High- resolution donor- recipient HLA matching contributes to the 
success of unrelated donor marrow transplantation. Blood, 110(13), 
4576– 4583. https://doi.org/10.1182/blood - 2007- 06- 097386
Little, A.- M., Green, A., Harvey, J., Hemmatpour, S., Latham, K., Marsh, 
S. G. E., Poulton, K., & Sage, D. (2016). BSHI guideline: HLA matching 
and donor selection for haematopoietic progenitor cell transplanta-
tion. International Journal of Immunogenetics, 43, 263– 286. https://
doi.org/10.1111/iji.12282
Ljungman, P. (2014). The role of cytomegalovirus serostatus on out-
come of hematopoietic stem cell transplantation. Current Opinion in 
Hematology, 21(6), 466– 469. https://doi.org/10.1097/MOH.00000 
00000 000085
Ljungman, P., Brand, R., Hoek, J., de la Camara, R., Cordonnier, C., 
Einsele, H., Styczynski, J., Ward, K. N., & Cesaro, S. (2014). Donor 
cytomegalovirus status influences the outcome of allogeneic stem 
cell transplant, a study by the European group for blood and marrow 
transplantation. Clinical Infectious Diseases, 59(4), 473– 481. https://
doi.org/10.1093/cid/ciu364
Lown, R. N., Marsh, S. G. E., Switzer, G. E., Latham, K. A., Madrigal, J. A., & 
Shaw, B. E. (2014). Ethnicity, length of time on the register and sex pre-
dict donor availability at the confirmatory typing stage. Bone Marrow 
Transplantation, 49, 525– 531. https://doi.org/10.1038/bmt.2013.206
Mack, S. J., Cano, P., Hollenbach, J. A., He, J., Hurley, C. K., Middleton, D., 
Moraes, M. E., Pereira, S. E., Kempenich, J. H., Reed, E. F., Setterholm, 
M., Smith, A. G., Tilanus, M. G., Torres, M., Varney, M. D., Voorter, C. 
E. M., Fischer, G. F., Fleischhauer, K., Goodridge, D., & Fernandez- 
Vina, M. (2013). Common and well- documented HLA alleles: 2012 
update to the CWD catalogue. Tissue Antigens, 81(4), 194– 203. 
https://doi.org/10.1111/tan.12093
Maiers, M., Gragert, L., & Klitz, W. (2007). High resolution HLA alleles 
and haplotypes in the United sates population. Human Immunology, 
68(9), 779– 788. https://doi.org/10.1016/j.humimm.2007.04.005
Mallhi, K. K., Smith, A. R., DeFor, T. E., Lund, T. C., Orchard, P. J., & Miller, 
W. P. (2017). Allele- level HLA matching impacts key outcomes fol-
lowing umbilical cord blood transplantation for inherited metabolic 
disorders. Biology of Blood and Marrow Transplantation, 23(1), 119– 
125. https://doi.org/10.1016/j.bbmt.2016.10.019
Mancusi, A., Ruggeri, L., Urbani, E., Pierini, A., Massei, M. S., Carotti, 
A., Terenzi, A., Falzetti, F., Tosti, A., Topini, F., Bozza, S., Romani, 
L., Tognellini, R., Stern, M., Aversa, F., Martelli, M. F., & Velardi, A. 
(2015). Haploidentical hematopoietic transplantation from KIR 
ligand- mismatched donors with activating KIRs reduces nonrelapse 
mortality. Blood, 125(20), 3173– 3182. https://doi.org/10.1182/
blood - 2014- 09- 599993
Mariotti, J., Maura, F., Spina, F., Roncari, L., Dodero, A., Farina, L., 
Montefusco, V., Carniti, C., Sarina, B., Patriarca, F., Rambaldi, A., 
Onida, F., Olivieri, A., Zallio, F., & Corradini, P. (2014). Impact of cy-
tomegalovirus replication and cytomegalovirus serostatus on the 
outcome of patients with B cell lymphoma after allogeneic stem cell 
transplantation. Biology of Blood and Marrow Transplantation, 20(6), 
885– 890. https://doi.org/10.1016/j.bbmt.2014.02.015
Marsh, S. G. E., Albert, E. D., Bodmer, W. F., Bontrop, R. E., Dupont, B., Erlich, 
H. A., Fernández- Viña, M., Geraghty, D. E., Holdsworth, R., Hurley, C. 
K., Lau, M., Lee, K. W., Mach, B., Maiers, M., Mayr, W. R., Müller, C. 
R., Parham, P., Petersdorf, E. W., Sasazuki, T., … Trowsdale, J. (2010). 
Nomenclature for factors of the HLA system, 2010. Tissue Antigens, 
75(4), 291– 455. https://doi.org/10.1111/j.1399- 0039.2010.01466.x
Martin, P. J., Levine, D. M., Storer, B. E., Nelson, S. C., Dong, X., & Hansen, 
J. A. (2020). Recipient and donor genetic variants associated with 
mortality after allogeneic hematopoietic cell transplantation. Blood 
Advances, 4(14), 3224– 3233. https://doi.org/10.1182/blood advan 
ces.20200 01927
Martínez- Losada, C., Martín, C., Gonzalez, R., Manzanares, B., García- 
Torres, E., & Herrera, C. (2017). Patients lacking a KIR- ligand of 
HLA group C1 or C2 have a better outcome after umbilical cord 
blood transplantation. Frontiers in Immunology, 8, 810. https://doi.
org/10.3389/fimmu.2017.00810
Maskalan, M., Grubic, Z., Serventi Seiwerth, R., Vrhovac, R., Mikulic, M., 
Burek Kamenaric, M., Stingl Jankovic, K., Durakovic, N., & Zunec, R. 
(2020). The MHC gamma block matching: Impact on unrelated hema-
topoietic stem cell transplantation outcome. Human Immunology, 81, 
12– 17. https://doi.org/10.1016/j.humimm.2019.10.005
Mayor, N. P., Hayhurst, J. D., Turner, T. R., Szydlo, R. M., Shaw, B. E., 
Bultitude, W. P., Sayno, J.- R., Tavarozzi, F., Latham, K., Anthias, C., 
Robinson, J., Braund, H., Danby, R., Perry, J., Wilson, M. C., Bloor, 
A. J., McQuaker, I. G., MacKinnon, S., Marks, D. I., … Marsh, S. G. 
E. (2019). Recipients receiving better HLA- matched hematopoietic 
cell transplantation grafts, uncovered by a novel HLA typing method, 
have superior survival: A retrospective study. Biology of Blood and 
Marrow Transplantation, 25(3), 443– 450. https://doi.org/10.1016/j.
bbmt.2018.12.768
Milano, F., Gooley, T., Wood, B., Woolfrey, A., Flowers, M. E., Doney, K., 
Witherspoon, R., Mielcarek, M., Deeg, J. H., Sorror, M., Dahlberg, 
A., Sandmaier, B. M., Salit, R., Petersdorf, E., Appelbaum, F. R., & 
Delaney, C. (2016). Cord- Blood Transplantation in Patients with 
Minimal Residual Disease. New England Journal of Medicine, 375(10), 
944– 953. https://doi.org/10.1056/nejmo a1602074
Morin- Zorman, S., Loiseau, P., Taupin, J.- L., & Caillat- Zucman, S. (2016). 
Donor- specific anti- HLA antibodies in allogeneic hematopoietic 
stem cell transplantation. Frontiers in Immunology, 7, 307. https://doi.
org/10.3389/fimmu.2016.00307
     |  105LITTLE ET aL.
Morishima, S., Shiina, T., Suzuki, S., Ogawa, S., Sato- Otsubo, A., 
Kashiwase, K., Azuma, F., Yabe, T., Satake, M., Kato, S., Kodera, Y., 
Sasazuki, T., & Morishima, Y. (2018). Evolutionary basis of HLA- 
DPB1 alleles affects acute GvHD in unrelated donor stem cell trans-
plantation. Blood, 131(7), 808– 817. https://doi.org/10.1182/blood 
- 2017- 08- 801449
Morishima, Y., Sasazuki, T., Inoko, H., Juji, T., Akaza, T., Yamamoto, K., 
Ishikawa, Y., Kato, S., Sao, H., Sakamaki, H., Kawa, K., Hamajima, N., 
Asano, S., & Kodera, Y. (2002). The clinical significance of human 
leukocyte antigen (HLA) allele compatibility in patients receiving a 
marrow transplant from serologically HLA- A, HLA- B, and HLA- DR 
matched unrelated donors. Blood, 99(11), 4200– 4206. https://doi.
org/10.1182/blood.v99.11.4200
Moyer, A. M., Hashmi, S. K., Kroning, C. M., Kremers, W. K., De Goey, 
S. R., Patnaik, M., Litzow, M., Gastineau, D. A., Hogan, W. J., Jacob, 
E. K., Kreuter, J. D., Wakefield, L. L., & Gandhi, M. J. (2017). Clinical 
outcomes of HLA- DPB1 mismatches in 10/10 HLA- matched unre-
lated donor- recipient pairs undergoing allogeneic stem cell trans-
plant. European Journal of Haematology, 99(3), 275– 282. https://doi.
org/10.1111/ejh.12916
Mrazek, F., Onderkova, J., Szotkowski, T., Königova, N., Ambruzova, Z., 
& Raida, L. (2014). Somatic mutation in acute myelogenous leuke-
mia cells imitate novel germline HLA- A allele, a case report. Tissue 
Antigens, 83(6), 414– 417. https://doi.org/10.1111/tan.12362
National Institute for Health and Care Excellence (2019). Letermovir 
for preventing cytomegalovirus disease after a stem cell transplant. 
Technology appraisal guidance [TA591]. Retrieved from https://www.
nice.org.uk/guida nce/ta591/ chapt er/3- Commi ttee- discu ssion
Neuchel, C., Fürst, D., Niederwieser, D., Bunjes, D., Tsamadou, C., 
Wulf, G., Pfreundschuh, M., Wagner, E., Stuhler, G., Einsele, H., 
Schrezenmeier, H., & Mytilineos, J. (2017). Impact of donor acti-
vating KIR genes on HSCT outcome in C1- ligand negative myeloid 
disease patients transplanted with unrelated donors – A retrospec-
tive study. PLoS One, 12, e0169512. https://doi.org/10.1371/journ 
al.pone.0169512
Nunes, E., Heslop, H., Fernandez- Vina, M., Taves, C., Wagenknecht, D. 
R., Eisenbrey, A. B., Fischer, G., Poulton, K., Wacker, K., Hurley, C. 
K., Noreen, H., & Sacchi, N. (2011). Definitions of histocompatibil-
ity typing terms. Human Immunology, 72(12), 1214– 1216. https://doi.
org/10.1016/j.humimm.2011.06.002 and Blood, 118, e180– e183. 
https://doi.org/10.1182/blood - 2011- 05- 353490
Oevermann, L., Michaelis, S., Mezger, M., Lang, P., Toporski, J., Bertaina, 
A., Zecca, M., Moretta, L., Locatelli, F., & Handgretinger, R. (2014). 
KIR B haplotype donors confer a reduced risk after haploidentical 
transplantation in children with ALL. Blood, 124(17), 2744– 2747. 
https://doi.org/10.1182/blood - 2014- 03- 565069
Oran, B., Cao, K., Saliba, R. M., Rezvani, K., de Lima, M., Ahmed, S., Hosing, 
C. M., Popat, U. R., Carmazzi, Y., Kebriaei, P., Nieto, Y., Rondon, G., 
Willis, D., Shah, N., Parmar, S., Olson, A., Moore, B., Marin, D., Mehta, 
R., … Shpall, E. J. (2015). Better allele- level matching improves trans-
plant related mortality after double cord blood transplantation. 
Haematologica, 100(10), 1361– 1370. https://doi.org/10.3324/haema 
tol.2015.127787
Page, K. M., Zhang, L., Mendizabal, A., Wease, S., Carter, S., Gentry, T., 
Balber, A. E., & Kurtzberg, J. (2011). Total colony- forming units are 
a strong, independent predictor of neutrophil and platelet engraft-
ment after unrelated umbilical cord blood transplantation: A single- 
center analysis of 435 cord blood transplants. Biology of Blood and 
Marrow Transplantation, 17(9), 1362– 1374. https://doi.org/10.1016/j.
bbmt.2011.01.011
Panagouli, E., Dinou, A., Mallis, P., Michalopoulos, E., Papassavas, 
A., Spyropoulou- Vlachou, M., Meletis, J., Angelopoulou, M., 
Konstantopoulos, K., Vassilakopoulos, T., & Stavropoulos- Giokas, 
C. (2018). Non- inherited maternal antigens identify acceptable 
HLA mismatches: A new policy for the Hellenic Cord Blood Bank. 
Bioengineering, 5(4), 77. https://doi.org/10.3390/bioen ginee ring5 
040077
Passweg, J. R., Baldomero, H., Basak, G. W., Chabannon, C., Corbacioglu, 
S., Duarte, R., Kuball, J., Lankester, A., Montoto, S., de Latour, R. P., 
Snowden, J. A., Styczynski, J., Yakoub- Agha, I., Arat, M., Mohty, M., & 
Kröger, N. (2019). The EBMT activity survey report 2017: A focus on 
allogeneic HCT for nonmalignant indications and on the use of non- 
HCT cell therapies. Bone Marrow Transplantation, 54(10), 1575– 1585. 
https://doi.org/10.1038/s4140 9- 019- 0465- 9
Passweg, J. R., Baldomero, H., Chabannon, C., Basak, G. W., Corbacioglu, 
S., Duarte, R., Dolstra, H., Lankester, A. C., Mohty, M., Montoto, S., de 
Latour, R. P., Snowden, J. A., Styczynski, J., Yakoub- Agha, I., & Kröger, 
N. (2020). The EBMT activity survey on hematopoietic- cell trans-
plantation and cellular therapy 2018. Bone Marrow Transplantation, 
55(8), 1604– 1613. https://doi.org/10.1038/s4140 9- 020- 0826- 4
Passweg, J. R., Zhang, M- J., Rocha, V., Kan, F., Champlin, R. E., Isola, 
L. M., Gee, A. P., Gibson, J., Laughlin, M. J., Lazarus, H. M., 
Loren, A., Marks, D. I., Gratwohl, A., & Eapen, M. (2011). Donor 
Characteristics Affecting Graft Failure, Graft- versus- Host Disease, 
and Survival after Unrelated Donor Transplantation with Reduced- 
Intensity Conditioning for Hematologic Malignancies. Biology of 
Blood and Marrow Transplantation, 17(12), 1869– 1873. https://doi.
org/10.1016/j.bbmt.2011.07.008
Patel, S. S., Rybicki, L. A., Yurch, M., Thomas, D., Liu, H., Dean, R., 
Jagadeesh, D., Hill, B., Pohlman, B., Bolwell, B., Hanna, R., Hamilton, 
B. K., Kalaycio, M., Gerds, A. T., Cober, E., Mossad, S., Zhang, A., 
Majhail, N. S., Askar, M., & Sobecks, R. (2020). Influence of major his-
tocompatibility complex class I chain- related gene A polymorphisms 
on cytomegalovirus disease after allogeneic hematopoietic cell 
transplantation. Hematology/Oncology and Stem Cell Therapy, 13(1), 
32– 39. https://doi.org/10.1016/j.hemonc.2019.10.001
Petersdorf, E. W. (2017). Role of major histocompatibility complex vari-
ation in graft- versus- host disease after hematopoietic cell transplan-
tation. F1000Research, 6, 617. https://doi.org/10.12688/ f1000 resea 
rch.10990.1
Petersdorf, E. W., Anasetti, C., Martin, P. J., Gooley, T., Radich, J., Malkki, 
M., Woolfrey, A., Smith, A., Mickelson, E., & Hansen, J. A. (2004). 
Limits of HLA mismatching in unrelated hematopoietic cell trans-
plantation. Blood, 104(9), 2976– 2980. https://doi.org/10.1182/blood 
- 2004- 04- 1674
Petersdorf, E. W., Carrington, M., O'hUigin, C., Bengtsson, M., De Santis, 
D., Dubois, V., Gooley, T., Horowitz, M., Hsu, K., Madrigal, J. A., 
Maiers, M. J., Malkki, M., McKallor, C., Morishima, Y., Oudshoorn, 
M., Spellman, S. R., Villard, J., Stevenson, P., Petersdorf, E. W., … 
International Histocompatibility Working Group in Hematopoietic 
Cell Transplantation (2020). Role of HLA- B exon 1 in graft- versus- 
host disease after unrelated haemopoietic cell transplantation: A 
retrospective cohort study. Lancet Haematology, 7, e50– e60. https://
doi.org/10.1016/S2352 - 3026(19)30208 - X
Petersdorf, E. W., Gooley, T. A., Malkki, M., Bacigalupo, A. P., Cesbron, 
A., Du Toit, E., Ehninger, G., Egeland, T., Fischer, G. F., Gervais, T., 
Haagenson, M. D., Horowitz, M. M., Hsu, K., Jindra, P., Madrigal, 
A., Oudshoorn, M., Ringdén, O., Schroeder, M. L., Spellman, S. R., 
… Carrington, M. (2014). HLA- C expression levels define permissi-
ble mismatches in hematopoietic cell transplantation. Blood, 124(26), 
3996– 4003. https://doi.org/10.1182/blood - 2014- 09- 599969
Petersdorf, E. W., Hansen, J. A., Martin, P. J., Woolfrey, A., Malkki, M., 
Gooley, T., Storer, B., Mickelson, E., Smith, A., & Anasetti, C. (2001). 
Major- histocompatibility- complex class I alleles and antigens in 
hematopoietic- cell transplantation. New England Journal of Medicine, 
345(25), 1794– 1800. https://doi.org/10.1056/NEJMo a011826
Petersdorf, E. W., Malkki, M., Horowitz, M. M., Spellman, S. R., Haagenson, 
M. D., & Wang, T. (2013). Mapping MHC haplotype effects in unre-
lated donor hematopoietic cell transplantation. Blood, 121(10), 1896– 
1905. https://doi.org/10.1182/blood - 2012- 11- 465161
106  |     LITTLE ET aL.
Petersdorf, E. W., Malkki, M., O'hUigin, C., Carrington, M., Gooley, T., 
Haagenson, M. D., Horowitz, M. M., Spellman, S. R., Wang, T., & 
Stevenson, P. (2015). High HLA- DP expression and graft- versus- host 
disease. New England Journal of Medicine, 373(7), 599– 609. https://
doi.org/10.1056/NEJMo a1500140
Petersdorf, E. W., & O'hUigin, C. (2019). The MHC in the era of next- 
generation sequencing: implications for bridging structure with func-
tion. Human Immunology, 80(1), 67– 78. https://doi.org/10.1016/j.
humimm.2018.10.002
Petersdorf, E. W., Stevenson, P., Malkki, M., Strong, R. K., Spellman, S. R., 
Haagenson, M. D., Horowitz, M. M., Gooley, T., & Wang, T. (2018). 
Patient HLA germline variation and transplant survivorship. Journal 
of Clinical Oncology, 36(24), 2524– 2531. https://doi.org/10.1200/
JCO.2017.77.6534
Pidala, J., Lee, S. J., Ahn, K. W., Spellman, S., Wang, H.- L., Aljurf, M., 
Askar, M., Dehn, J., Fernandez Viña, M., Gratwohl, A., Gupta, V., 
Hanna, R., Horowitz, M. M., Hurley, C. K., Inamoto, Y., Kassim, A. 
A., Nishihori, T., Mueller, C., Oudshoorn, M., … Anasetti, C. (2014). 
Nonpermissive HLA- DPB1 mismatch increases mortality after 
myeloablative unrelated allogeneic hematopoietic cell transplan-
tation. Blood, 124(16), 2596– 2606. https://doi.org/10.1182/blood 
- 2014- 05- 576041
Pidala, J., Wang, T., Haagenson, M., Spellman, S. R., Askar, M., Battiwalla, 
M., Baxter- Lowe, L. A., Bitan, M., Fernandez- Viña, M., Gandhi, 
M., Jakubowski, A. A., Maiers, M., Marino, S. R., Marsh, S. G. E., 
Oudshoorn, M., Palmer, J., Prasad, V. K., Reddy, V., Ringden, O., … 
Anasetti, C. (2013). Amino acid substitution at peptide- binding pock-
ets of HLA class I molecules increases risk of severe acute GVHD 
and mortality. Blood, 122(22), 3651– 3658. https://doi.org/10.1182/
blood - 2013- 05- 501510
Politikos, I., Davis, E., Nhaissi, M., Wagner, J. E., Brunstein, C. G., Cohen, 
S., Shpall, E. J., Milano, F., Scaradavou, A., & Barker, J. N. (2020). 
Guidelines for cord blood unit selection. Biology of Blood and 
Marrow Transplantation, 26, 2190– 2196. https://doi.org/10.1016/j.
bbmt.2020.07.030
Pond, G. R., Lipton, J. H., & Messner, H. A. (2006). Long- term survival 
after blood and marrow transplantation: Comparison with an age- 
and gender- matched normative population. Biology of Blood and 
Marrow Transplantation, 12(4), 422– 429. https://doi.org/10.1016/j.
bbmt.2005.11.518
Powley, L., Brown, C., Melis, A., Li, Y., Parkes, G., & Navarrete, C. V. (2016). 
Consideration of noninherited maternal Ags as permissible HLA mis-
matches in cord blood donor selection. Bone Marrow Transplantation, 
51(5), 675– 679. https://doi.org/10.1038/bmt.2015.344
Purtill, D., Smith, K., Devlin, S., Meagher, R., Tonon, J., Lubin, M., Ponce, D. 
M., Giralt, S., Kernan, N. A., Scaradavou, A., Stevens, C. E., & Barker, 
J. N. (2014). Dominant unit CD34+ cell dose predicts engraftment 
after double- unit cord blood transplantation and is influenced by 
bank practice. Blood, 124(19), 2905– 2912. https://doi.org/10.1182/
blood - 2014- 03- 566216
Querol, S., Gomez, S. G., Pagliuca, A., Torrabadella, M., & Madrigal, J. 
A. (2010). Quality rather than quantity: The cord blood bank di-
lemma. Bone Marrow Transplantation, 45(6), 970– 978. https://doi.
org/10.1038/bmt.2010.7
Querol, S., & Rocha, V. (2019). Procurement and management of cord 
blood. In E. Carreras, C. Dufour, M. Mohty, & N. Kröger (Eds.), The 
EBMT handbook: Hematopoietic stem cell transplantation and cellular 
therapies (7th ed., chapter 18, pp. 131– 136).Springer Open.
Rashidi, A., Hamadani, M., Zhang, M.- J., Wang, H.- L., Abdel- Azim, H., 
Aljurf, M., Assal, A., Bajel, A., Bashey, A., Battiwalla, M., Beitinjaneh, 
A. M., Bejanyan, N., Bhatt, V. R., Bolaños- Meade, J., Byrne, M., Cahn, 
J.- Y., Cairo, M., Ciurea, S., Copelan, E., … Saber, W. (2019). Outcomes 
of haploidentical vs matched sibling transplantation for acute my-
eloid leukemia in first complete remission. Blood Advances, 3(12), 
1826– 1836. https://doi.org/10.1182/blood advan ces.20190 00050
Reisner, Y., Hagin, D., & Martelli, M. F. (2011). Haploidentical hema-
topoietic transplantation: Current status and future perspec-
tives. Blood, 118(23), 6006– 6017. https://doi.org/10.1182/blood 
- 2011- 07- 338822
Robin, M., Porcher, R., Adès, L., Boissel, N., Raffoux, E., Xhaard, A., 
Larghero, J., Gardin, C., Himberlin, C., Delmer, A., Fenaux, P., 
Dombret, H., Socié, G., & Peffault de Latour, R. (2013). Matched 
unrelated or matched sibling donors result in comparable out-
comes after non- myeloablative HSCT in patients with AML or 
MDS. Bone Marrow Transplantation, 48(10), 1296– 1301. https://doi.
org/10.1038/bmt.2013.50
Robinson, J., Halliwell, J. A., Hayhurst, J. D., Flicek, P., Parham, P., & 
Marsh, S. G. E. (2015). The IPD and IMGT/HLA database: Allele vari-
ant databases. Nucleic Acids Research, 43, D423– 431. https://doi.
org/10.1093/nar/gku1161
Rocha, V., Cornish, J., Sievers, E. L., Filipovich, A., Locatelli, F., Peters, 
C., Remberger, M., Michel, G., Arcese, W., Dallorso, S., Tiedemann, 
K., Busca, A., Chan, K- W., Kato, S., Ortega, J., Vowels, M., Zander, 
A., Souillet, G., Oakill, A., & Gluckman, E. (2001). Comparison of 
outcomes of unrelated bone marrow and umbilical cord blood trans-
plants in children with acute leukemia. Blood, 97(10), 2962– 2971. 
https://doi.org/10.1182/blood.v97.10.2962
Rocha, V. R., Giannotti, F., Ruggeri, A., Chevallier, P., Blaise, D., Ceballos, 
P., Michallet, M., Deconinck, E., Cornelissen, J., de la Tour, R. P., 
Petersen, E., Karakasis, D., Volt, F., Paviglianiti, A., & Gluckman, E. 
(2015). Selecting double cord blood units for adults with hema-
tological malignancies: Impact of ABO, HLA and cell dose on out-
comes after double cord blood transplants a CBC- Cellular Therapy 
& Immunobiology Working Party, EBMT and Eurocord Study, [ab-
stract]. Blood, 126(23), Abstract 3214.
Rocha, V., Spellman, S., Zhang, M.- J., Ruggeri, A., Purtill, D., Brady, C., 
Baxter- Lowe, L. A., Baudoux, E., Bergamaschi, P., Chow, R., Freed, 
B., Koegler, G., Kurtzberg, J., Larghero, J., Lecchi, L., Nagler, A., 
Navarrette, C., Prasad, V., Pouthier, F., … Eurocord- European Blood 
and Marrow Transplant Group and the Center for International Blood 
and Marrow Transplant Research (2012). Effect of HLA- matching 
recipients to donor non- inherited maternal antigens on outcomes 
after mismatched umbilical cord blood transplantation for hemato-
logic malignancy. Biology of Blood and Marrow Transplantation, 18(12), 
1890– 1896. https://doi.org/10.1016/j.bbmt.2012.07.010
Rocha, V., Wagner, J. E., Sobocinski, K. A., Klein, J. P., Zhang, M.- J., Horowitz, 
M. M., & Gluckman, E. (2000). Graft- versus- host disease in children 
who have received a cord- blood or bone marrow transplant from an 
HLA- identical sibling. New England Journal of Medicine, 342(25), 1846– 
1854. https://doi.org/10.1056/NEJM2 00006 22342 2501
Roe, D., Vierra- Green, C., Pyo, C.- W., Eng, K., Hall, R., Kuang, R., 
Spellman, S., Ranade, S., Geraghty, D. E., & Maiers, M. (2017). 
Revealing complete complex KIR haplotypes phased by long- read 
sequencing technology. Genes and Immunity, 18(3), 127– 134. https://
doi.org/10.1038/gene.2017.10
Roelen, D., de Vaal, Y., Vierra- Green, C., Waldvogel, S., Spellman, S., 
Claas, F., & Oudshoorn, M. (2018). HLA mismatches that are iden-
tical for the antigen recognition domain are less immunogenic. Bone 
Marrow Transplantation, 53(6), 729– 740. https://doi.org/10.1038/
s4140 9- 018- 0108- 6
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., 
Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999). Role 
of natural killer cell alloreactivity in HLA- mismatched hematopoi-
etic stem cell transplantation. Blood, 94(1), 333– 339. https://doi.
org/10.1182/blood.V94.1.333.413a31_333_339
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, 
A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & 
Velardi, A. (2002). Effectiveness of donor natural killer cell alloreac-
tivity in mismatched hematopoietic transplants. Science, 295(5562), 
2097– 2100. https://doi.org/10.1126/scien ce.1068440
     |  107LITTLE ET aL.
Ruggeri, L., Mancusi, A., Urbani, E., & Velardi, A. (2016). Identifying NK 
alloreactive donors for haploidentical hematopoietic stem cell trans-
plantation. Methods in Molecular Biology, 1393, 141– 145. https://doi.
org/10.1007/978- 1- 4939- 3338- 9_14
Rutten, C. E., van Luxemburg- Heijs, S. A. P., Griffioen, M., Marijt, E. W. 
A., Jedema, I., Heemskerk, M. H. M., Posthuma, E. F. M., Willemze, 
R., & Falkenburg, J. H. F. (2008). HLA- DP as specific targetfor cellular 
immunotherapy in HLA class II- expressing B- cell leukemia. Leukemia, 
22(7), 1387– 1394. https://doi.org/10.1038/leu.2008.90
Rutten, C. E., van Luxemburg- Heijs, S. A. P., Halkes, C. J. M., van 
Bergen, C. A. M., Marijt, E. W. A., Oudshoorn, M., Griffioen, M., & 
Falkenburg, J. H. F. (2013). Patient HLA- DP- specific CD4+ T cells 
from HLA- DPB1- mismatched donor lymphocyte infusion can induce 
graft- versus- leukemia reactivity in the presence or absence of graft- 
versus- host disease. Biology of Blood and Marrow Transplantation, 
19(1), 40– 48. https://doi.org/10.1016/j.bbmt.2012.07.020
Sacchi, N., Sormani, M. P., Marcon, J., Lamparelli, T., Fanin, R., Garbarino, L., 
Miotti, V., Bandini, G., Bosi, A., Ciceri, F., Bacigalupo, A., Fleischhauer, 
K., & Gruppo Italiano Trapianto di Midollo Osseo, Cellule Staminale 
Ematopoietiche (CSE) e Terapia Cellulare, and the Italian Bone 
Marrow Donor Registry (2009). Nonpermissive HLA- DPB1 disparity 
is a significant independent risk factor for mortality after unrelated 
hematopoietic stem cell transplantation. Blood, 114(7), 1437– 1444. 
https://doi.org/10.1182/blood - 2009- 01- 200378
Sahin, U., Dalva, K., Gungor, F., Ustun, C., & Beksac, M. (2018). Donor- 
recipient killer immunoglobulin like receptor (KIR) genotype match-
ing has a protective effect on chronic graft versus host disease and 
relapse incidence following HLA- identical sibling hematopoietic 
stem cell transplantation. Annals of Hematology, 97, 1027– 1039. 
https://doi.org/10.1007/s0027 7- 018- 3274- 0
Sanchez- Mazas, A., Nunes, J. M., Middleton, D., Sauter, J., Buhler, S., McCabe, 
A., Hofmann, J., Baier, D. M., Schmidt, A. H., Nicoloso, G., Andreani, M., 
Grubic, Z., Tiercy, J.- M., & Fleischhauer, K. (2017). Common and well- 
documented HLA alleles over all of Europe and within European sub- 
regions: A catalogue from the European Federation for Immunogenetics. 
HLA, 89, 104– 113. https://doi.org/10.1111/tan.12956
Sanz, J., Montesinos, P., Saavedra, S., Lorenzo, I., Senent, L., Planelles, 
D., Larrea, L., Martín, G., Palau, J., Jarque, I., Martínez, J., de la Rubia, 
J., Moscardó, F., Martinez, D., Gómez, I., López, M., Sanz, M. A., 
Sanz, G. F. (2010). Single- Unit Umbilical Cord Blood Transplantation 
from Unrelated Donors in Adult Patients with Chronic Myelogenous 
Leukemia. Biology of Blood and Marrow Transplantation, 16, (11), 
1589– 1595. https://doi.org/10.1016/j.bbmt.2010.05.014
Scaradavou, A., Brunstein, C. G., Eapen, M., Le- Rademacher, J., Barker, 
J. N., Chao, N., Cutler, C., Delaney, C., Kan, F., Isola, L., Karanes, 
C., Laughlin, M. J., Wagner, J. E., & Shpall, E. J. (2013). Double unit 
grafts successfully extend the application of umbilical cord blood 
transplantation in adults with acute leukemia. Blood, 121, 752– 758. 
https://doi.org/10.1182/blood - 2012- 08- 449108
Scaradavou, A., Smith, K. M., Hawke, R., Schaible, A., Abboud, M., Kernan, 
N. A., Young, J. W., & Barker, J. N. (2010). Cord blood units with low 
CD34+ cell viability have a low probability of engraftment after dou-
ble unit transplantation. Biology of Blood and Marrow Transplantation, 
16, 500– 508. https://doi.org/10.1016/j.bbmt.2009.11.013
Schmidt, A. H., Solloch, U. V., Baier, D., Yazici, B., Özcan, M., Stahr, A., 
Schumacher, S., Ehninger, G., & Rutt, C. (2009). Criteria for initia-
tion and evaluation of minority donor programs and application to 
the example of donors of Turkish descent in Germany. Bone Marrow 
Transplantation, 44, 405– 412. https://doi.org/10.1038/bmt.2009.55
, Socié, G., Schwerdtfeger, R., Kröger, N., Ganser, A., Niederwieser, D., 
Polge, E., Blau, I. W., Mohty, M. (2013). CMV serostatus still has an 
important prognostic impact in de novo acute leukemia patients 
after allogeneic stem cell transplantation: a report from the Acute 
Leukemia Working Party of EBMT. Blood, 122, (19), 3359– 3364. 
https://doi.org/10.1182/blood - 2013- 05- 499830
Schöne, B., Bergmann, S., Lang, K., Wagner, I., Schmidt, A. H., Petersdorf, 
E. W., & Lange, V. (2018). Predicting an HLA- DPB1 expression 
marker based on standard DPB1 genotyping: Linkage analysis of 
over 32,000 samples. Human Immunology, 79(1), 20– 27. https://doi.
org/10.1016/j.humimm.2017.11.001
Sharma, P., Purev, E., Haverkos, B., Pollyea, D. A., Cherry, E., Kamdar, 
M., Mark, T., Forsberg, P., Sherbenou, D., Hammes, A., Rabinovitch, 
R., Smith, C. A., & Gutman, J. A. (2020). Adult cord blood trans-
plant results in comparable overall survival and improved GRFS vs 
matched related transplant. Blood Advances, 4, 2227– 2235. https://
doi.org/10.1182/blood advan ces.20200 01554
Shaw, B. E., Gooley, T. A., Malkki, M., Madrigal, J. A., Begovich, A. B., 
Horowitz, M. M., Gratwohl, A., Ringdén, O., Marsh, S. G. E., & 
Petersdorf, E. W. (2007). The importance of HLA- DPB1 in unrelated 
donor haematopoietic stem cell transplantation. Blood, 110, 4560– 
4566. https://doi.org/10.1182/blood - 2007- 06- 095265
Shaw, B. E., Logan, B. R., Spellman, S. R., Marsh, S. G. E., Robinson, 
J., Pidala, J., Hurley, C., Barker, J., Maiers, M., Dehn, J., Wang, H., 
Haagenson, M., Porter, D., Petersdorf, E. W., Woolfrey, A., Horowitz, 
M. M., Verneris, M., Hsu, K. C., Fleischhauer, K., & Lee, S. J. (2018). 
Development of an unrelated donor selection score predictive of 
survival after HCT: Donor age matters most. Biology of Blood and 
Marrow Transplantation, 24, 1049– 1056. https://doi.org/10.1016/j.
bbmt.2018.02.006
Shaw, B. E., Mayor, N. P., Richard, S., Bultitude, W. P., Keiren, K., Julia, 
P., Marie, W., Clark, A., Mackinnon, S., Marks, D. I., Pagliuca, A., 
Potter, M., Russell, N., Thomson, K., Madrigal, J. A., & Marsh, S. G. 
E. (2014). Patient/donor CMV matching is a critical determinant of 
survival in unrelated donor haematopoietic stem cell transplantation, 
[abstract]. Blood, 124(21), Abstract 1207. https://doi.org/10.1182/
blood.V124.21.1207.1207
Shaw, B. E., Mayor, N. P., Russell, N. H., Apperley, J. F., Clark, R. E., 
Cornish, J., Darbyshire, P., Ethell, M. E., Goldman, J. M., Little, A- M., 
Mackinnon, S., Marks, D. I., Pagliuca, A., Thomson, K., Marsh, S. G. E., 
Madrigal, J. A. (2010). Diverging effects of HLA– DPB1 matching sta-
tus on outcome following unrelated donor transplantation depend-
ing on disease stage and the degree of matching for other HLA al-
leles. Leukemia, 24(1), 58– 65. https://doi.org/10.1038/leu.2009.239
Shaw, B. E., Mayor, N. P., Szydlo, R. M., Bultitude, W. P., Anthias, C., 
Kirkland, K., Perry, J., Clark, A., Mackinnon, S., Marks, D. I., Pagliuca, 
A., Potter, M. N., Russell, N. H., Thomson, K., Madrigal, J. A., & Marsh, 
S. G. E. (2017). Recipient/donor HLA and CMV matching in recipients 
of T- cell- depleted unrelated donor haematopoietic cell transplants. 
Bone Marrow Transplantation, 52, 717– 725. https://doi.org/10.1038/
bmt.2016.352
Shaw, B. E., Robinson, J., Fleischhauer, K., Madrigal, J. A., & Marsh, S. G. 
E. (2013). Translating the HLA- DPB1 T- cell epitope- matching algo-
rithm into clinical practice. Bone Marrow Transplantation, 48, 1510– 
1512. https://doi.org/10.1038/bmt.2013.91
Shimoni, A., Vago, L., Bernardi, M., Yerushalemi, R., Peccatori, J., Greco, 
R., Shem- Tov, N., Russo, A. L., Danylesko, D., Apel, A., Bonini, C., 
Stanghellini, M. T. L., Nagler, A., & Ciceri, F. (2017). Missing HLA C 
group 1 ligand in patients with AML and MDS is associated with re-
duced risk of relapse and better survival after allogeneic stem cell 
transplantation with fludarabine and treosulfan reduced toxicity 
conditioning. American Journal of Hematology, 92, 1011– 1019. https://
doi.org/10.1002/ajh.24827
Shouval, R., Fein, J. A., Labopin, M., Kröger, N., Duarte, R. F., Bader, P., 
chabannon, C., Kuball, J., Basak, G. W., Dufour, C., Galimard, J- E., 
Polge, E., Lankester, A., Montoto, S., Snowden, J. A., Styczynski, J., 
Yakoub- Agha, I., Mohty, M., & Nagler, A. (2019). Outcomes of allo-
geneic haematopoietic stem cell transplantation from HLA- matched 
and alternative donors: A European Society for Blood and Marrow 
Transplantation registry retrospective analysis. Lancet Haematology, 
6, 573– 584. https://doi.org/10.1016/S2352 - 3026(19)30158 - 9
108  |     LITTLE ET aL.
Sobecks, R. M., Askar, M., Thomas, D., Rybicki, L., Kalaycio, M., Dean, 
R., Avery, R., Mossad, S., Copelan, E., & Bolwell, B. J. (2011). 
Cytomegalovirus reactivation after matched sibling donor reduced- 
intensity conditioning allogeneic hematopoietic stem cell transplant 
correlates with donor killer immunoglobulin- like receptor genotype. 
Experimental and Clinical Transplantation, 9(1), 7– 13.
Sobecks, R. M., Wang, T., Askar, M., Gallagher, M. M., Haagenson, 
M., Spellman, S., Fernandez- Vina, M., Malmberg, K- J., Müller, C., 
Battiwalla, M., Gajewski, J., Verneris, M.l R., Ringdén, O., Marino, 
S., Davies, S., Dehn, J., Bornhäuser, M., Inamoto, Y., Woolfrey, A., & 
Hsu, K. (2015). Impact of KIR and HLA Genotypes on Outcomes after 
Reduced- Intensity Conditioning Hematopoietic Cell Transplantation. 
Biology of Blood and Marrow Transplantation, 21(9), 1589– 1596. 
https://doi.org/10.1016/j.bbmt.2015.05.002
Solberg, O. D., Mack, S. J., Lancaster, A. K., Single, R. M., Tsai, Y., Sanchez- 
Mazas, A., & Thomson, G. (2008). Balancing selection and hetero-
geneity across the classical human leukocyte antigen loci: A meta 
analytic review of 497 population studies. Human Immunology, 69(7), 
443– 464. https://doi.org/10.1016/j.humimm.2008.05.001
Steinle, A., Li, P., Morris, D. L., Groh, V., Lanier, L. L., Strong, R. K., & Spies, 
T. (2001). Interactions of human NKG2D with its ligands MICA, MICB, 
and homologs of the mouse RAE- 1 protein family. Immunogenetics, 
53(4), 279– 287. https://doi.org/10.1007/s0025 10100325
Stern, M., Ruggeri, L., Mancusi, A., Bernardo, M. E., de Angelis, C., 
Bucher, C., Locatelli, F., Aversa, F., & Velardi, A. (2008). Survival after 
T cell- depleted haploidentical stem cell transplantation is improved 
using the mother as donor. Blood, 112, 2990– 2995. https://doi.
org/10.1182/blood - 2008- 01- 135285
Stevanovic, S., van Bergen, C. A. M., van Luxembourg- Heijs, S. A. P., van 
der Zouwen, B., Jordanova, E. S., Kruisselbrink, A. B., … Falkenburg, J. 
H. F. (2013). HLA- class II upregulation during viral infection leads to 
HLA- DP- directed graft- versus- host disease after CD4+ donor lym-
phocyte infusion. Blood, 122, 1963– 1973. https://doi.org/10.1182/
blood - 2012- 12- 470872
Stevens, C. E., Carrier, C., Carpenter, C., Sung, D., & Scaradavou, A. (2011). 
HLA mismatch direction in cord blood transplantation, impact on 
outcome and implications for cord blood unit selection. Blood, 118, 
3969– 3978. https://doi.org/10.1182/blood - 2010- 11- 317271
Taniguchi, K., Yoshihara, S., Maruya, E., Ikegame, K., Kaida, K., Hayashi, 
K., Kato, R., Inoue, T., Fujioka, T., Tamaki, H., Okada, M., Onuma, T., 
Fujii, N., Kusunoki, Y., Soma, T., Saji, H., & Ogawa, H. (2012). Donor- 
derived HLA antibody production in patients undergoing SCT from 
HLA antibody- positive donors. Bone Marrow Transplantation, 47, 
1338. https://doi.org/10.1038/bmt.2012.28
Tie, R., Zhang, T., Yang, B. O., Fu, H., Han, B., Yu, J., Tan, Y., & Huang, 
H. E. (2017). Clinical implications of HLA locus mismatching in un-
related donor hematopoietic cell transplantation: A meta- analysis. 
Oncotarget, 8(16), 27645– 27660. https://doi.org/10.18632/ oncot 
arget.15291
Tiercy, J. M. (2016). How to select the best available related or unrelated 
donor of hematopoietic stem cells? Haematologica, 101, 680– 687. 
https://doi.org/10.3324/haema tol.2015.141119
Tiercy, J.- M., Bujan- Lose, M., Chapuis, B., Gratwohl, A., Gmür, J., Seger, 
R., Kern, M., Morell, A., & Roosnek, E. (2000). Bone marrow trans-
plantation with unrelated donors, what is the probability of iden-
tifying an HLA- A/B/Cw/DRB1/B3/B5/DQB1 – Matched donor? 
Bone Marrow Transplantation, 26, 437– 441. https://doi.org/10.1038/
sj.bmt.1702529
Tiercy, J.- M., Nicoloso, G., Passweg, J., Schanz, U., Seger, R., Chalandon, 
Y., Heim, D., Güngör, T., Schneider, P., Schwabe, R., & Gratwohl, A. 
(2007). The probability of identifying a 10/10 HLA allele- matched 
unrelated donor is highly predictable. Bone Marrow Transplantation, 
40, 515– 522. https://doi.org/10.1038/sj.bmt.1705787
Tozatto- Maio, K., Giannotti, F., Labopin, M., Ruggeri, A., Volt, F., 
Paviglianiti, A., Kenzey, C., Hayashi, H., Cornelissen, J., Michallet, M., 
Karakasis, D., Deconinck, E., Rohrlich, P.- S., de la Tour, R. P., Blaise, 
D., Petersen, E., D'Aveni, M., Sengeloev, H., Lamy, T., … Rocha, V. 
(2018). Cord blood unit dominance analysis and effect of the win-
ning unit on outcomes after double- unit umbilical cord blood trans-
plantation in adults with acute leukemia: A retrospective study on 
behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, 
Immunobiology Working Party, and the Acute Leukemia Working 
Party of the European Group for Blood and Marrow Transplantation. 
Biology of Blood and Marrow Transplantation, 24(8), 1657– 1663. 
https://doi.org/10.1016/j.bbmt.2018.02.014
Uhrberg, M., Valiante, N. M., Shum, B. P., Shilling, H. G., Lienert- 
Weidenbach, K., Corliss, B., Tyan, D., Lanier, L. L., & Parham, P. (1997). 
Human diversity in killer cell inhibitory receptor genes. Immunity, 7, 
753– 763. https://doi.org/10.1016/s1074 - 7613(00)80394 - 5
Ustun, C., Giannotti, F., Zhang, M.- J., Wang, H.- L., Brunstein, C., Labopin, 
M., Rocha, V., de Lima, M., Baron, F., Sandmaier, B. M., Eapen, M., 
Gluckman, E., Nagler, A., Weisdorf, D. J., & Ruggeri, A. (2017). 
Outcomes of UCB transplantation are comparable in FLT3+ AML: 
Results of CIBMTR, EUROCORD and EBMT collaborative analysis. 
Leukemia, 31, 1408– 1414. https://doi.org/10.1038/leu.2017.42
Valcárcel, D., Sierra, J., Wang, T., Kan, F., Gupta, V., Hale, G. A., Marks, 
D. I., McCarthy, P. L., Oudshoorn, M., Petersdorf, E. W., Ringdén, O., 
Setterholm, M., Spellman, S. R., Waller, E. K., Gajewski, J. L., Marino, 
S. R., Senitzer, D., & Lee, S. J. (2011). One- antigen mismatched related 
versus HLA- matched unrelated donor hematopoietic stem cell trans-
plantation in adults with acute leukemia: Center for International 
Blood and Marrow Transplant Research results in the era of molec-
ular HLA typing. Biology of Blood and Marrow Transplantation, 17(5), 
640– 648. https://doi.org/10.1016/j.bbmt.2010.07.022
van Balen, P., van Luxemburg- Hejis, S. A. P., van de Meent, M., van Bergen, 
C. A. M., Halkes, C. J. M., Jedema, I., & Falkenburg, J. H. F. (2017). 
Mismatched HLA- DRB3 can induce a potent immune response 
after HLA 10/10 matched stem cell transplantation. Transplantation, 
101(12), 2850– 2854. https://doi.org/10.1097/TP.00000 00000 
001713
Van der Zanden, H. G. M., Van Rood, J. J., Oudshoorn, M., Bakker, J. 
N. A., Melis, A., Brand, A., Scaradavou, A., & Rubinstein, P. (2014). 
Noninherited maternal antigens identify acceptable HLA mis-
matches: Benefit to patients and cost- effectiveness for cord blood 
banks. Biology of Blood and Marrow Transplantation, 20(11), 1791– 
1795. https://doi.org/10.1016/j.bbmt.2014.07.011
van Rood, J. J., Scaradavou, A., & Stevens, C. E. (2012). Indirect evidence 
that maternal microchimerism in cord blood mediates a graft- versus- 
leukaemia effect in cord blood transplantation. Proceedings of the 
National Academy of Sciences of the United States of America, 109(7), 
2509– 2514. https://doi.org/10.1073/pnas.11195 41109
van Rood, J. J., Stevens, C. E., Smits, J., Carrier, C., Carpenter, C., & 
Scaradavou, A. (2009). Reexposure of cord blood to noninherited 
maternal HLA antigens improves transplant outcome in hematolog-
ical malignancies. Proceedings of the National Academy of Sciences 
of the United States of America, 106(47), 19952– 19957. https://doi.
org/10.1073/pnas.09103 10106
Venstrom, J.M., Pittari, G., Gooley, T. A., Chewning, J. H., Spellman, S., 
Haagenson, M., Gallagher, M. M., Malkki, M., Petersdorf, E., Dupont, 
B., & Hsu, K. C. (2012). HLA- C– Dependent Prevention of Leukemia 
Relapse by Donor ActivatingKIR2DS1. New England Journal of 
Medicine, 367(9), 805– 816. https://doi.org/10.1056/nejmo a1200503
Vierra- Green, C., Roe, D., Hou, L., Hurley, C. K., Rajalingam, R., Reed, 
E., Lebedeva, T., Yu, N., Stewart, M., Noreen, H., Hollenbach, J. A., 
Guethlein, L. A., Wang, T., Spellman, S., & Maiers, M. (2012). Allele- 
level haplotype frequencies and pairwise linkage disequilibrium for 
14 KIR loci in 506 European- American individuals. PLoS One, 7(11), 
e47491. https://doi.org/10.1371/journ al.pone.0047491
Wang, Y. U., Chang, Y.- J., Xu, L.- P., Liu, K.- Y., Liu, D.- H., Zhang, X.- H., 
Chen, H., Han, W., Chen, Y.- H., Wang, F.- R., Wang, J.- Z., Chen, Y., 
     |  109LITTLE ET aL.
Yan, C.- H., Huo, M.- R., Li, D., & Huang, X.- J. (2014). Who is the best 
donor for a related HLA haplotype- mismatched transplant? Blood, 
124(6), 843– 850. https://doi.org/10.1182/blood - 2014- 03- 563130
Watz, E., Remberger, M., Ringden, O., Lundahl, J., Ljungman, P., Mattsson, 
J., Wikman, A., & Uhlin, M. (2014). Analysis of donor and recipient 
ABO incompatibility and antibody- associated complications after 
allogeneic stem cell transplantation with reduced- intensity condi-
tioning. Biology of Blood and Marrow Transplantation, 20(2), 264– 271. 
https://doi.org/10.1016/j.bbmt.2013.11.011
Weisdorf, D. (2008). Should all unrelated donors for transplantation be 
matched? Best Practice & Research Clinical Haematology, 21(1), 79– 83. 
https://doi.org/10.1016/j.beha.2007.11.011
Weisdorf, D., Cooley, S., Wang, T., Trachtenberg, E., Haagenson, M. 
D., Vierra- Green, C., Spellman, S., Spahn, A., Vogel, J., Kobusingye, 
H., Fehninger, T., Woolfrey, A., Devine, S., Ross, M., Waller, E. K., 
Sobecks, R., Parham, P., Guethlein, L. A., Marsh, S. G. E., & Miller, J. 
(2019). KIR donor selection: Feasibility in identifying better donors. 
Biology of Blood and Marrow Transplantation, 25(1), e28– e32. https://
doi.org/10.1016/j.bbmt.2018.08.022
Weisdorf, D., Eapen, M., Ruggeri, A., Zhang, M.- J., Zhong, X., Brunstein, 
C., Ustun, C., Rocha, V., & Gluckman, E. (2014). Alternative donor 
transplantation for older patients with acute myeloid leukemia 
in first complete remission: A Center for International Blood and 
Marrow Transplant Research- Eurocord analysis. Biology of Blood and 
Marrow Transplantation, 20(6), 816– 822. https://doi.org/10.1016/j.
bbmt.2014.02.020
Woolfrey, A., Klein, J. P., Haagenson, M., Spellman, S., Petersdorf, E., 
Oudshoorn, M., Gajewski, J., Hale, G. A., Horan, J., Battiwalla, M., 
Marino, S. R., Setterholm, M., Ringden, O., Hurley, C., Flomenberg, 
N., Anasetti, C., Fernandez- Vina, M., & Lee, S. J. (2011). HLA- C anti-
gen mismatch is associated with worse outcome in unrelated donor 
peripheral blood stem cell transplantation. Biology of Blood and 
Marrow Transplantation, 17(6), 885– 892. https://doi.org/10.1016/j.
bbmt.2010.09.012
Woolfrey, A., Wang, T., Lee, S. J., Haagenson, M. D., Chen, G. E., 
Fleischhauer, K., Horan, J., Hsu, K., Verneris, M., Spellman, S. R., & 
Fernandez- Vina, M. (2019). Donor- specific anti- HLA antibodies in 
unrelated hematopoietic cell transplantation for non- malignant dis-
orders. Bone Marrow Transplantation, 54(3), 494– 496. https://doi.
org/10.1038/s4140 9- 018- 0334- y
Wu, G. Q., Zhao, Y. M., Lai, X. Y., Luo, Y., Tan, Y. M., Shi, J. M., Li, L., Zheng, 
W. Y., Zhang, J., Hu, X. R., Jin, A. Y., He, J. S., Xie, W. Z., Ye, X. J., Cai, 
Z., Lin, M. F., & Huang, H. (2010). The beneficial impact of missing KIR 
ligands and absence of donor KIR2DS3 gene on outcome following 
unrelated hematopoietic SCT for myeloid leukemia in the Chinese 
population. Bone Marrow Transplantation, 45(10), 1514– 1521. https://
doi.org/10.1038/bmt.2010.3
Wulf, G., Glass, B., Pfreundschuh, M., Einsele, H., Arnold, R., Stuhler, G., 
Schaefer- Eckart, K., Freitag, S., Casper, J., Kaufmann, M., Wattad, M., 
Hertenstein, B., Klein, S., . . ., Mytilineos, Joannis (2016). Matching 
for the MICA- 129 polymorphism is beneficial in unrelated hemato-
poietic stem cell transplantation. Blood, 128(26), 3169– 3176. https://
doi.org/10.1182/blood - 2016- 05- 716357
Yabe, T., Azuma, F., Kashiwase, K., Matsumoto, K., Orihara, T., Yabe, 
H., Kato, S., Kato, K., Kai, S., Mori, T., Morishima, S., Satake, M., 
Takanashi, M., Nakajima, K., & Morishima, Y. (2018). HLA- DPB1 
mismatch induces a graft- versus- leukemia effect without severe 
acute GVHD after single- unit umbilical cord blood transplantation. 
Leukemia, 32(1), 168– 175. https://doi.org/10.1038/leu.2017.202
Yuji, K., Ohno, N., Kawamata, T., Jo, N., Yokoyama, K., Uchimaru, K., 
Tojo, A., & Takahashi, S. (2014). Impact of sex incompatibility on the 
outcome of single- unit cord blood transplantation for adult patients 
with hematological malignancies. Bone Marrow Transplantation, 49(5), 
634– 639. https://doi.org/10.1038/bmt.2014.10
Zhao, X. Y., Huang, X. J., Liu, K. Y., Xu, L. P., & Liu, D. H. (2007). Prognosis 
after unmanipulated HLA- haploidentical blood and marrow trans-
plantation is correlated to the numbers of KIR ligands in recipi-
ents. European Journal of Haematology, 78(4), 338– 346. https://doi.
org/10.1111/j.1600- 0609.2007.00822.x
Zhao, X.- Y., Yu, X.- X., Xu, Z.- L., Cao, X.- H., Huo, M.- R., Zhao, X.- S., Chang, 
Y.- J., Wang, Y. U., Zhang, X.- H., Xu, L.- P., Liu, K.- Y., & Huang, X.- J. 
(2019). Donor and host coexpressing KIR ligands promote NK ed-
ucation after allogeneic hematopoietic stem cell transplantation. 
Blood Advances, 3, 4312– 4325. https://doi.org/10.1182/blood advan 
ces.20190 00242
Zino, E., Frumento, G., Marktel, S., Sormani, M. P., Ficara, F., Terlizzi, S. 
D., Parodi, A. M., Sergeant, R., Martinetti, M., Bontadini, A., Bonifazi, 
F., Lisini, D., Mazzi, B., Rossini, S., Servida, P., Ciceri, F., Bonini, C., 
Lanino, G., Bandini, G., & Fleischhauer, K. (2004). A T- cell epitope 
encoded by a subset of HLA- DPB1 alleles determines nonpermissive 
mismatches for hematologic stem cell transplantation. Blood, 103, 
1417– 1424. https://doi.org/10.1182/blood - 2003- 04- 1279
How to cite this article: Little A- M, Akbarzad- Yousefi A, Anand 
A, et al. BSHI guideline: HLA matching and donor selection for 
haematopoietic progenitor cell transplantation. Int J 
Immunogenet. 2021;48:75– 109. https://doi.org/10.1111/
iji.12527
